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ABSTRACT 
 
Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases worldwide. It is 
primary associated with impaired insulin secretion by the pancreatic β-cells and/or insulin 
resistance. Current treatments are often associated with variations of normalizing glycemic 
levels, off-target effects and do not significantly impact disease progression. New therapies 
are, therefore, urgently needed to overcome this social burden.  
Incretin based treatments, especially using glucagon-like peptide-1 (GLP-1), an 
incretin hormone which is a glucose-dependent insulinotropic peptide, are now widely 
investigated and used to manage T2DM. The oral route is, by far, the most desirable way for 
drug delivery, but when it comes to peptides and proteins, it is traditionally challenging and 
frequently compromised using conventional dosage form approaches. This is due to the main 
barriers encountered along the gastrointestinal tract, namely the enzymatic and chemical 
degradations, mucus layer and the epithelial barrier. Thus, the oral administration of GLP-1 is 
still a huge challenge in the pharmaceutical field, requiring administration by parenteral 
routes, which severely decrease patient adherence to the treatment.  
Recent developments in materials science and nanomedicine, and specific surface 
functionalization strategies, are providing new tools for the rational design of precisely 
engineered drug delivery systems. Particular interest has been paid to the exploitation of 
tailored nanomaterials for the administration of peptides and proteins by the oral route. Using 
such materials for producing nanoparticulate systems is a promising approach to obtain 
advanced drug delivery systems capable of providing stable and biocompatible environments 
for these drugs and allowing for a targeted delivery of the associated biopharmaceuticals.  
The main aim of this thesis was to develop safe particulate-based GLP-1 carrier 
systems and evaluate their efficiency in increasing GLP-1 oral bioavailability. The first part of 
this was focused on selecting the most adequate material in terms of particle size and 
surface charge, GLP-1 association efficiency (AE), drug release and interaction with 
intestinal cell lines. Poly(lactide-co-glycolide) (PLGA), Witepsol E85 lipid (solid lipid 
nanoparticles, SLN) and porous silicon (PSi) nanoparticles were tested. All the particles 
presented a size approximately around 200 nm with negative zeta potential and narow 
polydispersity index. Due to their negative charge, the interactions with the intestinal cells 
were expected to be minimal. Chitosan (CS), a polycationic and partially mucoadhesive 
biopolymer, with known permeation enhancing effect, was used to modify the surface of the 
nanoparticles. When coated with CS, nanoparticles size increased and there was an 
ABTRACT 
xxii 
 
inversion of the zeta potential to positive values. CS functionalized PLGA and PSi 
nanoparticles presented the best properties, namely mucoadhesion, closer interaction with 
intestinal cell lines and an AE with GLP-1 of 60% and 85%, respectively. 
A complex multistage delivery system was further developed to improve GLP-1 
delivery. In order to enhance the transcellular permeability of GLP-1, a cell penetrating 
peptide (CPP) was further attached to the nanoparticles surface. In addition, the 
nanoparticles were subsequently encapsulated into pH-sensitive 
hydroxypropylmethylcellulose acetylsuccinate (HPMC-AS)-based microparticles of size of ca. 
60 µm, using a microfluidics technique, to protect the nanoparticles and the premature GLP-1 
release from the very low gastric pH. HPMC-AS dissolves only at pH ≥ 6.0, which allows 
controlling the release of GLP-1 until the particles reach the small intestine. A small molecule 
drug, able to inhibit the dipeptidyl peptidase 4 (DPP4) enzyme, responsible to cleave and 
hence inactivate GLP-1 in vivo, was simultenously loaded into HPMC-AS microparticles (AE 
≈ 20%). The loading degree of GLP-1 was of 0.030 ± 0.007% and 0.730 ± 0.001 % for the 
PLGA and PSi systems encapsulated into HPMC-AS, respectively, and for iDPP4 was of 
1.00 ± 0.01% and 1.26 ± 0.01%, respectively. This multistage platform showed a pH-
dependency, with regular and smooth particle shape and surface morphology at acidic pH, 
thus protecting nanoparticles and GLP-1 in acidic conditions. In turn, at more neutral 
intestinal pH, HPMC-AS microparticles disaggregate, thereby releasing the CS-CPP 
conjugated nanoparticles and providing stronger interactions with the intestinal cells. CS-
CPP conjugated PLGA and PSi nanoparticles presented a 5.6 and 1.3-fold increase in the 
interaction with the intestinal cells, compared to the unmodiﬁed nanoparticles, respectively. 
The presence of the DPP4 inhibitor decreased the DPP4 activity over 20-fold and increased 
GLP-1 permeability across a triple co-culture intestinal monolayer, with a ca. 5-fold increase 
for the PLGA systems and a ca. 1.5-fold increase for the PSi ones. 
When tested in vivo after oral administration in a non-obese T2DM rat model, the 
HPMC-AS microparticles with CS-CPP conjugated PLGA nanoparticles, containing the 
combination of GLP-1 and DPP4 inhibitor, resulted in a decreased in the hyperglycemia in a 
sustained and prolonged manner. After oral administration of the system, blood glucose 
levels decreased ca. 45%, from 4h until at least 8h after administration, presenting half of the 
glucose area under the curve when compared to the control (GLP-1 + DPP4 inhibitor in 
solution). The insulin plasmatic levels were also increased 6h after particles oral 
administration as well as the pancreatic insulin content. 
Overall, a multistage composite system was developed for oral dual delivery of GLP-1 
and DPP4 inhibitor. This platform showed to be successful in overcoming the barriers along 
the gastrointestinal tract and increasing the GLP-1 oral bioavailabilty, thus showing clinical 
ABTRACT 
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potential as an oral peptide and protein delivery system for T2DM therapy, and, potentially, 
for other biopharmaceutical-based therapies. 
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RESUMO 
 
A diabetes mellitus tipo 2 (T2DM) é uma das doenças mais prevalentes em todo o 
mundo, caracterizada pela incorreta produção de insulina pelas células β do pâncreas e/ou 
pela resistência do organismo na utilização da insulina produzida. As terapias usadas 
atualmente para o controlo da sintomatologia da T2DM estão, na maioria das vezes, 
associadas a múltiplas variações dos níveis de glucose e a efeitos secundários, não tendo, 
por isso, um grande impacto na sua progressão. Assim, novas terapias são necessárias de 
forma a controlar a sintomatologia desta doença com maior efetividade, e racionalizar os 
custos associados ao seu tratamento. 
Terapias com base em incretinas, especialmente o glucagon-like peptide-1 (GLP-1), 
uma hormona com efeito insulinotrópico dependente de glucose, têm sido investigados e 
utilizados no controlo da T2DM. A via de administração oral é, sem dúvida, a preferida para 
a administração de fármacos, mas quando estes são de origem proteica, como é o caso do 
GLP-1, a sua atividade está normalmente comprometida quando formulados em formas 
farmacêuticas convencionais. Assim, a administração de GLP-1 é realizada por vias 
parentéricas invasivas, o que diminui drasticamente a adesão dos pacientes à terapia. 
O recente aumento do conhecimento da ciência dos materiais, e em especial na 
funcionalização da sua superfície, tem proporcionado novas ferramentas para o 
desenvolvimento de sistemas de elevada precisão para a administração de fármacos, com 
particular interesse para a administração de péptidos e proteínas por via oral. O uso desses 
biomateriais para a produção de sistemas multiparticulares é uma abordagem cada vez mais 
comum, obtendo-se assim sistemas mais inteligentes de administração de fármacos, 
capazes de fornecer um microambiente estável e biocompatível para o fármaco e permitindo 
uma administração mais orientada. 
O principal objetivo desta tese foi desenvolver sistemas particulares para 
administração oral de GLP-1, que aumentassem a sua biodisponibilidade. A primeira etapa 
do trabalho foi escolher, entre diferentes materiais como o ácido poli(láctico-co-glicólico) 
(PLGA), lípido Witepsol E85 e sílica porosa (PSi), os mais promissores relativamente ao 
tamanho das partículas, à sua carga superficial, à eficiência de associação (AE), libertação 
do GLP-1 e interação com células intestinais. Todas as nanopartículas apresentaram 
tamanhos próximos dos 200 nm, com índice de polidispersão baixos e carga superficial 
negativa. Devido a esta carga, as interações com as células intestinais são expectavelmente 
reduzidas. Assim, os sistemas particulares foram modificados com quitosano (CS), um 
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polímero policatiónico e parcialmente mucoadesivo, conhecido também por aumentar a 
permeabilidade celular. Quando modificadas com o CS, o tamanho médio das partículas 
aumentou e a carga inverteu para valores positivos. As nanopartículas de PLGA e PSi, 
ambas modificadas com CS, foram as que apresentaram melhores resultados, com 
propriedades de mucoadesão e maior interação com as linhas celulares do que os sistemas 
não-modificados. As suas AE foram de 60% e 85%, respetivamente. 
Numa etapa posterior, os sistemas foram melhorados para que conseguissem resistir 
e ultrapassar todas as barreiras encontradas ao longo do trato gastrointestinal. Para isso, foi 
feita uma funcionalização com um péptido penetrador de células (CPP) na sua superfície, 
com a finalidade de melhorar a permeabilidade transcelular de GLP-1. As nanopartículas 
foram depois encapsuladas em micropartículas constituídas por um polímero sensível ao 
pH, o hidroxipropilmetilcelulose acetil succinato (HPMC-AS), através da técnica de 
microfluidos, dando origem a micropartículas com diâmetro ≈ 60 µm. Esta 
microencapsulação das nanoparticulas foi realizada para que permitisse uma proteção das 
nanoparticulas no pH muito baixo do estômago. O HPMC-AS, que se dissolve apenas a um 
pH ≥ 6.0, permite controlar a libertação das nanoparticulas e do GLP-1 até que as 
micropartículas atinjam o intestino. A este polímero sensível ao pH foi simultaneamente 
adicionado um fármaco de baixo peso molecular, inibidor da enzima dipeptidyl-peptidase 4 
(DPP4), responsável por clivar e inativar o GLP-1 in vivo (AE ≈ 20%). A dosagem de GLP-1 
para os sistemas the PLGA e PSi encapsulados em HPMC-AS foram de 0.030 ± 0.007 % e 
0.730 ± 0.001 %, respetivamente, e a dosagem do iDPP4 foi de 1 ± 0.01 % e 1.26 ± 0.01%, 
respectivamente. Estas micropartículas apresentavam uma superfície lisa e morfologia 
regular, e demonstraram ter um perfil de libertação pH-dependente, retendo o GLP-1 no seu 
interior a pH ácido. Por sua vez, a pH intestinal, o polímero dissolveu-se e as nanopartículas 
libertadas apresentaram maior interação com as células intestinais em comparação com os 
sistemas não-modificados. Isto mostra que a encapsulação das nanoparticulas nas 
micropartículas de HPMC-AS utilizando a técnica de microfluidos foi eficaz e que as 
nanopartículas foram protegidas em condições ácidas. As nanopartículas de PLGA e PSi 
modificadas com CS-CPP apresentaram 5.6 e 1.3 vezes mais interação com as células 
intestinais, relativamente às nanopartículas não-modificadas, respetivamente. A presença do 
inibidor da DPP4 diminuiu a actividade enzimática da DPP4 mais de 20 vezes e aumentou 
também a permeabilidade de GLP-1 através de um modelo triplo intestinal em ≈ 5 vezes 
para os sistemas contendo PLGA e ≈ 1.5 vezes para os sistemas contendo PSi, em 
comparação com sistemas sem o inibidor.  
Quando testados in vivo, num modelo de rato de T2DM não-obesos, após 
administração oral, as micropartículas de HPMC-AS com as nanopartículas de PLGA 
modificadas com CS-CPP, contendo GLP-1 e o inibidor da DPP4, originaram uma 
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diminuição da hiperglicemia de uma forma sustentada e prolongada. Com a administração 
oral do sistema, os níveis de glicose no sangue foram reduzidos em 45%, pelo menos das 4 
h às 8 h após administração, apresentando ainda metade da área sob a curva de glucose 
quando comparado com o controlo (solução de GLP-1 + inibidor da DPP4). Também os 
valores plasmáticos de insulina aumentarem 6 h após a administração das partículas assim 
como o conteúdo pancreático de insulina. 
Em conclusão, uma plataforma para a co-administração oral do GLP-1 e do inibidor 
da DPP4 foi desenvolvida, aumentando a biodisponibilidade oral do GLP-1 quando 
administrada oralmente. Esta plataforma mostrou ter sucesso em resistir e ultrapassar as 
barreiras do trato gastrointestinal, mostrando ter potencial para o seu uso clínico como 
sistemas de entrega oral de péptidos e proteínas para a terapia da T2DM e, eventualmente, 
para outras terapias dependentes de biofármacos. 
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GLP-1 Glucagon-like peptide-1 
GLP-1R Glucagon-like peptide-1 receptor 
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H-PSi Multisystem constituted by porous silicon nanoparticles modified with 
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1. Diabetes mellitus 
Diabete mellitus (DM) is a group of chronic metabolic diseases, characterized by high 
blood glucose levels (hyperglycemia) due to disturbances in the metabolism of 
carbohydrates, fats and proteins (American Diabetes Association, 2009). DM is either caused 
due to relative or absolute insufficiency in insulin production and/or decreased insulin 
sensitivity. It is often associated with major complications such as renal failure, retinopathy, 
amputation, and major risk of myocardial infarction and stroke (Flower, 2008). According to 
the International Diabetes Federation, in 2015, there were 415 million individuals suffering 
from DM worldwide, and this number is expected to rise to 642 million by 2040 (International 
Diabetes Federation, 2016). This makes DM one of the biggest health problems in the world, 
with very high socio-economic impact. In Europe, around 60 million people suffer from 
diabetes, out of which 33% remain undiagnosed (International Diabetes Federation, 2016). 
Portugal, in particular, is estimated to have ca. 1 million people suffering from DM 
(International Diabetes Federation, 2016). 
DM can be classified into three main types: Type 1 DM (T1DM), Type 2 DM (T2DM) 
and gestational diabetes. Other specific types of DM also exist but are not common. T1DM, 
also known as insulin dependent diabetes mellitus or juvenile-onset diabetes, accounts for 5–
10% of the total DM cases. T1DM is associated with progressive and specific destruction of 
pancreatic β cells, caused by cellular-mediated autoimmune destruction, which are 
responsible for producing insulin, leading to absolute insulin deficiency. T2DM, also known 
as noninsulin-dependent diabetes mellitus or adult-onset diabetes, is a complex disease 
characterized by resistance to insulin action and inadequate insulin secretion due to 
pancreatic β-cell dysfunction (Tahrani et al., 2010). T2DM accounts for 90–95% of the total 
DM cases, in which sedentary lifestyle and obesity are often identified as the major causes. 
According to the World Health Organization (WHO), from 20102030, a steep increase of 
69% in adults suffering from T2DM is predicted (Shaw et al., 2010).  Gestational diabetes is, 
from these three, the least common type of DM. It is associated with pregnancy, without 
previous diagnosis of DM, which may evolve to T2DM post-pregnancy (American Diabetes 
Association, 2008; Uma et al., 2012; Xu et al., 2003).  
 
1.2. Type 2 diabetes mellitus (T2DM) 
T2DM is not only the most prevalent type of DM, but also one of the most prevalent 
and rapidly spreading diseases worldwide. The increase in the frequency of occurrence of 
this disorder and the morbidity associated to the disease leads to a socio-economic burden, 
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with huge amounts of money being spent every single day (Namba et al., 2013; Nicholson 
and Hall, 2011; Zhang et al., 2010). Based on the current understanding of the 
pathophysiology of T2DM, multiple non-pharmacological interventions (e.g., diet and 
exercise) and pharmacological therapies have been developed to control this disease. 
However, none of the used therapies have a significant impact on disease progression 
(Arulmozhi and Portha, 2006; Tahrani et al., 2010). Therefore, there is an urgent need to 
keep on searching for better drugs and delivery systems that could control the disease and 
reduce the complications and associated side effects. 
 
2. Incretin hormones 
Currently, the clinical use of incretins is in the pipeline of T2DM therapy. Incretins are 
hormones produced by intestinal cells and their function is to enhance the glucose-
dependent production of insulin through the target of pancreatic β-cells. The incretin concept 
relates to the fact that oral food intake provides a more potent insulinotropic stimulus 
compared to isoglycemic intravenous challenge, reducing postprandial hyperglycaemia 
(Campbell and Drucker, 2013; Drucker, 2006; Drucker and Nauck, 2006). Thus, incretins are 
thought to act as amplifiers of the glucose signal, being involved in approximately 50–70% of 
the total insulin secreted following oral glucose administration (Baggio and Drucker, 2007). 
As they are glucose-dependent, some side effects of the current therapies, such as 
hypoglycemia, can be overcome making these hormones the most desirable for therapy 
(Khan et al., 2013; Vilsboll et al., 2001). The most important incretin hormones are glucose-
dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). 
 
2.1. Glucose-dependent insulinotropic polypeptide (GIP) 
GIP was the first described incretin hormone. It is a 42 amino acids peptide secreted 
by enteroendocrinal K-cells in duodenum and proximal jejunum, which turns into an active 
form (GIP (130)) after being processed by the prohormone convertase 2 (PC2), still in K-
cells. It stimulates insulin secretion through its action on the pancreatic β-cells where it up-
regulates the biosynthesis and transcription of the insulin gene (Baggio and Drucker, 2007; 
Campbell and Drucker, 2013). 
However, despite all the promising effects of GIP, patients suffering from T2DM were 
found to be resistant to it, and thus, they have a decrease acute insulinotropic response to 
native GIP, even with the GIP levels either normal or increased (Bavec, 2014; Tahrani et al., 
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2010). This resistance is still unclear, but some studies suggest that it may be associated 
with a down-regulation of GIP receptor expression (Baggio and Drucker, 2007). Moreover, in 
contrast to GLP-1, described below, it has neither effect on α-cells that secrete glucagon nor 
in food intake, satiety, and gastric emptying nor body weight (Bavec, 2014; Tahrani et al., 
2010). Moreover, due to GIP resistance in humans, the majority of clinical studies have 
focused on the therapeutic potential of GLP-1. 
 
2.2. Glucagon-like peptide-1 (GLP-1) 
GLP-1 is an incretin hormone synthetized in enteroendocrinal L cells, at the distal 
small bowel and colon, as a 37 amino acid peptide (GLP-1 (1–37)) (Campbell and Drucker, 
2013). It derives from a proglucagon gene, witch after post-translational processing by 
prohormone convertase 1/3 (PC 1/3), results into two bioactive circulating peptide forms: 
GLP-1(7–37) (Figure 1A)  and GLP-1(7–36) amide (Figure 1B), both with similar potency 
(Drucker, 2006). In the fasted state, GLP-1 blood values range from 5-10 pmol/L but can 
reach, with a rapidly increasing, up to 15–50 pmol/L after feeding (Drucker and Nauck, 2006; 
Nauck, 2011; Nauck et al., 2011).  
 
Figure 1. Primary structure of (A) GLP-1 (7–37) and (B) GLP-1 (7-36) amide. 
 
 
GLP-1 acts by binding to its G protein-coupled receptor [GLP-1 receptor (GLP-1R)], at 
membrane of β cells, which activates the GLP-1R signaling pathway (Baggio and Drucker, 
2007; Portha et al., 2011). As it is not in the scope of this thesis, the molecular mechanisms 
through which GLP-1 acts will not be addressed, but detailed explanations can be found 
elsewhere (Baggio and Drucker, 2007; Campbell and Drucker, 2013; Drucker, 2006; Drucker 
and Nauck, 2006). GLP-1R is widely expressed in the pancreatic islets, stimulating insulin 
secretion and the neogenesis and proliferation of β cells, thereby decreasing or suppressing 
the glucagon release (Holst et al., 2011; Perfetti and Merkel, 2000). Similarly, GLP-1R are 
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also expressed along the gastrointestinal tract (Gutzwiller et al., 1999), in the brain 
(Neumiller, 2011) in the heart (Davidson, 2011; Khan et al., 2013), and within the liver, 
kidney, muscle and adipose tissue as can be seen in Figure 2 (Baggio and Drucker, 2007; 
Campbell and Drucker, 2013; Drucker, 2006; Drucker and Nauck, 2006). 
It is commonly accepted that patients with T2DM have reduced GLP-1 activity due to 
reduced insulin response to GLP-1. However, despite being controversial, some authors also 
claim that the secreted GLP-1 is deficient and that is why pancreatic β-cells are not sensitive 
to it (Nauck et al., 2011). Nevertheless, the insulinotropic effect of GLP-1 remains 
unchanged, as well as the number of GLP-1R, leading to the restoration of normal GLP-1 
activity when external administered in therapeutic doses (Arulmozhi and Portha, 2006; Marre 
and Penfornis, 2011; Nauck et al., 2011; Russell, 2013). 
However, GLP-1 has a very short half-life (less than 2 minutes), mainly due to 
enzymatic degradation caused by dipeptidyl peptidase-4 (DPP-4) enzyme. DPP-4 cleaves 
GLP-1 in its N-terminal (in the alanine at position 2), resulting in GLP-1(9–36) amide or GLP-
1(9–37), both of them inactive peptides (Arulmozhi and Portha, 2006). GLP-1 is further 
metabolized in the liver which leads to only 2.53.75% of the total secreted GLP-1 reaching 
the systemic circulation (Baggio and Drucker, 2007; Drucker and Nauck, 2006; Holst, 2007). 
 
Figure 2. The action of GLP-1 on several peripheral tissues. GLP-1 acts directly on 
endocrine pancreas, heart, stomach and brain, and indirectly on liver and muscle (Drucker, 
2006). 
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Some strategies to overcome this premature GLP-1 metabolism have been pursued, 
which resulted in two incretin-based therapies available (using separately or together): the 
substitution of GLP-1 for GLP-1 analogs and/or the use of DPP-4 inhibitors (Marre and 
Penfornis, 2011). The pharmacological potency of GLP-1 analogs is much higher than the 
DPP-4 inhibitors since they are dependent on the glucose levels, on the concentration of 
endogenous GLP-1 and on the number of the existing receptors. Moreover, DPP-4 besides 
cleave GLP-1, is also a protease involved in the digestion of Pro/Ala-containing oligopeptides 
and nutrients and in the absorption of their fragments, a receptor associated with CD45 and 
adenosine deaminase (ADA), a co-stimulatory for lymphocytes among other functions 
(Juillerat-Jeanneret, 2013). Thus, the inhibition of DPP-4 actions could also lead to some 
heath issues (Araújo et al., 2012; Gerich, 2013). 
GLP-1 analogs used for the treatment of T2DM have been studied for a long time 
now. GLP-1 analogs are GLP-1 receptor agonists that are structurally similar to native GLP-
1, but with some chemical modifications that make them resistant to DPP-4 degradation and 
delay their clearance from the bloodstream (Unger and Parkin, 2011). This will impart them a 
longer half-life in vivo than native GLP-1. Some of those GLP-1 analogs are in clinical trials 
and others have been approved by the US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA), and are already in the market, such as Exenatide 
(Byetta®) from Amylin/Eli Lilly and Liraglutide (Victoza®) from Novo Nordisk (Table 1) (Li et 
al., 2011). Exenatide is the synthetic form of exendin 4, a peptide isolated from the salivary 
gland of Gila monster (Heloderma suspectum), and presents 53% homology with native 
GLP-1. In turn, liraglutide is very similar to the native peptide, with 97% homology to GLP-1, 
differing only in one amino acid and linked with a fatty acid side chain (Araújo et al., 2012; Li 
et al., 2011). Both exenatide and liraglutide have been proven to improve the glycemic 
control (Deacon, 2009; Li et al., 2011; Marre and Penfornis, 2011).  
Despite alternatives have been developed to improve the problem associated with 
short half-life of GLP-1, the therapeutic use of GLP-1 analogs is still limited. This is mainly 
due to the need of parenteral administration, which has a very poor patient adherence, as 
well as the gastrointestinal side effects encountered in people under this therapy (Table 1). 
The oral route is by far the most desirable way for drug administration, however, the 
therapeutic activity of labile biomolecules, such as proteins and peptides, is severely 
compromised when exposed to the harsh physical, chemical and enzymatic gastrointestinal 
environment due to their physicochemical (solubility), biophysical (conformational and 
structural stability), and biopharmaceutical (permeability and metabolic stability) properties 
(Date et al., 2016; Pérez et al., 2016; Swierczewska et al., 2016). In the case of T2DM, it is 
particularly troublesome due to the chronic therapy nature, requiring frequent drug 
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Table 1. Characteristics, advantages, disadvantages and stage of drug development (clinical trial/approval) of GLP-1 analogs. Adapted from Khan et al. 2013. 
Name Characteristic Advantages Disadvantages Stage of drug development 
Exenatide (Byetta) 
Amylin/Eli Lilly 
Exendin 4 analogue 
Minimal hypoglycemia, 
counteracts stress-induced 
hyperglycemia, weight loss 
Gastrointestinal side effects Approved 2005 (USA) 
Liraglutide (Victoza) 
Novo Nordisk 
GLP-1 analogue Minimal hypoglycemia, weight loss Gastrointestinal side effects Approved 2009 (EU) 
Exenatide (Bydureon) 
Amylin/Eli Lilly 
Long-acting microencapsulated 
exendin analogue 
Minimal hypoglycemia, weight 
loss, injected once a week 
Gastrointestinal side effects Approved 2011 (EU) 
Lixisenatide (Lyxumia) 
Sanofi 
Exendin 4 analogue 
Minimal hypoglycemia, superior 
reduction in postprandial plasma 
glucose, weight loss 
Gastrointestinal side effects Approved 2013 (EU) 
Albiglutide 
GlaxoSmithKline 
Long-acting GLP-1 analogue 
Minimal hypoglycemia, improved 
cardiovascular outcomes, weight 
loss, injected once a week or 
month 
Minor gastrointestinal side 
effects 
Approved 2014 (EU and USA) 
Taspoglutide 
Roche/Ipsen 
Long-acting GLP-1 analogue 
Minimal hypoglycemia, weight 
loss, injected once a week 
Very severe gastrointestinal 
side effects 
Phase III clinical trials 
Dulaglutide 
Eli Lilly 
Long-acting GLP-1 analogue 
Minimal hypoglycemia, weight 
loss, reduced immunogenicity and 
renal clearance, injected once a 
week 
Gastrointestinal side effects Approved 2014 (USA) 
CJC-1134-PC 
ConjuChem 
Long-acting exendin 4 analogue 
Minimal hypoglycemia, reduced 
renal clearance, weight loss, 
injected once a week 
Minor gastrointestinal side 
effects 
Phase II clinical trials 
Semaglutide 
Novo Nordisk 
Long-acting GLP-1 analogue 
Half-life of 160 h. Reduced risks of 
cardiovascular disease 
Mild-moderate gastrointestinal 
side effects 
Phase III clinical trials 
Deglutec and liraglutide 
(IdegLira) 
Novo Nordisk 
Long-acting insulin analogue and 
GLP-1 analogue combination 
Weight loss, effective against 
elevated fasting and postprandial 
plasma glucose 
Hypoglycemia. Minor 
gastrointestinal side effects  
Approved 2015 (EU and USA) 
CHAPTER I 
9 
 
administrations, in some cases several times daily, which leads to poor patient compliance 
(Araújo et al., 2015a; Gupta et al., 2013). 
 
3. Barriers to the oral delivery of biologicals 
The gastrointestinal tract provides an optimum environment for the digestion of 
ingested macromolecules from diet into their molecular building blocks, which can then be 
easily absorbed in the intestine (Chen et al., 2011). Besides contributing to basic nutritional 
intake, the digestion process accomplished by enzymes and pH variations found along the 
gastrointestinal tract, as well as the gut mobility, also acts as a gatekeeper of the human 
body, being the first line of defense against pathogens and xenobiotics (Araújo et al., 2012). 
Likewise, the natural course of the orally administrated therapeutic biomolecules will lead to 
their entrapment within the gastrointestinal lumen and eventual breakdown, with consequent 
structure and bioactivity loss (Chen et al., 2011). Even if the biochemical barriers can be 
overcome, when reaching the absorptive interfaces, therapeutic biomolecules would face 
other frequently unsurpassable hurdles, such as the mucus layer and the epithelial cell lining 
that limit their permeation/absorption and efficient translocation to the blood circulation 
(Figure 2). Understanding the characteristics and functions of these three main barriers is 
crucial in designing and developing effective carriers for the oral administration of therapeutic 
biomolecules. 
 
3.1. The biochemical barrier 
The biochemical is the first barrier that peptides and proteins face after oral 
administration. It essentially comprises different pH values and the enzymatic activity that 
occur within the gastrointestinal tract. Hydrogen ion concentrations oscillate widely, with very 
acidic values (pH 1.2−3) at the stomach, but dramatically increasing to slightly alkaline in the 
intestine (pH 6.5−8.0) in the fasted state (Figure 3) (Yun et al., 2013). Peptides and proteins 
are susceptible to these changes, which may lead to their oxidation, deamination or 
hydrolysis, thus potentially causing loss of activity (Yun et al., 2013). They are also 
vulnerable to the enzymatic activity that drives their degradation (Rekha and Sharma, 2013). 
These enzymes can be found in the luminal space of the gastrointestinal tract, namely pepsin 
(at gastric level) or trypsin (in the intestine), being the greatest enzymatic activity observed at 
the brush border in the cytosol and in the cellular organelles (e.g., lysosomes) of the 
enterocytic intestinal cells of the duodenum and jejunum. Due to their immune nature, 
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Peyer’s patches of the jejunum and the ileum also present high catabolic activity, with around 
20−30% of the total intestinal enzymatic activity (Rekha and Sharma, 2013; Roger et al., 
2010; Yun et al., 2013). 
 
Figure 3. Gastrointestinal tract barriers to the oral delivery of biomolecules. Figure produced 
using Servier Medical Art. 
 
3.2. The mucus barrier 
  The mucus layer is another challenging obstacle to be overcome. In fact, this is the 
first physical barrier encountered by peptides and proteins after their oral administration 
(Cone, 2009; Ensign et al., 2012b). Mostly constituted by water, mucin glycoproteins (1-5%) 
and electrolytes, mucus comprises a randomly organized mucin fiber mesh, forming a 
heterogeneous 3D scaffold-like structure of variable porosity (Johansson et al., 2011). 
Besides molecular entanglement, binding between these fibers occurs mostly by disulfide 
linkages and hydrophobic interactions that form dense mesh-pores (50–1800 nm) creating a 
steric and potentially highly adhesive barrier to the transport of biomolecules and supra-
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molecular structures, including drug delivery systems, from the intestinal lumen to the 
mucosal tissue (Lai et al., 2009; Sosnik et al., 2014; Thornton and Sheehan, 2004). In 
general, structures above 1000 nm are unable to permeate the mucus due to the limited pore 
size of the mucin mesh (das Neves et al., 2011). Mucins are rich in both negatively-charged 
glycosylated regions and hydrophobic domains, making it possible the establishment of 
interactions of variable nature (Ensign et al., 2012b). The typical viscoelastic properties of 
mucus layer allow for this sticky layer to protect the gastrointestinal epithelial cell lining from 
mechanical damage. Mucus also acts as a buffer barrier to pH oscillations in the 
gastrointestinal lumen. It rapidly traps and removes large molecules and matter due to fast 
turnover and clearance, usually measured from minutes to few hours (Lai et al., 2009; Tang 
et al., 2009). Due to its important protection role, mucus is continuously secreted and spread 
throughout the entire gastrointestinal tract, with the help of the peristaltic movements. Mucus 
blanket is determined by the balance between the rate of secretion and the rate of 
degradation and shedding, and in a balance between the protective capability and nutrient 
absorption rate (Atuma et al., 2001; Cone, 2009). According to the different locations, mucus 
presents different thickness: it is thicker at the stomach and colon, which helps protecting the 
epithelial cell lining from the acidic pH and bacteria, respectively, while in the small intestine, 
the major region of nutrients absorption, it is thinner and more loosely adherent to the 
mucosa, varying greatly on digestive activity (Ensign et al., 2012b; Rekha and Sharma, 2013; 
Yun et al., 2013). Penetration and transport across this mucus barrier is necessary in order to 
reach the absorptive epithelial cells. Interested readers can find excellent reviews on the 
mucus barrier to macromolecules and nanoparticles published over the past few years 
(Cone, 2009; Ensign et al., 2012b; Lai et al., 2009). 
 
3.3. The epithelial barrier 
As previously mentioned, the harsh acidic environment and the presence of enzymes, 
as well as its small surface area, reduce the stomach to an unfeasible site for biomolecules 
absorption (Renukuntla et al., 2013). In contrast, the human intestinal epithelium is a highly 
absorptive region. With a tightly arranged structure, the small intestine is made-up of a 
monolayer of polarized epithelial cells, organized into crypts and villi. The small intestinal 
epithelium is mainly composed by enterocytes, which present at their apical side well-ordered 
projections called microvilli greatly increase the absorptive area, rendering a total intestinal 
adult surface area of 300–400 m2 (Date et al., 2016; Pawar et al., 2014). Besides the 
enterocytes, the intestine also comprises mucus-secreting goblet cells, the second most 
abundant cell type, interspersed between the remaining intestinal cells. Antimicrobial 
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peptides-secreting Paneth cells are also present in the crypts, as well as the hormone-
secreting enteroendocrine cells (Gerbe et al., 2012; Pridgen et al., 2015). Another cell type, 
the specialized microfold (M) cells, are responsible for antigen transportation through a non-
degradative pathway to dendritic cells, and thus, may constitute a good target to the 
delivery/absorption of biomolecules (Kristensen and Nielsen, 2016; Pawar et al., 2014).  
While the small intestine is primarily responsible for digestion and absorption of 
nutrients, the colon participates in the maintenance of fluid and electrolyte balance, not being 
ideally suited for promoting the absorption of biomolecules. Moreover, colon does not fold 
upon itself to create additional microvilli, limiting the available surface area (Pawar et al., 
2014). However, colon may offer some advantages over the small intestine, such as lower 
levels of enzymatic activity, higher responsiveness to permeation enhancers, and prolonged 
transit/residence time (Maroni et al., 2012).  
The intestinal epithelium rests on top of the basal lamina (extracellular matrix), which 
separates it from the lamina propria. After being transported across the epithelial lining, 
molecules transpose into the lamina propria, which contains a network of capillaries that is 
responsible for their drainage into blood circulation. The capillaries converge into venules 
and, eventually, the portal vein that conveys material to the liver (Pridgen et al., 2015). All of 
the epithelial cells are interconnected with each other by tight junctions that have paramount 
importance in retaining the polarization of the epithelial cells and maintaining the integrity of 
the epithelium (Tsukita et al., 2001) (Figure 4). Tight junctions are structures formed by 
several proteins, including transmembrane proteins (occludin and claudin), cytoplasmic 
plaque proteins (Zona Occludens 1, 2 and 3 (ZO-1, ZO-2, ZO-3), cingulin, and 7H6) and 
regulatory proteins (Salama et al., 2006). This yields to very narrow spaces between 
neighboring cells, with typically average gap sizes of less than 15 Å (Pawar et al., 2014). The 
assemble of these junctional proteins is dynamic and they are constantly remodeling, forming 
pores possessing size and charge selectivity, which act as strict regulators of permeation 
through the paracellular space (Anderson and Van Itallie, 2009; Van Itallie et al., 2008). 
However, the paracellular space comprises less than 1% of the intestinal surface area, thus 
limiting the transport through this route to small hydrophilic drugs up to 700 Da (smaller than 
1 nm) (Chen et al., 2011; Renukuntla et al., 2013).  
On the other hand, transport across cells (transcellular transport) is largely limited by 
the cell membranes, consisting mainly of phospholipid bilayers, and restricted to lipophilic 
molecules (Chen et al., 2011). However, cells are able to use other mechanisms then just the 
passive diffusion and can take-up biomolecules with hydrophilic nature. This transport 
pathway may be divided into different endocytic mechanisms: phagocytosis, 
macropinocytosis, clathrin-mediated endocytosis and caveole-mediated endocytosis, which 
are adenosine triphosphate (ATP) dependents, and clathrin- and caveolae-independent 
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endocytosis, which are not ATP dependents (Chen et al., 2011; Conner and Schmid, 2003). 
These uptake mechanisms occur at the apical cell membrane, where biomolecules are 
taken-up, and then the transport occurs through cells within vesicles, releasing their contents 
at the basolateral pole (Chen et al., 2011). Thus, the transcellular transport is the most 
probable route for the absorption of biomolecules. 
 
Figure 4. The physical barrier of the intestinal epithelium to passage of peptides and proteins 
from the gut lumen to the basal lamina propria. Molecules may cross the cell membrane 
barrier by different mechanisms: (A) transcellular transport or (B) paracellular transport. 
Adapted from (Aguirre et al., 2016). 
 
 
4. Multistage platforms based in particulate carrier systems for the 
oral delivery of peptides and proteins 
  More than ever, the field of materials science is providing interesting tools to meet the 
challenge of developing drug carriers that are able to orally deliver peptides and proteins in a 
controlled manner and overcome the gastrointestinal hurdles, enhancing their bioavailability 
(Nitta and Numata, 2013). Polymeric, porous and lipid-based particulate delivery systems are 
the most commonly used for this purpose. The main advantages of these systems are the 
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protection of the peptides and proteins from degradation, the ability to control nanoparticle 
physicochemical properties, such as size and charge, and the high surface-volume ratio 
(Danhier et al., 2012; Yun et al., 2013; des Rieux et al., 2006).  
  Among the polymers, poly(lactic-co-glycolic acid) (PLGA), an aliphatic synthetic 
polyester co-polymer, is one of the most used to produce nanoparticles for the oral delivery 
of peptides and proteins. Besides the advantages above referred, PLGA is biodegradable 
and biocompatible, being FDA and EMA approved in drug delivery systems for parenteral 
administration. PLGA features can be modulated by the ratio between the monomers which 
constitute the polymer, exhibiting a wide range of erosion times, favorable degradation 
characteristics, leading to sustained release profiles, and tunable mechanical properties. 
There is also the possibility to modify the surface properties of PLGA particles and the 
described formulations and methods of production can be adapted to various types of drugs 
(Araújo et al., 2014; Fonte et al., 2015). Moreover there are several in vitro and in vivo 
studies demonstrating its efficiency (Araújo et al., 2014; Danhier et al., 2012; Reix et al., 
2012; Santander et al., 2009). However, poor drug loading (≈ 1%) and possible drug 
degradation, due to exposure to organic solvents and high shear stress during the 
preparation process, are disadvantages associated with their production techniques (Danhier 
et al., 2012). 
  Lipid-based carriers have well-known safety profiles, with some of them already 
established for large-scale production (Muller et al., 2011). As compared to some other 
systems, the solid-lipid nanoparticles (SLN), which represent a class of colloidal particles 
composed of lipids that are solid at both room and body temperatures, are promising. They 
have additional benefits to protect the encapsulated peptides and proteins and their physical 
stability, enhanced pharmacokinetic properties and modulated release of drugs (Geszke-
Moritz and Moritz, 2016). However, the SLN are often associated with poor drug 
encapsulation and loading, and drug release after polymorphic transition during storage. 
Moreover, the conditions used for their production can be severe, with the use of organic 
solvents and high temperatures (Geszke-Moritz and Moritz, 2016; Mehnert and Mader, 
2001). 
  Between the porous-biomaterials, porous silicon (PSi) has attracted a lot of attention 
for the administrations of proteins and peptides (Santos et al., 2014). PSi-based particulate 
systems have a large surface area and pore volume with adjustable diameters (2 - 50 nm), 
that can be easily controlled by altering the fabrication parameters, as well as higher drug 
loading capacity compared to the majority of the other materials. They present high stability, 
biocompatibility and biodegradability (Liu et al., 2013a; Liu et al., 2014; Salonen and Lehto, 
2008; Santos et al., 2014; Shahbazi et al., 2013). The modification of their surface is an easy 
process and it offers a unique advantage of mild aqueous drug loading conditions and the 
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possibility to avoid the use of harsh organic solvents, making it a simple process where the 
drug is retained inside the pores by physical adsorption or electrostatic interactions (Salonen 
and Lehto, 2008; Santos et al., 2014; Shahbazi et al., 2014). The top-down fabrication 
process also allows an easy scaling-up (Mäkilä et al., 2014). Likewise other particular 
systems, also PSi systems have some drawbacks. To produce the particles, very time 
consuming techniques need to be employed wich leads to a more expensive material in 
comparison to the other materials. Besides that, they have a burst release of loaded proteins 
and peptides and their safety profile is not established yet (Araújo et al., 2014; Shahbazi et 
al., 2014;   Shrestha et al., 2015). 
  Several strategies based on these three particulate delivery systems (polymeric-
based (Attivi et al., 2005; Damge et al., 2007; Ensign et al., 2012a), lipid-based (Li et al., 
2013; Zhang et al., 2006; Zhang et al., 2009; Zhang et al., 2012) and porous-based 
particulate delivery systems (Huotari et al., 2013; Kilpelainen et al., 2011)) have been 
proposed over the last years to address the abovementioned concerns for the oral 
administration of GLP-1 and GLP-1 analogs. However, none of the systems used for the oral 
administration of GLP-1 and GLP-1 analogs was able to fully address all the needs to 
overcome the barriers of the gastrointestinal milieu. Indeed, despite all the investment and 
time spent on the development of particulate systems over the past 40 years, not only for 
GLP-1 but also for other biopharmaceuticals as well, few formulations have reached clinical 
testing and significantly impacted the human healthcare (Valencia et al., 2013). 
  Thus, continuous efforts to understand these complex biomaterial−biological 
interactions would lead to ameliorate surface functionalities of particulate drug delivery 
systems. The functionalization of biologically inactive and biocompatible materials, to impart 
precise biological functions and provide physicochemical characteristics that can radically 
change the properties observed in bulk materials is considered a promising approach in drug 
delivery (Goldberg et al., 2007; Solanki et al., 2008).  
  The major advantages of the drug delivery system functionalization are: (i) the 
improvement of retention and transport properties; (ii) the increase in drug solubility, 
diffusivity and distribution along mucosal fluids; and (iii) the potential for targeted drug 
delivery to a specific tissue with minimal distribution to the surrounding ones (Lopes et al., 
2016; Plapied et al., 2011). Some important aspects of particle surface functionalization, 
however, need to be addressed during translation from experimental success to clinical 
practice (Mout et al., 2012). These are summarized in Table 2 and discussed in detailed 
elsewhere (Araújo et al., 2016b).  
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Table 2. Summary of the most important parameters and respective considerations for an adequate particle surface functionalization. 
 
Parameter Observations Refs. 
Conjugation 
methods 
Covalent conjugation is stronger and long lasting; 
Non-covalent conjugation is simpler and occurs spontaneously. 
(Doane and Burda, 2013; Leitner et al., 
2003) 
Hydrodynamic 
size 
Interaction between particles-cells is highly dependent on particle size: smaller particles 
present higher interaction when compared to larger particles. 
(Byrne et al., 2008; Gaumet et al., 2008; 
Nel et al., 2009; Roger et al., 2010; 
Shinde Patil et al., 2001) 
Surface charge 
Particularly important for non-covalent conjugation methods; 
Strong surface charge is often advocated to guarantee colloidal stability of the particulate 
systems; 
Positively charged particles exhibit higher internalization into cells; 
Neutrally charged particles avoid non-specific interactions in vivo. 
(Bourganis et al., 2015; Cho et al., 2009; 
das Neves et al., 2012; Griffin et al., 2016; 
Hirsch et al., 2013; Kaaki et al., 2012; 
Moulari et al., 2013; Plapied et al., 2011; 
Rahme et al., 2013; Verma and Stellacci, 
2010; Yu et al., 2011) 
System shape 
and surface 
topography 
Affect particles diffusivity and adhesion to cells; 
Spherical particles are internalized more efficiently due to constant contact angle with cells 
than other shaped particles; 
Interactions with cells are enhanced when particles present a rough topography. 
(Agueros et al., 2009; Amin et al., 2015; 
Champion et al., 2007; des Rieux et al., 
2013; Dunne et al., 2000; Nel et al., 2009; 
Niu et al., 2013; Panyam et al., 2003) 
Timing of 
conjugation 
Before production of the particles: conditions in which surface functionalization takes place 
may promote the release of active molecules and cross-reaction may occur with 
biopharmaceuticals; 
After production of the particles: poor control over the extent of ligand coupling to the 
surface of the particles after production. 
(des Rieux et al., 2013; Plapied et al., 
2011) 
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  Nevertheless, to successfully fulfill the oral delivery of peptides and proteins, there is 
the need to evolve and take advantage of the enormous progress made in biomaterials 
science, to design "smart” particulate drug delivery systems that can respond to the 
gastrointestinal environmental features. These characteristics may be variations in pH, ionic 
strength, redox potential or enzymatic activity (Gao et al., 2010). The response to stimuli can 
assume many forms like changing size, shape, surface characteristics, biomaterial solubility, 
degree of intermolecular association with the cargo, among others (You et al., 2010). 
Similarly, particles can also be tuned to provide selective or specific recognition and/or 
biocompatibility (De et al., 2009).  
  However, in certain cases, the use of individual materials and/or the manufacturing 
approaches to produce the particulate systems seem to compromise the potential of the final 
carrier, failing the goals to what they were designed for. To overcome these limitations, 
several techniques are being employed for adequate tailoring of drug delivery systems, and 
achieve what are called multistage platforms. A multistage platform can comprise one or 
more biomaterials, as individual or composite, resulting in entirely new systems embracing 
the best properties of each material. Biomaterials with tailored surface design are 
demonstrating to be exciting multifunctional tools that hold promise in overcoming the failures 
of the delivery of biopharmaceuticals based on traditional drug dosage forms and drug 
delivery approaches. Interestingly, such platforms may even capitalize from otherwise 
potentially deleterious features of the gastrointestinal tract to improve the absorption of orally 
delivered biopharmaceuticals. A summary of the main strategies and respective platforms 
can be found in Table 3. 
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Table 3. Strategies to improve absorption of biopharmaceutics loaded into particulate-based oral delivery systems. 
 
Parameter Strategies Platforms Refs. 
Mucoadhesion 
Increasing the gastrointestinal 
retention time of the carrier 
systems and drugs 
CS coated liposomes 
Mixed micelles 
PAA-coated nanoparticles 
Pectin-liposome nanocomplexes 
PEG coated nanoparticles 
pHPMA coated nanoparticles 
PMVC microparticles 
Polydimethylaminoethylmethacrylate sub-microparticles  
SLNs 
TMC nanoparticles 
(Bajka et al., 2015; Coco et al., 
2013; Cui et al., 2006; Fricker 
et al., 2010; Han et al., 2012; 
Kollner et al., 2015; Muller et 
al., 2014; Netsomboon and 
Bernkop-Schnurch, 2016; 
Niebel et al., 2012; Perera et 
al., 2015; Sajeesh and Sharma, 
2011; Shan et al., 2015; Sonia 
and Sharma, 2013; Thirawong 
et al., 2008; Tobio et al., 2000; 
Wilcox et al., 2015) 
pH 
pH-Sensitive platforms for 
tailoring the release of 
biopharmaceuticals 
BLG-pectin composite 
CS coated PLGA nanoparticles 
CS-Eudragit
®
 composite 
CS nanoparticles PLGA-Eudragit
®
 composite 
PLGA/porous silicon nanoparticles encapsulated in HPMC-AS 
polymer 
(Abouelmagd et al., 2015; 
Araújo et al., 2015b; Izadi et al., 
2016; Jelvehgari et al., 2010; 
Makhlof et al., 2009; 
Mukhopadhyay et al., 2015; 
Prasad and Dangi, 2015; 
Sharma et al., 2011; Shrestha 
et al., 2015; Sonaje et al., 
2010a; Sun et al., 2015; Wang 
et al., 2015) 
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Active and passive 
targeting 
Targeting at the absorption site: 
membrane transporters and 
receptors on the gastrointestinal 
tract 
Fc fragment conjugated to PLA-PEG nanoparticles 
Fab’ portion of the F4/80 Ab conjugated to PLGA-PEG 
nanoparticles 
UEA-1 modified PLGA nanoparticles and liposomes 
Alginate coated CS nanoparticles 
WGA functionalized PLGA nanoparticles 
Hydrophobic NPs (PS, PMMA, PHB, PLA, PLGA) 
AAL targeted albumin microparticle 
(Gao et al., 2013; Harokopakis 
et al., 1998; Jin et al., 2012; 
Kang et al., 2008; Laroui et al., 
2014; Pridgen et al., 2013; 
Rajapaksa et al., 2010; Roger 
et al., 2012; Wang et al., 2010; 
Xiao et al., 2013; Xiao et al., 
2014) 
Redox potential 
Redox potential-responsive drug 
carriers for controlled release 
Thioketal nanoparticles 
Glutathione treated single-protein nanocapsules 
CS and PASP composite 
RNP
O
 
(Vong et al., 2012; Wilson et al., 
2010; Zhao et al., 2011; Zheng 
et al., 2013) 
Absorption 
enhancers and 
enzymatic inhibitors 
Co-delivery of biopharmaceuticals 
with other modulators 
CS-PLGA nanoparticles conjugated with CPP (R8) 
CS-porous silicon nanoparticles conjugated with CPP (R8) 
CS-PLGA nanoparticles conjugated with CPP (Tat) 
SNEDDS conjugated with CPP (Tat) 
CS-PLGA nanoparticles conjugated with CPP (R8) 
encapsulated in HPMC-AS loaded with iDPP4 
CS-porous silicon nanoparticles coated with HPMC-AS loaded 
with iDPP4 
Na-CMC covalently bound to elastinal and BBI  
(Araújo et al., 2016; Araújo et 
al., 2015b; Guo et al., 2016; 
Mahmood et al., 2016; 
Marschutz and Bernkop-
Schnurch, 2000; Shrestha et 
al., 2016; Shrestha et al., 2015; 
Werle et al., 2007) 
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Abbreviations: AAL. Aleuria aurantia lectin; BBI. Bowman-Birk inhibitor; BLG. β-lactoglobulin; CS. Chitosan; CPP. Cell Penetrating Peptide; HPMC-AS. 
Hydroxypropyl methyl cellulose acetate succinate; IBD. Inflammatory bowel disease; iDPP4 – DPP4 inhibitor; LMW. Low molecular weight; Na-CMC. Sodium 
carboxymethylcellulose; PAA. Poly(acrylic acid); PASP. Poly(L-aspartic acid); PEG. Poly(ethylene glycol); PHB. Poly(hydroxybutyrate); pHPMA. N-(2-
hydroxypropyl) methacrylamide copolymer; PLGA. Poly(lactide-co-glycolide); PMMA. Poly(methyl methacrylate); PMVC. Poly (methacrylic acid-vinyl 
pyrrolidone)-chitosan; PPM. Mannosylated bioreducible cationic polymer; PS. Polystyrene; RNP
O
. Nitroxide radical-containing nanoparticle; SNEDDS. Self-
nanoemulsifying drug delivery systems; SLN. Solid lipid nanoparticle; TMC. Trimethyl chitosan; UEA-1. Ulex europaeus 1 lectin; WGA. Wheat germ agglutinin. 
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4.1. Increasing the gastrointestinal retention time 
  In order to avoid short transit time through the entire gastrointestinal tract, and thus, 
potentially increase the absorption of biopharmaceuticals, several drug delivery systems 
have been surface functionalized towards higher association with the mucus. This may allow 
slowing particle transport to the time scale of mucus renewal, avoiding their early clearance 
and increasing the proximity of peptides and proteins with the absorption site. Hydrophilic 
polymers possessing polar functional groups capable of forming hydrogen bonds with 
mucosal surfaces typically have excellent mucoadhesive properties (Andrews et al., 2009; 
Khutoryanskiy, 2011). The higher the density of surface functional groups able to establish 
adhesive bounds, the stronger the interaction with mucus will be (Andrews et al., 2009; 
Khutoryanskiy, 2011). Mucoadhesive polymers should have appropriate features regarding 
their concentration, flexibility, molecular weight, conformation, surface tension, chain 
structure and length, which are detailed elsewhere (Andrews et al., 2009; Rekha and 
Sharma, 2013). Among other commonly used polymers (described in more detail by Sosnik 
et al. (Sosnik et al., 2014)), such as alginate and derivatives (Deat-Laine et al., 2013; Yang et 
al., 2011a), pectin (Gungor et al., 2010; Li et al., 2014; Sharma et al., 2012), poly(acrylic 
acid) (PAA) (Kriwet et al., 1998; Makhlof et al., 2011) and cellulose derivatives (Rahmat et 
al., 2013; Suwannateep et al., 2011), CS is one of the most well-investigated and most used 
(Andrade et al., 2011; Prego et al., 2005; Takeuchi et al., 2001), featuring excellent ability to 
interact with mucus (Sigurdsson et al., 2006; Sosnik et al., 2014). 
  Particles functionalized with mucoadhesive polymers are able to bind to mucins at 
mucosae by either specific or non-specific interactions. Bonding may be categorized into 
ionic, covalent, hydrogen and van der Waals’ forces and hydrophobic interactions (Smart, 
2005). Despite several decades of research, the mucoadhesion phenomenon is still not fully 
understood. There are several theories that attempt to explain mucoadhesion mechanisms 
(Sosnik et al., 2014). However, due to the complex nature of adhesive interactions, these 
theories can only provide satisfactory understanding of mucoadhesion when combined. The 
more consensual theory in the biomedical field though is the diffusion (or interpenetration) 
theory. Briefly, it considers that after intimate contact is established, polymer chains diffuse 
into and entangle with the mucin fibers composing mucus, while simultaneously establishing 
adhesive bonding. The consolidation of adhesion occurs through the dynamic balance 
between diffusion, physical entanglement and adhesive/repulsive interactions (Rekha and 
Sharma, 2013; Smart, 2005). 
  Considering all the characteristics summarized in Table 2, such as the size and 
charge of the delivery systems, maximum mucoadhesive potential can only be achieved if 
multiple features of particulate systems are considered. Owing to the high surface area-to-
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volume ratio, nanoparticulate systems are once more promising carriers for the oral delivery 
of peptides and proteins, since the interface available to establish bonding with mucus 
dramatically increases, thus promoting long lasting bonding (Prego et al., 2005). 
Theoretically, decreasing size is associated with more intimate interactions and prolonging of 
residence time and drug oral bioavailability. Due to the width of the mesh spaces delimited by 
mucin fibers, it is expected that particulate systems below 1000 nm do not only adhere to the 
mucus, but also potentially penetrate it without causing harm (das Neves et al., 2011; 
Pearson et al., 2016). It was recently demonstrated by Bajka et al. that 100 nm bile salt 
coated particles diffuse more rapidly through porcine intestinal mucus than 500 nm bile salt 
coated particles (Bajka et al., 2015). More important than size, surface properties are able to 
define the adhesive behavior of nanosystems within the range of about 100−500 nm (Tang et 
al., 2009; Yang et al., 2011b). Indeed, as long as adhesive interactions are minimal, larger 
particles can also diffuse through mucus. Thirawonget et al. produced liposomes conjugated 
with pectin to improve the oral bioavailability of calcitonin (Thirawong et al., 2008). Modified 
liposomes were larger but had prolonged residence time in the gut, over at least 6 h, as 
compared to plain liposomes (Thirawong et al., 2008).  
  One additional interesting approach might be the sequential combination of both 
adhesive and penetrating properties in the same system. In one hand, mucoadhesion may 
contribute for prolonged residence time close to the absorption site while, on the other hand, 
overcoming the mucus barrier may enhance diffusion towards the absorptive surfaces of the 
gut. Köllner et al. presented a study in which they tested different drug delivery systems, 
namely a mucoadhesive nanocarrier based on thiolated PAA nanoparticles (PAA-cys), 
papain-modified PAA (PAA-pap) nanoparticles exhibiting mucolytic properties to enhance 
particle diffusion into deeper mucus regions before adhesion, as well as particles containing 
both conjugates (PAA-cys-pap nanoparticles) (Kollner et al., 2015). All the systems had a 
size range between 158−214 nm and presented negative zeta potential values. Reported 
data showed that the combination of both conjugates had a 2.0-fold higher penetration into 
the mucus layer in comparison with PAA-cys nanoparticles and a 1.9-fold increase in 
mucoadhesion for the nanoparticulate system based on thiolated PAA compared to PAA-pap 
nanoparticles (rheological studies). This render to the particles a higher retention time at the 
absorption site as well as a more intimacy contact with the epithelial cells (Kollner et al., 
2015). 
  As mentioned before, the effect of size is strongly dependent on the particle surface 
chemistry, in particular surface charge (Yildiz et al., 2015). Mucins have a low isoelectric 
point, which determines its negative charge at all physiological pH values of the 
gastrointestinal tract. This severely affects its interaction with the carrier systems as particles 
will undergo either repulsive or attractive electrostatic forces depending on whether these 
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systems present negative or positive surface charge, respectively. Thus, positively charged 
particles tend to present higher mucoadhesiveness even though there are some other 
players than just the electrostatic interactions that do not follow this “rule”, as for thyomers 
(Fonte et al., 2011; Miller et al., 1998; Shrestha et al., 2015). By contrast, negatively charged 
and uncharged particles, while still being able to promote hydrophobic bonding and van der 
Waals’ forces with mucin, are prone to have more mucopenetrating capacity (Netsomboon 
and Bernkop-Schnurch, 2016). The functionalization of nanoparticulate systems with 
polyethylene glycol (PEG) is the most commonly used strategy to render the systems 
mucopenetrating properties (Moulari et al., 2013). PEG not only renders a more neutral 
charge to the systems, but also make these more hydrophilic promoting unhindered transport 
across the mucus, which facilitates reaching intestinal epithelial cells and has the potential to 
enhance bioavailability (Crater and Carrier, 2010; Maisel et al., 2015; Plapied et al., 2011; Xu 
et al., 2015). 
  Using a system able of changing its surface charge from slightly negative to positive 
values at the intestinal level, for example, under the influence of intestinal alkaline 
phosphatase, may be an interesting approach to enhance the delivery of biopharmaceuticals 
(Figure 5) (Bonengel et al., 2015; Netsomboon and Bernkop-Schnurch, 2016; Perera et al., 
2015). Such carriers are able to feature unhindered transport until the intestine without 
significantly binding to gastric mucus or mucosa, but dramatically change their behavior to 
mucoadhesive by enzymatic influence. This possibility may favor the drug release at the 
absorptive site, i.e., the intestine, while abbreviating gastric residence and consequent loss of 
active biopharmaceuticals.  
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Figure 5. Schematic represents the design of a system capable of changing its zeta-potential 
from slightly negative to positive values at the intestinal level, favoring drug release at the 
absorptive site (Pereira de Sousa et al., 2015). 
   
  Besides charge, specific chemical moieties that may be present at the surface of 
particulate systems can also impact on the mucoadhesive behavior. The immobilization of 
mucolytic enzymes, such as papain, on the surface of nanoparticles will render them a 
mucopenetrating permeability of functionalized than plain particles. When formulated as 
enteric coated capsules and orally administered in Sprague Dawley rats, Muller et al. 
detected that the majority of papain-functionalized nanoparticles were able to traverse across 
the mucus layer and remained in the duodenum and jejunum of the small intestine, where 
drug absorption primarily occurs (Muller et al., 2014). A similar study was conducted by 
Pereira de Sousa et al. where they show that besides papain also bromelain can be used as 
a mucopenetrating agent character (Pereira de Sousa et al., 2015). The viscosity of the 
mucus strongly decreases leading to 3-fold higher penetration. 
  Overall, particulate systems with mucoadhesive properties are able to prolong the 
residence time in the gastrointestinal tract, ameliorating the contact between carrier systems 
and the mucus that covers the epithelial cells. In turn, mucopenetrating capacity has gained a 
lot of attention in the last years, since it allows a closer contact between the particles and the 
cells, thus increasing intestinal permeability. There is still a lot to discuss and to investigate 
regarding if one characteristic is better than the other, but a dual behavior of the particulate 
systems can be advantageous over a single one. 
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4.2 pH-sensitive platforms for tailoring peptides and proteins release 
Oscillations in the pH along the gastrointestinal tract are a big hurdle to overcome 
when administration of peptides and proteins is made by the oral route. Taking advantage of 
these variations, however, is becoming a popular approach towards the enhanced delivery of 
biopharmaceuticals. For example, pH-responsive systems can be tailor-made to circumvent 
the release of biological molecules in the stomach, while promoting site-specific release in 
the small or large intestine. Most of such pH-responsive systems are typically composed by 
polymers of anionic nature, alone or in mixture with each other or with other biomaterials, 
with great attention being devoted to acrylic, methacrylic and cellulose polymers (Colombo et 
al., 2009; Karimi et al., 2016; Rekha and Sharma, 2013). By changing the ratio between the 
components of the particulate systems, one can yield different release profiles (Yoshida et 
al., 2013). Polyacidic polymer chains are reticulated and condensed at low pH because their 
acidic groups will be protonated, and thus, unionized (Balamuralidhara et al., 2011). Particles 
can be either prepared from or simply functionalized with these pH-sensitive polymers by 
surface coating. When particles are exposed to biological fluids at an appropriate pH, their 
porosity changes and polymeric chains swell or shrink in a controllable manner in response 
to proton concentration, which represents the key point for the controlled release of 
biopharmaceuticals (Colombo et al., 2009). Thus, the release from the particles is largely 
dependent on the properties of the peptides and proteins and the swelling pattern of the 
polymer(s) at a specific pH (Lowman et al., 1999; Peppas, 2004).  
Most of the pH-sensitive carriers used for oral administration of biopharmaceuticals 
have been used as enteric coating materials of classical pharmaceutical dosage forms and 
several of them have been approved by the FDA (Renukuntla et al., 2013; Yoshida et al., 
2013). The most commonly used for oral delivery purposes are poly(methacrylic acid-co-
methyl methacrylate) (Eudragit® L, S and F), (hydroxypropyl)methyl cellulose phthalate 
(HPMCP) and (hydroxypropyl)methyl cellulose acetate succinate (HPMC-AS). These 
polymers have different grades, corresponding to the different pH values at which the 
polymers are soluble (Yoshida et al., 2013).  
Different works have already proven the efficacy of these systems in controlling the 
release of biopharmaceuticals in a pH-dependent manner, i.e., at specific site, which resulted 
in their higher absorption, and hence in ameliorated biological response (Jelvehgari et al., 
2010; Sharma et al., 2011). Sun et al. encapsulated a complex of insulin-sodium oleate into 
PLGA nanoparticles (213 nm), which were further encapsulated into Eudragit® FS 30D by 
organic spray-drying method, originating microcapsule composites of 1–5 µm (Sun et al., 
2015). In vitro results revealed that drug release was pH-dependent, and in vivo results using 
a Streptozotocin (STZ) induced T1DM rat model demonstrated a relative bioavailability of 
CHAPTER I 
26 
about 16%, while for free insulin it was less than 0.5%. Thus, the microcapsule composites 
were demonstrated to be an effective candidate for oral insulin delivery (Sun et al., 2015).  
Shrestha et al. proposed an alternative system for the GLP-1 delivery, in which CS-
coated PSi nanoparticles (208 nm) were incorporated into HPMC-AS nanoparticles (≈ 830 
nm) by using an aerosol flow reactor (AFR) (Figure 6) (Shrestha et al., 2015). In vitro results 
indicated that there was no release of the peptide at pH 1.2, but at pH 6.8 the release was 
40% after 6 h (Shrestha et al., 2015). When tested in vivo using a T2DM rat model, blood 
glucose levels were reduced by 32% at 8h after particles administration (Shrestha et al., 
2016). 
Other systems have also been tested. In those studies, particulate systems (either 
nanoparticles or microparticles) were mainly composed of positively-charged CS and 
negatively-charged polymer, such as Eudragit® (Jarvinen et al., 1998; Li et al., 2006), poly(γ-
glutamic acid) (Sonaje et al., 2010a; Sonaje et al., 2010b; Sonaje et al., 2010c), alginate 
(Chen et al., 2004; Li et al., 2007; Mukhopadhyay et al., 2015), or methacrylic acid (de Moura 
et al., 2008). Sonaje et al., for example, used insulin-loaded particulate systems (≈ 200 nm) 
made of CS and poly(γ-glutamic acid) (Sonaje et al., 2010b). After oral administration using a 
T1DM STZ-induced rat model, significant hyperglycemia occurred, and the corresponding 
relative bioavailability of insulin was ≈ 15% (Sonaje et al., 2010b). Mukhopadhyay et al. 
attempted to deliver insulin in a pH-responsive manner by using CS/alginate core-shell 
nanoparticles (100-200 nm) (Mukhopadhyay et al., 2015). In vitro release studies showed 
that almost all the encapsulated insulin was retained inside the system in simulated gastric 
buffer. However, sequential sustained insulin release in simulated intestinal conditions was 
demonstrated. When tested in vivo, in a diabetic mice model, the insulin-relative 
bioavailability was 8 % with significant hypoglycemic effects observed (Mukhopadhyay et al., 
2015).  
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Figure 6. Schematic representation of the different steps involved in the preparation of pH-
sensitive polymer coated CS-modified PSi nanoparticles (H-CSUn). The PSi nanoparticles 
(UnPSi) (1) are modified with CS using carbodiimide crosslinker chemistry to form CSUn 
nanoparticles (2). (3) Glucagon-like peptide-1 (GLP-1) is loaded into the CSUn nanoparticles 
by immersion technique at room temperature (RT) for 90 min. (4) The CSUn nanoparticles 
are dispersed in the aqueous pH-responsive polymeric solution of HPMCSAS-MF containing 
an inhibitor of the dipeptidyl peptidase-1 enzyme (iDPP4) to prepare the feed dispersion. The 
dispersion is fed into the AFR via atomizer, where is first broken down into aerosol, which is 
then carried out to the heating chamber by nitrogen (N2) gas. The aerosols are dried in the 
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heating chamber (5), and then collected in the collection chamber (6). For synergistic 
therapy, along with an antidiabetic peptide (GLP-1) which was loaded into the pores of CSUn 
nanoparticles and iDPP4 was loaded in the matrix of the polymeric layer. (7) Schematic 
representation of the final H-CSUn particles (Shrestha et al., 2015). 
 
4.3 Redox potential-responsive drug carriers for controlled release 
The course of various cellular signaling pathways depends on the redox state of the 
cells and their surrounding environment (González-Flecha and Demple, 2002; Sun and 
Oberley, 1996). The redox state consists in the ratio of the interconvertible oxidized and 
reduced form of a specific redox pair (Schafer and Buettner, 2001). Several studies have, in 
fact, reported that the difference in potential redox level observed between intra and 
extracellular environments varies in several orders of magnitude, specifically <0.01 nM 
glutathione (GSH) for the extracellular fluid, while for the cytoplasm ranges from 1  to 11 mM 
of GSH (Remant et al., 2014; Schafer and Buettner, 2001). 
Beyond the abovementioned pH-responsiveness, a new generation of drug carriers 
has been also endowed with stimuli-responsive features in terms of redox potential, 
contributing to satisfy the trend of non-invasive therapy. In this context, and taking advantage 
of physiological signals, redox-responsive drug carriers hold enormous potential for varying 
biomedical applications. The basic principle of such systems consists on the proper 
molecular design and related synthetic methodology to enable the utilization of distinct 
differences in redox potentials. 
In fact, polymeric nanomaterials incorporating different redox-responsive functional 
groups acquire “intelligence” that allows for drug transport to the required region (Huo et al., 
2014). Zhao el al., for example, engineered single-protein polymeric nanocapsules with a 
redox-responsible, disulfide-containing crosslinker for escorting proteins to the cytosol in a 
controlled release fashion (Zhao et al., 2011). The authors describe the non-covalent 
encapsulation of the target protein through in situ interfacial polymerization into a positively-
charged polymeric shell interconnected by disulfide-containing crosslinkers (Figure 7). The 
nanocapsules were shown to be rapidly degraded when treated with physiologically relevant 
concentrations of GSH, being then internalized into cells and efficiently delivered functional 
proteins in a variety of cell lines (Zhao et al., 2011).  
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Figure 7. Formation of redox-responsive protein nanocapsules. (a) Schematic of protein 
nanocapsules with redox-responsive polymeric matrix (R and R’ represent different 
monomers’ moieties); and (b) Chemical structures of monomers and crosslinker for disulfide 
nanocapsules (Zhao et al., 2011). 
 
4.4 Targeting at the absorption site: membrane transporters and receptors on 
the gastrointestinal tract 
One of the greatest advantages in functionalizing the surface of multistage delivery 
systems is the possibility to tune them for selective or specific recognition of molecules or 
sites. In the particular case of oral delivery of peptides and proteins, this strategy allows for 
the direct targeting of molecules present at the small or large intestine cells, increasing the 
local concentration of the administered biopharmaceuticals by releasing them when the 
particle is bound to the target, and potentially increasing the uptake and endocytosis of orally 
delivered molecules (Subbiah et al., 2010).  
Even constituting solely 1% of the total cell population, M cells are the most studied 
among the different cell types present at the intestinal epithelium when considering the oral 
delivery of particulate systems (des Rieux et al., 2006). Due to their physiological functions, 
these cells seem to be the perfect target for the uptake of carrier systems. Many potential 
target ligands, either specific or non-specific, have been described as expressed by M cells 
(des Rieux et al., 2006; des Rieux et al., 2013; Wong et al., 2003). Lectins, for example, are 
commonly used to target M cells (Figure 8). Lectins are a structurally diverse group of 
proteins and glycoproteins that reversibly and with relatively high affinity bind to carbohydrate 
moieties and tether mucins at cell membranes, (des Rieux et al., 2006; des Rieux et al., 
2013). Due to the variability of carbohydrate expression from cell-to-cell type, the use of 
lectins allows targeting for specific sites within the intestinal tract. Binding of particles 
functionalized with lectins to M cells can occur by either adsorption or covalent coupling 
(Clark et al., 2001; des Rieux et al., 2006; des Rieux et al., 2013; Plapied et al., 2011). The 
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most used lectin is wheat germ agglutinin (WGA), known to bind to N-acetyl-D-glucosamine 
and sialic acid residues. Wang et al. conjugated WGA to the surface of PLGA nanoparticles 
and observed increased cytoadhesive and cytoinvasive properties when comparing to non-
functionalized nanoparticles, attributed to the over expression of N-acetyl-D-glucosamine-
containing glycoproteins in the colon intestinal cells (Wang et al., 2010). Other lectins, such 
as galectin 9 and sialyl Lewis A antigen, have also been described as ligands for M-cells 
(Pielage et al., 2007). Noticeably, Ulex europaeus agglutinin-1 (UEA-1) and Aleuria aurantia 
lectin (AAL), which are able to bind to α-L-fucose and are often considered as M cell ligands, 
can target some animal species, but not humans (Clark et al., 2001; D'Souza et al., 2012; 
Gupta et al., 2013). These are non-conserved inter-species epitopes, losing thus their appeal 
for clinic use. 
 
 
 
 
 
 
 
 
Figure 8. Strategies for surface modification of carrier systems targeting M cells, including 
lectin-anchored systems that specifically recognize glycoproteins expressed in the surface of 
M cells, specific targeting though carrier coating and specific targeting to the transmembrane 
receptor claudin 4. Figure produced using Servier Medical Art. 
 
Another strategy for targeting M cells is related to their own function. M cells are 
responsible for presenting pathogens to neighboring immune cells through endocytic 
pathways (des Rieux et al., 2013). Therefore, it has been hypothesized that functionalization 
of carrier systems with microbial molecules might also lead to increased cell uptake  (Clark et 
al., 2001). In this context, coupling microbial adhesins from bacterial species, such as protein 
invasion (Yersinia) and long polar fimbria (LPF) (Salmonella), to the surface of particulate 
systems would favor their internalization in the intestinal mucosa (Clark et al., 2001; des 
Rieux et al., 2006; Pielage et al., 2007). Moreover, specific viral proteins or peptides 
responsible for M cell adhesion, such as those expressed in the reovirus (8 haemagglutinin 
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σ1 protein) can be attached to particles in order to target M cells (Clark et al., 2001). In a 
similar approach, Rajapaksa et al. produced sub-micron sized PLGA particles incorporating 
influenza hemagglutinin with or without the c-terminal targeting peptide clostridium 
perfringens enterotoxin (CPE)30, which is known for its binding ability to claudin 4, another 
transmembrane protein highly expressed in M cells (Rajapaksa et al., 2010). The authors 
observed increased uptake of targeted nanoparticles in both in vitro and in vivo uptake 
studies. Thus, targeting particles to claudin 4 can also be considered as a potential strategy 
to ultimately increase biopharmaceuticals uptake (Figure 8) (Lo et al., 2012; Rajapaksa et 
al., 2010). 
M cells apical membrane receptors have also been suggested as other promising 
targeting molecules for oral delivery of biopharmaceuticals. Cholera toxin (Ctx) and its 
derivatives, for example, are frequently co-administered with mucosal antigens in order to 
enhance immunogenicity (Mestecky et al., 1997; Williams et al., 1999). In fact, these mucosal 
adjuvants display high affinity to its non-toxic B subunit (CtxB) present in Ganglioside GM1 
receptor of the apical membranes of M cells (Clark et al., 2001; des Rieux et al., 2006; 
Fievez et al., 2009). Consistently, Haropakis et al. demonstrated amplified effectiveness of 
liposomes as antigen delivery systems after conjugation with recombinant CtxB following oral 
administration in mice (Harokopakis et al., 1998). Several specific pathogen recognition 
receptors (PRR), also present and overexpressed at the apical membrane of M cells, such as 
platelet-activating  factor  receptor, Toll-like receptor-4 (TLR-4) (Kyd and Cripps, 2008), 
glycoprotein 2 (GP2) (Kim et al., 2012) and α5β1 integrin (Kyd and Cripps, 2008) could serve 
the same purpose (des Rieux et al., 2006; Plapied et al., 2011).  Thus, the use of peptides, 
such as Arg-Gly-Asp (RGD) and Leu-Asp-Val (LDV) or peptidomimetics (RGDp and LDVp), 
can be useful ligands for targeting these receptors aiming for ameliorated strategies for 
increased uptake of orally delivered biopharmaceuticals (Fievez et al., 2009; Mundargi et al., 
2008). Interestingly, previous studies have reported the use of such ligands to functionalize 
the surface of PLGA and PLGA-based nano- and micro-particles with encouraging results 
(Fievez et al., 2009; Mundargi et al., 2008). 
Similarly to M cells, enterocytes have also been investigated for targeting at the 
absorption site. Enterocytes are the main responsible for nutrient absorption and are the 
most abundant cells in the small intestine, being therefore an immediate target for particulate 
systems. As in the case of M cells, lectins are also moieties that can be used for targeting 
enterocytes. WGA, tomato lectin (TL) and concanavalin A (ConA) are examples of such 
lectins; WGA and TL bind specifically to N-acetyl-D-glucosamine, whereas the ConA binds to 
α-D-mannose residues (des Rieux et al., 2013; Zhang et al., 2005).  
Molecules that bind specifically to receptors of the apical membrane of enterocytes, 
such as biotin, vitamin B12, vitamin B1 (thiamide) and folic acid, reveal to have promising 
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features for developing strategies to achieve absorption and/or particle uptake by enterocytes 
(Roger et al., 2012; Simons and Fuller, 1985; Youn et al., 2008). Roger et al. evaluated the 
effect of folic acid functionalization on transcellular transport of PLGA nanoparticles (213 
nm), and observed an 8-fold higher transport compared to the free therapeutic agent tested 
(Roger et al., 2012). Interestingly, confocal microscopy studies revealed that the 
functionalized particles internalized by the cells did not compromise the integrity of the tight 
junctions, reinforcing the potential of this system to enhance the absorption of drugs with 
poor oral bioavailability (Roger et al., 2012). 
Other receptors, such as TLR-4 or the neonatal Fc receptor (FcRn), can be a target 
also for enterocytes (Neal et al., 2006). FcRn is receiving particular attention over the last 
years for therapeutic applications, since it naturally mediates the transport of immunoglobulin 
G (IgG) antibodies across epithelial barriers, by interacting with the Fc portion of IgG (Martins 
et al., 2016). Recently, Pridgen et. al. described a PLA-PEG block copolymer-based 
particulate system (55 nm), loaded with insulin and functionalized with an Fc-thiol surface 
ligand groups to target the FcRn (Figure 9) (Pridgen et al., 2013). After oral administration of 
Fc-decorated nanoparticles to mice, a prolonged hypoglycemic response was elicited in wild-
type animals, superior to that observed in animals treated with untargeted systems. Also 
interestingly, hypoglycemia was absent in FcRn knock-out mice (Pridgen et al., 2013). 
 
Figure 9. Schematic of Fc-targeted nanoparticle transport across the intestinal epithelium by 
the FcRn through a transcytotic pathway. IgG Fc on the nanoparticles surface binds to the 
FcRn on the apical side of absorptive epithelial cells under acidic conditions in the intestine, 
nanoparticles-Fc are then trafficked across the epithelial cell through the FcRn transcytosis 
pathway in acidic endosomes. Upon exocytosis on the basolateral side of the cell, the 
physiological pH causes IgG Fc to dissociate from the FcRn, and nanoparticles-Fc are free to 
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diffuse through the intestinal lamina propria to the capillaries or lacteal and enter systemic 
circulation. Figure produced using Servier Medical Art. 
 
Another approach to consider for achieving specific target of particulate systems 
could be the use of receptors of bacteria present within the intestinal flora. For example, 
enterocytes can be targeted by the conjugation of Ctx or F4 fimbriae to particulate systems. 
Ctx is a protein complex which binds to GM1 gangliosides, being also present on the surface 
of enterocytes, and F4 fimbriae allow the microorganisms to adhere to F4-specific receptors 
present on the brush borders of villi (Melkebeek et al., 2012; Van den Broeck et al., 2000). 
Among enteroendocrine cells, L cells are the most promising targets for functionalized 
carrier systems. Plenty of lipidic ligands can bind to their various surface-expressed, G-
protein-coupled receptors (GPCRs), namely GPR109a, GPR119, GPR120 and GPR40, and 
could serve as targets for coated particles (des Rieux et al., 2013). TGR5 receptor (also 
known as M-BAR, GPBAR-1 or GPR131), also belonging to the GPCRs superfamily, could 
also be targeted by bile acids, and therefore, promote increased cellular uptake of 
functionalized particles (des Rieux et al., 2006). 
Even representing the second most abundant cell type in the intestine and the 
responsible for mucus production, goblet cells are not a common choice for targeting. In fact, 
most strategies involving goblet cells are usually based on establishing interactions with 
mucins present at mucus. For instance, Jin et al. used the peptide CSKSSDYQC (CSK), 
which shows affinity to the mucus released by these cells, to modify particulate systems (318 
– 342 nm) and allow them to use goblet cells as their specific gateway (Kang et al., 2008). 
Nevertheless, Jin et al. extensively investigated the effects of targeting nanoparticles to 
goblet cells and the influence of the functionalization if oral absorption of insulin (Jin et al., 
2012). For this purpose, the authors developed insulin loaded nanoparticles using trimethyl 
CS chloride (TMC) modified with CSK. In summary, in vitro, ex vivo and in vivo studies 
revealed that CSK functionalized particles enhanced the uptake of the TMC nanoparticles, 
even when the targeting recognition was partially affected by mucus, and increased the 
insulin permeation across the epithelium. Additionally, the modified particles induced a 
significant increase in insulin internalization via clathrin and caveolae mediated endocytosis 
on the goblet cells (Jin et al., 2012). Consistently, better hypoglycemic effects were observed 
in diabetic rats after oral administration of the CSK-TMC nanoparticles when compared to the 
results obtained from the administration of unmodified particles. 
The examples described within this section are still at early preclinical stages and 
have been developed mostly by academia. However, several technologies are also being 
developed by the pharmaceutical industry towards the oral delivery of biopharmaceuticals 
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using intestinal targeted systems. TrabiOral™ (Transgene Biotek Ltd, India), for example, is 
a platform using SLN functionalized with an active ligand claimed to be specific for a 
previously undescribed intestinal transporter. It has been suggested that targeting this 
receptor may be advantageous when compared to vitamin B12 and transferrin receptor 
targeting, namely due to its ability to provide relatively higher uptake, as well as the low cost 
and versatility of ligand conjugation (Aguirre et al., 2016). Similarly, the same company has 
another patent that claims a surface modification of lipid nano/micro particles containing 
WGA as a ligand, which targets the particulate systems to the intestine (Rao, 2008).  
 
4.5 Co-delivery of biopharmaceuticals with other modulators 
A final alternative strategy to maximize drug systemic bioavailability after oral 
administration consists in the concomitant delivery of peptides and proteins with other 
modulators, such as absorption enhancers or enzymatic inhibitors. In spite of not being 
considered as a direct functionalization of drug delivery systems, the inclusion of modulators 
in the formulation of nanoparticulate systems holds potential as a parallel strategy to 
enhance oral absorption of drugs with non-optimal delivery properties. Several modulators 
have already been tested and are therefore reviewed in this section. 
 
4.5.1 Absorption enhancers 
Absorption enhancers may be considered functional excipients, which can be 
included in the formulation of particulate systems to improve the absorption of orally 
delivered peptides and proteins (Aungst, 2012). These compounds have been investigated 
as such since the 1960s and, as suggested by their name, are recognized for increasing the 
transport of the molecules through the epithelial barriers. Enhancement can be reached by 
either of two mechanisms: (i) increasing paracellular permeability, due to a slight and 
reversible modification of tight junctions conformation, which leads to larger paracellular 
spaces, and thus, less steric hindrance, or (ii) increasing the transcellular permeation, by 
which disruption of the packing of membrane lipids and changes in membrane fluidity lead to 
the modification of the cell membrane structural integrity (Figure 10) (Aungst, 2012; Kondoh 
and Yagi, 2007; Maher et al., 2016). In all cases, these approaches can compromise 
mucosal membrane barriers and thus can be considered potentially toxic (Maher et al., 
2009), especially in the case of long-term usage. Chronic administration of absorption 
enhancers may cause serious side effects such as permanent damage to the intestinal 
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epithelium and undesirable passage of certain toxins, viruses and pathogens across the 
intestine (McCartney et al., 2016; Scott Swenson and Curatolo, 1992).   
 
 
 
 
Figure 10. Strategies for oral delivery of peptides and proteins that act on local or systemic 
targets. Absorption enhancers and enzymatic inhibitors can also be included in the 
formulation to further improve gastrointestinal resistance. To achieve meaningful systemic 
exposure, absorption enhancement by tight junction-disrupting excipients is often needed. 
Adapted from (Moroz et al., 2016). 
 
  Some of the most traditional absorption enhancers with prominent effects are bile 
salts, fatty acids, chelating agents (form complexes with calcium ions, leading to tight junction 
rupture (Aungst, 2000; Park et al., 2011)), zonula occludins toxin (ZOT) peptide (Lee et al., 
2016), and polymers like CS (Lee et al., 2016) or thiolated polymers (Kondoh and Yagi, 
2007). Particulate systems themselves can also act as absorption enhancers if surfactants 
are used during their production (Aungst, 2000), or due to their possible lipophilic nature, 
which is able to promote pore formation and damage the integrity of cell membranes (Lee et 
al., 2005; Leone-Bay et al., 2001).  
  Short peptide sequences, known as cell-penetrating peptides (CPP), have also been 
described for acting as absorption enhancers when conjugated with particulate systems 
(Wang et al., 2014). Originally considered as a “Trojan horses”, CPPs have the ability to 
enter cells and increase transcellular transport without causing damage or eliciting a cellular 
response (Palm-Apergi et al., 2009; Shi et al., 2014; Wang et al., 2014). CPPs can be divided 
according to their nature into cationic peptides, such as HIV-1 Tat and oligoariginine, or 
amphiphilic peptides, such as penetratin. Different from ligands described in the previous 
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section, CPPs have the ability to increase the permeability of various types of cells with no 
specificity for one particular type over the others (Amin et al., 2015). A study made by Guo et 
al. (Guo et al., 2016) showed that the cellular uptake amount and transcellular transportation 
performance of PLGA nanoparticles modified with CS and a Tat CPP were enhanced 
compared with those of without CS and plain particles. The efficacy evaluation, using a 
diabetic rat model, demonstrated that the hypoglycemic effect of Tat-CS functionalized 
nanoparticles, loaded with insulin, was 6.89 times higher than that of plain particles and 1.79 
times higher than the CS modified particles (Guo et al., 2016).  
  Due to the positive charge of some CPPs, zeta-potential is thought to be one of the 
possibilities for their role in cellular uptake. However, even particulate systems which are 
conjugated with CPP and have negative zeta-potential still present effective cellular uptake. 
The mechanism through which CPP enter the cells is still unclear, but there is a consensus in 
two major mechanisms: direct penetration and endocytosis (Barany-Wallje et al., 2005; 
Christiaens et al., 2004). Nevertheless, CPPs like any other peptide in general, suffer from 
shortcomings, such as typical short duration of action. 
  Considering all of the above discussed features of absorption enhancers, only few of 
them are presently in use in clinical practice due to the difficulty of developing enhancers with 
high specificity and low toxicity. Though not based in the use of nano or micro particulate 
systems, there are already products in clinical trials or even in the market using absorption 
enhancers, showing their positive role in the absorption of biopharmaceuticals that may be 
promising candidates to use in further developments of particulate systems for oral delivery 
of biopharmaceuticals (Aungst, 2012; Choonara et al., 2014; Ding et al., 2004; Kidron, 2007; 
Luzio et al., 2010; Maher et al., 2009; Maher et al., 2016; Tillman et al., 2008). 
 
4.5.2 Enzymatic inhibitors 
Proteins and peptides are highly susceptible to degradation by several enzymes 
present in the gastrointestinal tract, as previously discussed. Therefore, inhibiting these 
degrading enzymes can be an interesting approach to increase the amount of biologically 
active molecules that can reach the intestinal cell layer and may undergo absorption (Figure 
10). Selection of the appropriate enzymatic inhibitor is entirely dependent upon the structure 
and nature of the peptide or protein to be delivered and its overall metabolism (Pawar et al., 
2014). Common examples of intestinal protease inhibitors include: aprotinin (inhibitor of 
trypsin and chymotrypsin), soybean trypsin inhibitor (inhibitor of pancreatic endopeptidases), 
FK448 (chymotrypsin inhibitor), and chicken ovomucoid (trypsin inhibitor) (Choonara et al., 
2014). The inhibitors may be further divided regarding their nature in either aminoacid-based 
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or non-aminoacid-based inhibitors. Those based on aminoacids bind in a competitive way to 
the active site of the enzyme and may not be completely effective due to their rapid dilution, 
digestion and/or absorption along the gastrointestinal tract (Bernkop-Schnurch, 1998; Moroz 
et al., 2016). One example of the use of aminoacid-based enzymatic inhibitors is the study 
performed by Marschutz et al. (Marschutz and Bernkop-Schnurch, 2000). This group 
developed a carrier system for the oral delivery of insulin using elastatinal and Bowman–Birk 
inhibitors covalently bound to sodium carboxymethylcellulose (Na-CMC), a mucoadhesive 
polymer. They showed that the activity of trypsin and chymotrypsin was inhibited to a great 
extent with only 22.3 ± 2.5% (mean ± SD, n=3) of peptide degradation in comparison with the 
system without inhibitor, in which all of the drug was metabolized after 1 h (98.7 ± 0.4%) 
(mean ± SD, n=3) (Marschutz and Bernkop-Schnurch, 2000). In another work, Werle et al. 
(Werle et al., 2007) produced a carrier system by covalently attaching a trypsin/chymotrypsin 
inhibitor (aprotinin) to CS. These conjugates were proven to protect proteins against 
proteolytic enzymes in vitro through enzyme assays and in vivo using a rat model. Here, the 
mean blood glucose level was decreased to 84 ± 6% 8 h after administration, in contrast to 
the control where the mean blood glucose level increased to 121 ± 8% of the initial measured 
blood glucose level (Werle et al., 2007).  
  Besides the use of inhibitors that directly bind to enzymes and reduce or hinder their 
activity in a reversible or irreversible way, metabolism of active peptides and proteins may 
also be preventable, in an indirect fashion, by using modulators that change pH. Modifying 
proton concentration to values that inhibit specific enzymes may be considered for protecting 
active biopharmaceuticals, such as in the case of using citric acid, which changes the pH 
from 6 to 3 (Aungst, 2012; Friedman and Amidon, 1991; Moroz et al., 2016; Welling et al., 
2014). As in the case of absorption enhancers, the long term use of enzyme inhibitors may 
also cause some toxic events at the gastrointestinal tract and induce non-specificity in action 
via altering the normal metabolic pathways, which may lead to delayed digestion of proteins 
from the normal diet, intestinal mucosal damage and feedback-regulated protease secretion 
(Choonara et al., 2014; Moroz et al., 2016; Pawar et al., 2014). 
  Considering the pros and cons of the co-delivery of peptides and proteins with a 
single modulator, either an absorption enhancer or an enzymatic inhibitor, it seems that a 
combination of both may prove to be more feasible in improving oral bioavailability (Araújo et 
al., 2012). Enteris BioPharma Inc. (Boonton, New Jersey, United States) has developed the 
clinically tested Peptelligence™ technology, which comprises an enteric-coated tablet with 
two key components: a permeation enhancer and an enzyme inhibitor. These excipients are 
released in the small intestine, where the permeation enhancer loosens tight junctions 
between the intestinal epithelial cells and the enzyme inhibitor transiently decreases the 
intestinal pH in order to inactivate the enzymatic activity. As an example of the application of 
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Peptelligence™ technology for the oral delivery of biopharmaceuticals, Unigene Laboratories 
Inc. (New Jersey, USA) scientists formulated salmon calcitonin as an enteric-coated tablet, 
choosing lauroyl L-carnitine as preferred permeation enhancer. The company licensed the 
developed formulation of oral calcitonin to Tarsa Therapeutics Inc. (Philadelphia, USA), and 
the product TBRIA™ is currently in late-stage clinical trials for the treatment and prevention 
of postmenopausal osteoporosis in collaboration with Novartis (Crotts et al., 2002).  
 
 
5. Microfluidics for multisystems platforms production 
Traditional methos are still extensively employed in the preparation of multistage 
platforms based on particulate carrier systems. However, due to the lack of precision in the 
control of the production processes, these methods have faced critical challenges, such as 
the polydisperse size distribution and batch-to-batch variability, which hinder their scale-up. 
Moreover, frequently these methods require personal staff while doing the production of the 
systems, with a high amount of lab glassware and other equipment needed and with the 
produced batches having low yields (Kim et al., 2012; Liu et al., 2013b). 
Hence, biomaterials science together with physics, chemistry and nanotechnology 
sciences, among others, took a step forward in the the development of miniaturized systems 
for drug delivery applications (Craighead, 2006; DeMello, 2006; Valencia et al., 2012; Yager 
et al., 2006). These miniaturized systems, with few square centimeters, offer several 
advantages over the traditional macroscale systems for the production of particulate carriers, 
shrinking thus traditional bench systems (Mazzitelli et al., 2013; Janasek et al., 2006). 
Microfluidics is one of these miniaturized systems and gained a lot of popularity due 
to the possibility of manipulating nanoliter and sub-nanoliter volumes in microscale fluidic 
channels, with dimensions of tens to hundred micrometers (Valencia et al., 2012; Whitesides, 
2006). Using the microfluidic technique it is possible to assemble different biomaterials 
towards the production of multistage platforms. Microfluidics offers an effective control over 
the characteristics of produced systems, leading to a narrow size distribution and high batch-
to-batch reproducibility. Moreover, it has the advantage of encapsulate different cargos with a 
theoretical efficiency of 100% (Valencia et al., 2012; Yang et al., 2012).  
Very briefly, the preparation of emulsions through microfluidics involves the injection 
of the dispersed phase into another immiscible or partially immiscible continuous phase, 
through a specially design microfluidics device. The most commonly used geometries are the 
T-junction (Garstecki et al., 2006; Murshed et al., 2009), co-flow (Cramer et al., 2004; Xiong 
et al., 2007), cross-flow (Xu et al., 2005; Wagdarea et al.) and flow focusing (Schmid and 
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Franke, 2013; Yobas et al., 2006). These devices can be also fabricated using four different 
materials as glass capillaries (Duncanson et al., 2012), polydimethylsiloxane (PDMS) 
(Whitesides, 2006), metal (Görke et al., 2005) or poly(methyl) methacrylate (Ogilvie et al., 
2010).  
Since in the work described below, only microchips made with glass capillaries with a 
flow-focusing geometry were used, a focus on these systems seems relevant in relation to 
the others. These chips have a real three-dimensional geometry and consist of the coaxial 
assembly of a series of glass capillaries on glass slides. Glass capillaries present the 
advantages of having chemical resistance, excellent optical properties, low electric 
conductivity, smooth surface and easily and precisely controlled surface wettability 
(Duncanson et al., 2012; Shah et al., 2008; Vladisavljević et al., 2013). For the production of 
single emulsion particles in the flow-focusing geometry devices, the dispersed phase flows 
inside the square capillary and the continuous phase flows between the square and round 
capillary in the opposite direction (Figure 11). The dispersed phase is focused by the 
continuous phase through the narrow orifice of the tapered round capillary, which is known 
as hydrodynamic flow-focusing. The continuous phase exerts pressure and shear stress that 
force the dispersed phase into a narrow thread, which breaks inside and downstream of the 
orifice and generates droplets in the collection capillary. A major advantage of these 
geometry devices is that smaller particles can be produced comparing with the other 
geometries (Schmid and Franke, 2013; Yobas et al., 2006). 
 
 
Figure 11. Microfluidic strategy of a flow-focusing capillary device for making single emulsion 
droplets (Duncanson et al., 2012). 
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6. Safety, toxicity and regulatory concerns of multisystems 
platforms based in particulate carrier systems 
Materials and thereof products require to be proven safe and compliant with the 
requirements of healthcare regulatory bodies in order to be considered for medical use. 
Nevertheless, issues regarding the safety and toxicity of materials and how these may affect 
human health and the environment have been raised over the years (Austin and Lim, 2008; 
Bimbo et al., 2012; Klaine et al., 2012; Nel et al., 2006; Sharifi et al., 2012). It seems clear, 
however, that adverse effects are dependent on the nature and type of usage of materials, as 
well as on the route, dose and duration of exposure (Bimbo et al., 2012; Oberdörster et al., 
2005). Various tools and techniques for assessing the toxicity of materials were developed 
over the last decades in order to address specific necessities in the medical field. Still, 
standards for the assessment of the toxicity of materials and compendia methods are eagerly 
needed (Alkilany et al., 2016; Arora et al., 2012), which, in turn, may be partially responsible 
for the slow pace towards the approval of new products, as discussed below. 
Carrier systems are typically produced with biodegradable, biocompatible and low 
toxicity materials allowing for overall safety (Elsabahy and Wooley, 2012). Nevertheless, 
using materials previously demonstrated as safe does not necessarily translate into the same 
outcome when used at different scales, such as the nanoscale (Bartlett et al., 2015). The 
specific engineered surface of the carrier systems and its functionalization may help 
modifying the original properties of these materials and improve biodegradability, 
biocompatibility and toxicity profiles (Bianco et al., 2011; Bimbo et al., 2012; Liu et al., 2011; 
Nurunnabi et al., 2013; Shahbazi et al., 2013). However, the functional moieties incorporated 
into the systems may present intrinsic bioactivity and, possibly, relevant toxicity. Their 
evaluation must, therefore, consider possible biological effects while non-associated to 
systems, as well as after being released upon disassembly, cleavage or 
degradation/biotransformation of the systems.  
The dimensions and surface properties of carrier systems seem to particularly affect 
their ability to distribute and accumulate in the human body, but that alone may not be 
determinant of any deleterious effects in health (Kulkarni and Feng, 2013). Other important 
factors, such as solubility, biodegradability, biocompatibility and inherent toxicity of used 
materials, as well as processing, stability, physical state, agglomeration, geometry, porosity 
and surface chemistry of produced carrier systems need to be taken into account (Luyts et 
al., 2013; Podila and Brown, 2013; Yu et al., 2012). The routes by which particulate systems 
are intended to be administered will also impact their interactions with biological systems (Fu 
et al., 2013). In the particular case of oral delivery, the administration of biopharmaceuticals 
must be done in much higher amounts than in a subcutaneous route. Such amounts in the 
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intestine may raise toxicological problems that the majority of investigations usually neglect 
or underestimate (Fonte et al., 2015).  
From a pharmaceutical perspective and in a broader sense, materials (apart from 
active pharmaceutical ingredients) used in the design and production of carrier systems may 
be considered as excipients (Bansal, 2014). Therefore, their evaluation should comply with 
general requirements for toxicity and safety evaluation of common excipients as defined by 
different regulatory authorities (Elder et al., 2016; Osterberg et al., 2011). Thus, general 
statements on specific materials and delivery routes are not straightforward and a case-by-
case analysis supported with consistent experimental data is highly recommended (Hoet et 
al., 2009).  
Due to the nature and particular complexity of carrier systems, regulators have been 
considering and discussing specific guidance for multistage platforms-based products 
intended to be used in human and veterinary medicine. Despite of that, there is a stringent 
lack of usable regulations. The debate has been intense and, in most cases, inconclusive 
(Satalkar et al., 2015). The FDA has long been engaged in promoting various endeavors in 
order to establish standards and rules for such products (Sadrieh and Espandiari, 2006). 
Despite of these and following efforts in establishing new and specific regulations, review 
processes of material-containing products have been essentially conducted over the years in 
a similar way as those for “conventional” medicines through the Center for Drug Evaluation 
and Research. The FDA considers that current regulatory pathways are robust but flexible 
enough, thus abbreviating any urgent need for additional regulation (Tyner et al., 2015) and 
chosen deliberately to work mostly on a product-orientated fashion (Hamburg, 2012). Indeed, 
available specific guidance on particulate-based medicinal products from the FDA is still quite 
ambiguous and, in many cases, without binding character or still in draft form. 
Strategies for the regulatory approval of particular product by the FDA are well 
documented at the agency website. Still, there is some controversy concerning this issue, 
namely when drugs and devices are associated (Bartlett et al., 2015). Apart from the general 
guidance on whether a product involves the application of nanotechnology, the only other 
available (draft) guidance concerning particulate-based systems addresses liposome drug 
products and polymer-coated superparamagnetic iron oxide nanoparticles (SPIONs). This 
lack of specific regulation and active guidance has been interpreted by some experts has 
potentially harmful to the development and market introduction of new products (Bawa, 
2011). 
These systems also require complying with current European legislation on medicinal 
products. EMA has issued a few Reflection Papers on that over recent years but guidelines 
are still missing. Different products already approved by this agency have been the focus of 
such guidance, including those based on liposomes (e.g., Caelyx® and MEPACT®), albumin 
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nanoparticles (Abraxane®), SPIONs (Sinerem®) and nanocrystals (Rapamune®). Still, 
recommendation whether or not a new product should be considered safe is based on a 
case-by-case analysis. The European agency also recognizes the fast trends in the field 
towards increasingly complex products, and is already looking at next-generation products 
(de la Ossa, 2015). Various information on past approvals is also available from EMA, 
namely in the form of European public assessment reports. It should be stressed that efforts 
for regulatory issues are not an exclusive of the FDA and EMA and that many other agencies 
are actively engaged in sorting out this enduring gap (Bartlett et al., 2015; Guo et al., 2014; 
Tinkle et al., 2014). 
The road ahead seems bumpy and various challenges face the regulation of 
technology-based medicinal products. Despite of the novelty and complexity as compared to 
“conventional” medicinal products, currently approved products are still relatively simple and 
increasing regulatory issues are expected when it comes to systems comprising multiple 
active agents and functionalities. Another huge challenge for further regulation concerns the 
development of analytical tools that can help establishing which and how physicochemical 
properties of materials will impact safety and effectiveness of medicinal products (Bartlett et 
al., 2015; Jiang et al., 2011; Tyner et al., 2015). It is not hard to expect that the greater the 
complexity of developed systems, namely when facing surface functionalization, the most 
difficult it will be to define and standardize characterization techniques. Different worldwide 
agencies are aware of the coming hurdles regarding the approval of such products and 
extensive advances in regulations is urgently needed (Bowman and Gatof, 2015). Overall, 
analytical tools and mandatory testing should assure that materials used throughout the life 
cycle of a medicinal product are consistent in terms of their properties defining quality, safety 
and efficacy (Tyner et al., 2015). This should, however, allow facilitating the development 
process of new products and not constitute overwhelming barriers towards approval, 
particularly regarding the cost associated with developing technology-based products and the 
typical typology of applicants (small to medium sized companies). Current lack of 
international standardization and harmonization may stand in the way of such goal, even if 
small but important steps have been taken in order to abbreviate such hurdles. For example, 
procurement of parallel advice from EMA and FDA is currently possible. Furthermore, on-
going efforts are being made in order to establish bridging between global regulators and 
with other scientific, economic and political organizations, moving forward through 
convergent pathways (Bartlett et al., 2015). Coordination between different agencies will be 
crucial in order to achieve harmonization and boost the development of new surface 
functionalized materials for the oral delivery of biopharmaceuticals (Sainz et al., 2015). 
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1. Overview 
Research on nanotechnology has become considerably relevant in healthcare, where 
the potential benefit for patients is high. A focus on diseases with the most relevant socio-
economic impact, such as diabetes mellitus, is needed. Due to its chronic nature and high 
prevalence, diabetes mellitus has become one of the main burdens for modern society. 
Peptides and proteins, due to their exquisite specificity, typically with no adverse 
effects and low interference with other biological processes, are important in the 
management of this disorder. Such activity and effectiveness cannot be, in general, 
mimicked by conventional small-molecule drugs. However, despite the fact that the oral route 
is by far the most desirable way for drug administration and classically the first goal for any 
new active molecule, the poor oral bioavailability (usually less than 1–2%) of peptides and 
proteins has been severely compromising their therapeutic outcome. When compared to 
simple peptide solution formulations, peptide-loaded nanoparticles are less degradable, 
resulting in an increased bioavailability and accumulation in the required site of action, with 
less harmful side-effects. These particulate-based drug delivery systems may have other 
benefits, such as modifiable surface properties to acquire tailored cellular interactions, dual 
drug delivery for synergistic therapeutic outcome, pH-responsiveness that allows protection 
from the harsh gastric conditions, as well as site specific controlled drug release. 
 In the framework of this thesis, a collaborative work between the Institute for 
Research and Innovation in Health (i3S) at the University of Porto (Portugal) and the Faculty 
of Pharmacy of University of Helsinki (Finland) was established. The i3S group has a vast 
experience and expertise in the formulation of several advanced delivery systems for 
biomolecules and drugs, including peptides and proteins, using lipid and polymer-based 
particulate carrier systems. The main interests of the group are to try to overcome the 
physiological barriers and to develop increasingly “smart” systems to efficiently and in a 
target way delivery drugs, decreasing the effects in the surrounding tissues. The group from 
the University of Helsinki is internationally reputed for their expertise in porous silicon 
particulate carrier systems for drug delivery applications, having consistently demonstrated 
their effectiveness in improving the properties of the drugs. Their research interest areas are 
also immunotherapy, diagnosis and bio-imaging, heart diseases and diabetes and obesity. 
The combined expertise and close collaboration between these groups constituted a great 
benefit to carry out the work reported in this thesis, dedicated to developing and exploring 
different biomaterials to prepare new formulations for the oral delivery of GLP-1. 
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2. Aims 
 
The main aim of this thesis project was to develop safe particulate-based carrier systems and 
evaluate they efficiency in the encapsulation of GLP-1 and in the improvement of its oral 
bioavailability. The ultimate objective was to use the developed system as a therapy for 
T2DM. 
 
The specific objectives of this thesis were: 
 
i) To investigate the influence of distinct biomaterial compositions on the development of 
nanoparticles for the encapsulation of GLP-1, on their efficiency as the carrier systems 
and in interacting with intestinal cells and on enhancing GLP-1 permeability across an 
intestinal monolayer (Chapter III). 
 
ii) To improve the most promising delivery system previously developed in terms of 
intestinal cell targeting and penetration by further modifying its surface, as well as in 
terms of availability of delivered GLP-1 by co-loading a DPP4 inhibitor (which prolongs 
GLP-1 half-life) for dual-drug release, and studying the site-specific intestinal delivery, 
the cellular interactions and intestinal GLP-1 permeation across an intestinal monolayer 
(Chapter IV). 
 
iii) To assess in vivo the ability of the multistage platforms developed to reduce glycaemia 
in a T2DM non-obese rat model (Chapter V and Appendix C). 
   
 
 
 
CHAPTER III 
 
 
The impact of nanoparticles on the mucosal translocation 
and transport of glucagon-like peptide-1across the 
intestinal epithelium 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was based in the following published paper: 
- Araújo, F., Shrestha, N., Shahbazi, M.A., Fonte, P., Mäkilä, E.M., Salonen, J.J., 
Hirvonen, J.T., Granja, P.L., Santos, H.A. and Sarmento, B. 2014. The impact of 
nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal 
epithelium. Biomaterials. 35(33):9199-207. 
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1. Abstract 
 
GLP-1 is an incretin hormone that is in the pipeline for T2DM therapy. However, oral 
administration of GLP-1 is hindered by the harsh conditions of the gastrointestinal tract and 
poor bioavailability. In this study, three nanosystems composed by three different 
biomaterials (poly(lactide-co-glycolide) polymer (PLGA), Witepsol E85 lipid (solid lipid 
nanoparticles, SLN) and porous silicon (PSi) were developed and loaded with GLP-1 to study 
their pemeability in vitro. All the nanoparticles presented a size of approximately 200 nm. The 
nanoparticles’ interaction with the mucus and the intestinal cells were enhanced after coating 
with CS. PSi nanosystems presented the best association efficiency (AE) and loading degree 
(LD), even though a high AE was also observed for PLGA nanoparticles and SLN. Among all 
the nanosystems, PLGA and PSi were the only nanoparticles able to sustain the release of 
GLP-1 in biological fluids when coated with CS. This characteristic was also maintained 
when the nanosystems came in contact with the intestinal Caco-2 and HT29-MTX cell 
monolayers. The CS-coated PSi nanoparticles showed the highest GLP-1 permeation across 
intestinal in vitro models. In conclusion, the PLGA+CS and PSi+CS are promising 
nanocarriers for the oral delivery of GLP-1.    
 
KEYWORDS: Glucagon like peptide-1; oral delivery systems; nanoparticles; chitosan; triple co-
culture; diabetes 
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2. Introduction 
 
T2DM is the most prevalent metabolic disorder worldwide, making it the fourth leading 
cause of death in the developed countries (Russell, 2013). Currently, incretin hormones are 
in the pipeline for the treatment of T2DM due to their ability to potentiate insulin secretion 
after meal in a glucose-dependent manner. This incretin effect represents approximately 50–
70% of the total insulin secreted following oral glucose administration in normoglycemics 
(Baggio and Drucker, 2007; Campbell and Drucker, 2013). Among all the incretin hormones, 
the 30 amino acids peptide GLP-1 is the most studied. Besides insulin production, GLP-1 
also stimulates the neogenesis and proliferation of pancreatic β cells, which slows the 
progression of T2DM, and also suppresses the glucagon release (Tahrani et al., 2010). 
Moreover, its insulinotropic effect is lost when glucose concentration is below 77 mg/dL, thus 
overcoming hypoglycaemia which is the major side effect of the currently available therapy 
(Nauck et al., 2002; Rekha and Sharma, 2013). 
Nevertheless, GLP-1 is currently administrated by parenteral routes, which are not 
well accepted by patients, and also do not mimic the endogenous pathway of GLP-1 
secretion (Araújo et al., 2012; Gupta et al., 2013). Aiming to overcome the known 
disadvantages of this delivery route, attempts to deliver GLP-1 orally have been made, 
specially using alternative delivery systems to protect it from the harsh conditions of the 
gastrointestinal (GI) tract and prolong release and effect (Chae et al., 2008; Joseph et al., 
2000; Nguyen et al., 2011). However, these studies are still very preliminary and none of 
these formulations have progressed towards further studies. 
In this work, three different kinds of nanosystems were developed in order to deliver 
GLP-1 orally. These nanosystems were prepared from three different types of materials with 
known biocompatibility and biodegradability properties: (i) poly(lactide-co-glycolide) polymer 
(PLGA), (ii) lipid Witepsol E85, and (iii) porous silicon (PSi) (Bimbo et al., 2010; Danhier et 
al., 2012; Sarmento et al., 2007a; Shahbazi and Santos, 2013). These are well known 
biomaterials that have been extensively studied in the drug delivery field. They have the 
ability to help drugs to overcome the GI barriers and sustain and/or control the drug release, 
thus improving the therapeutic efficiency of the drug and reducing unwanted side effects. 
Moreover, the surface chemistry can be tailored conferring them specific properties, which is 
another advantage of these materials (Danhier et al., 2012; Fredenberg et al., 2011; Salonen 
et al., 2008; Sarmento et al., 2007a; Zhang et al., 2012a).  
Nonetheless, the successful protection of the cargos from GI environment merely is 
not enough. The nanoparticles still have to face the protective mucus layer present in the 
intestine, which makes it difficult for the nanoparticles to approach the epithelial cells (Ensign 
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et al., 2012). Thus, modifying the surface of the particles with mucoadhesive biomaterial, 
such as CS, will promote mucus and cellular adhesion leading to the retention of the delivery 
systems at the site of absorption for longer periods of time, thereby increasing the oral 
bioavailability. Moreover, CS is also described as being able to increase the permeability of 
the drugs by transiently opening the cellular tight junctions (Andrade et al., 2011; Sarmento 
et al., 2007b; Shahbazi and Hamidi, 2013).  
The aim of this work was to compare three different developed nanosystems with 
different properties, and select the one with most advantageous characteristics to the 
nanoparticles for oral delivery. Moreover, the effect of CS adsorption on the surface of these 
nanoparticles was also studied. For that, an extensive characterization of the nanoparticles 
was made, as well as the study of the GLP-1 release in biological fluids performed. The 
interaction studies of the nanoparticles with intestinal cell lines were also performed together 
with the evaluation of GLP-1 permeation across intestinal cellular monolayers.  
 
 
3. Material and Methods 
3.1 Materials and cell lines 
GLP-1 was manufactured by United Peptides, USA. PLGA 50:50 was obtained from 
Purac Biomaterials, Purasorb® PDLG 5004 and Witepsol E85 from Sasol, Germany. 
Polyvinyl alcohol (PVA), low molecular weight CS, fluorescein isothiocyanate (FITC), 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and glutaraldehyde were purchased 
from Sigma-Aldrich®, USA. Culture flasks and Transwell® plates were purchased from 
Corning Inc., USA. Dulbecco’s Modified Eagle medium (DMEM), L-glutamine, non-essential 
amino acids, Penicillin (100 IU/mL), Streptomycin (100 mg/mL) and trypsin–EDTA were 
purchased from HyClone (USA). Hank’s balanced salt solution (HBBS) and heat inactivated 
fetal bovine serum (FBS) were purchased from Life Technologies Gibco®, USA. Human colon 
carcinoma (Caco-2) and Raji B cell lines were obtained from American Type Culture 
Collection (ATCC, USA) and HT29-MTX cell line was kindly provided by Dr. T. Lesuffleur 
(INSERM U178, Villejuif, France). 
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3.2 Preparation of PLGA nanoparticles and SLNs 
Different formulations of polymeric and lipidic nanoparticles were prepared through 
modified solvent emulsificationevaporation method, based on the water-in-oil-in-water 
(w/o/w) double emulsion technique (Garcı́a-Fuentes et al., 2003; Zhang et al., 2006). The 
polymer/lipid was dissolved in heated ethyl acetate in a concentration of 100 mg/mL. Then, 
100 µL of GLP-1 solution in MilliQ-water (2.5 mg/mL) was added to this solution and 
homogenised for 30 sec using a Vibra-Cell™ ultrasonic processor (Sonics®, Sonics and 
Matrials, Inc., USA). The primary emulsion (w/o) formed was then added into 4 mL of the 
surfactant solution, 2% of PVA in Milli-Q water, and homogenised again for 30 sec with the 
same amplitude. The second emulsion formed (w/o/w) was finally added to 7.5 mL of the 
same surfactant solution and was left under magnetic stirring at 300 rpm for at least 3 h for 
organic solvent evaporation.  
CS solution was prepared by dissolving CS in deionized water containing 1% (v/v) 
acetic acid overnight under magnetic stirring with pH adjustment to 5.5, followed by filtration 
through a paper filter Millipore #2 and stored at 4ºC. To coat the nanoparticles with CS, the 
formulation was added into a solution of CS, at a ratio of 5:1 (w/w) regarding the solid content 
of the solutions, and left overnight under magnetic stirring, allowing surface layer deposition 
of the polymer on the surface of the particles.  
Nanoparticles were washed three times in MilliQ-water and separated through 
centrifugation, using an ultra-centrifuge (Optima™ TL, Beckman Coulter, USA), at 34300  g 
for 20 min for PLGA nanoparticles and 250000 × g for 150 min for SLNs. After centrifugation, 
nanoparticles were re-dispersed in water and stored at 4°C for further analysis.  
Drug-free nanoparticles were prepared according to this procedure but using MilliQ-
water instead of GLP-1 solution as internal aqueous solution. In order to visualize the 
nanoparticles, FITC was also loaded into the nanoparticles according to the procedure 
described before, but using FITC-solution instead of GLP-1 solution.  
 
3.3 Preparation of the PSi nanoparticles 
  Free-standing multilayer PSi films were anodized using single crystal Si wafers 100 
of p+-type with resistivity values of 0.01–0.02 Ωcm in hydrofluoric acid (40%)–ethanol 
mixture. The anodization profile consisted of successive low, high and zero current pulses 
applied on the Si wafer. Hydrocarbonization treatment for the multilayer films consisted of 
exposing the particles to a 1:1 (v/v) flow of N2 and acetylene for 15 min at room temperature, 
followed by 15 min at 500 °C, and then cooling down to room temperature under N2 flush. 
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The obtained thermally hydrocarbonized PSi (THCPSi) was then modified with 10-
undecenoic acid for 16 h at 120 °C to obtain partially carboxylic acid terminated PSi 
(UnTHCPSi). Wet ball milling was used to reduce the size of the modified PSi films, while the 
surface oxidation was minimized by using a 5 vol-% 10-undecenoic acid - dodecane solution 
as the milling liquid. The final size separation and exchange of the suspension media were 
done by centrifugation (Bimbo et al., 2010; Shahbazi et al., 2014). 
  For the GLP-1 loading, a ratio of 1:5 (w/w; GLP-1:PSi) was used for GLP-1-loaded 
PSi nanoparticles. The GLP-1 loading was performed by dispersing the PSi nanoparticles in 
GLP-1 solution and stirring at room temperature for 90 min at 300 rpm. After that, the 
suspension was centrifuged at 27600 g for 5 min to remove the excess free GLP-1. To coat 
the nanoparticles with CS through physical adsorption, the nanoparticles were first 
centrifuged at 27,600  g for 5 min, and then mixed with a solution of CS at a ratio of 5:1 
(w/w) regarding the solid content of the solutions, and left overnight under magnetic stirring at 
300 rpm. For the nanoparticles coated by physical adsorption with CS, the GLP-1 loading 
was performed prior to the coating in order to prevent the blockage of the nanoparticles’ 
pores by CS (Shrestha et al., 2014). 
 
3.4 Nanoparticles characterization 
After production, nanoparticles were characterized for their average particle size (Z-
average), polydispersity index (PdI) and average zeta–potential by electroforethic light 
scattering using a Malvern Zetasizer Nano ZS instrument (Malvern Instruments Ltd, UK). For 
these measurements, samples were diluted in MilliQ-water.  
To characterize the morphology of the nanoparticles and confirm their size 
distribution, nanoparticles were observed by transmission electron microscopy (TEM, 
TecnaiTM F12, FEI Company, USA) using an acceleration voltage of 120 kV. For sample 
preparation, nanoparticles were diluted in MilliQ-water, placed on copper coated grids, and 
contrasted with uranyl acetate. In each step, the excess of water was removed using a filter 
paper, and finally, grids were left at room temperature for a few minutes to dry before the 
imaging.  
 
3.5 Association efficiency (AE) and loading degree (LD) 
To determine the AE and LD of the developed nanosystems, the amount of GLP-1 
associated to the nanoparticles was calculated. This calculation was made by the difference 
between the total amount of GLP-1 used to prepare the systems, and the amount of GLP-1 
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that remained in the aqueous phase after nanoparticles isolation by centrifugation, according 
to the follow equations (Li et al., 2013; Sarmento et al., 2006): 
 
AE (%) =  x 100 
 
 
 
LD (%) =  x 100 
 
The amount of GLP-1 was determined by HPLC (Agilent 1260, Agilent Technologies, 
USA), using a C18 column (4.6  150 mm, 5 µm, Zorbax Eclipse plus C18, USA). The mobile 
phase consisted of 0.1% trifluoroacetic acid (pH 2.0) and acetonitrile initially set at the ratio of 
70:30 (v/v), which linearly changed to 60:40 (v/v) as a gradient over 5 min. Afterwards, the 
ratio was kept constant for 5 more minutes. The flow rate was 1.0 mL/min and the injected 
volume of the sample was 75 µL. The column temperature was set at room temperature and 
the detection wavelength at 240 nm. The total area under the curve (AUC) was used to 
quantify the GLP-1. 
 
3.6 In vitro release studies 
The GLP-1 loaded nanoparticles (corresponding to 30 µg of GLP-1) were added to 20 
mL of pH 1.2 buffer (50 mM KCl) to simulate the gastric fluid. After 2 h, nanoparticles were 
centrifuged and introduced in a fasted state stimulated intestinal fluid (FaSSIF) (50 mM 
KH2PO4, 15 mM NaOH, 1.0 % (w/v) pancreatin; pH 6.5) for 4 h more. Aliquots of 750 µL were 
collected at specific time points (0.5, 1, 2, 3, 4, 5 and 6 h) during the dissolution experiments 
and withdrawn volume was replaced with fresh buffer, keeping the volume constant. All the 
collected aliquots were centrifuged at 27,600  g for 20 min and the supernatant was used 
for HPLC analysis in order to quantify the GLP-1 released from the nanoparticles over time. 
All the tests were performed at 37ºC and 100 rpm under sink conditions. 
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3.7 Cell culturing 
Caco-2 (passages #3140) and HT29-MTX (passage #15–30) cells grew separately 
in culture flasks in a complete medium consisting of DMEM supplemented with 10% (v/v) 
FBS, 1% (v/v) L-glutamine, 1% (v/v) NEAA, and 1% (v/v) antibiotic–antimitotic mixture (final 
concentration of 100 U/ml Penicillin and 100 U/ml Streptomycin). Cells were sub-cultured 
once a week using 0.25% trypsin–EDTA (1×) to detach the cells from the flasks and seeded 
at a density of 0.5 × 106 cells per 75 cm2 flask. The culture medium was replaced every other 
day. Cells were maintained in an incubator (BB 16 gas incubator, Heraeus Instruments 
GmbH) at 37ºC and 5% CO2 and 95% relative humidity. Raji B cells (passages #26–35) were 
cultured in flasks with DMEM supplemented and at the same conditions as described above. 
  
3.8 Cell viability studies 
For the viability tests, 100 μL of Caco-2 and HT29-MTX cells, at 0.5 × 106 cells/mL, 
were seeded separately in 96-well plates and were allowed to attach for 24 h. After that, the 
medium was aspirated and the wells were washed twice with 100 µL of fresh HBSS-HEPES 
buffer (pH 7.4). After washing, 100 µL of the nanoparticle solutions corresponding to GLP-1 
amounts of 1.5, 3.75, 7.5 and 15 µg/mL of GLP-1 were added to each well and the plates 
were incubated for a period of 3 and 12 h at 37ºC. Afterwards, the plates were equilibrated at 
room temperature for about 30 min and then washed twice with 100 µL of HBSSHEPES (pH 
7.4). About 50 µL of the reagent assay CellTiter-Glo® (Promega Corporation, USA) were 
added to 50 µL of HBSSHEPES (pH 7.4) in each well; negative (HBSS buffer) and positive 
(1% Triton X-100) control wells were also used and treated similarly as described above. The 
plate was mixed for 10 min on an orbital shaker at room temperature, protected from the 
light. Finally, the luminescence was measured using Varioskan Flash plate reader (Thermo 
Fisher Scientific Inc., USA). The assay is based on the amount of ATP produced by 
metabolically active cells, which is directly proportional to the number of living cells present in 
the culture (Bimbo et al., 2011). All data sets were compared with a negative control of 
HBSS-HEPES (pH 7.4), considered as 100% viability. 
 
3.9 Cellnanoparticles interactions 
To verify the interactions between cells and nanoparticles, Caco-2:HT29-MTX co-
cultures in the proportion of 90:10 were seeded in Lab-Tek 8-chamber slides (Thermo Fisher 
Scientiﬁc Inc., USA) and allowed to attach for 24 h. Afterwards, cells were washed twice with 
fresh HBSSHEPES buffer (pH 7.4). Then, FITC-loaded nanoparticles were added to cells 
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and incubated at 37C for 3 h. After incubation, cells were washed twice with fresh 
HBSSHEPES buffer (pH 7.4). Then, the plasma membrane was stained by adding 200 µL 
of CellMask™ Orange (Invitrogen, USA) and incubated for 3 min at 37C. The excess of 
staining solution was washed twice with fresh HBSSHEPES buffer and cells were fixed 
using 2.5% glutaraldehyde for 20 min. The localization of the FITC-loaded nanoparticles was 
then observed using a Leica SP5 confocal microscope (Leica Microsystems, Germany).  
 
3.10 Permeability experiments 
For the permeability experiments, 7  104 cells/cm2 of Caco-2 and HT29-MTX cells in 
a ratio of 90:10 were seeded in 12-Transwell cell culture inserts and were allowed to grow 
and differentiate for 14 days with medium replacement every other day. Then, 1.0  105 Raji 
B cells were added to the basolateral chamber for 7 days more, in order to induce the 
phenotype change of Caco-2 cells into M cells and to obtain a triple co-culture model (Araújo 
and Sarmento, 2013). The permeability experiments across the cell monolayers were 
performed in the apical-to-basolateral direction in HBSSHEPES at pH 6.5 (apical 
compartment) and pH 7.4 (basolateral compartment) at 37ºC using an orbital shaker (100 
rpm). After removing the cell culture medium, 0.5 mL of pure GLP-1 or nanoparticles in the 
concentration of 2 µg/mL were pipetted into the apical side of the inserts. At different time 
points (0.5, 1, 2 and 3 h), 0.75 mL samples were taken from the basolateral side of the 
inserts and the same volume of fresh HBSSHEPES (pH 7.4) buffer was added to replace 
withdrawn volume. Sample concentrations were quantified by EIA GLP-1 Kit (Sigma-Aldrich®, 
USA) according to manufacturer’s instructions. The integrity of the cell monolayers was 
checked before and after the permeability experiment by measuring the trans epithelial 
electric resistance (TEER) using Millicell®-Electrical Resistance System (Millipore, USA).  
 
3.11 Morphological characterization of co-culture monolayers  
After the drug permeation studies, the nanoparticles suspension was carefully 
removed and cells were fixed with 2.5% glutaraldehyde for 20 min at room temperature. The 
wells were then washed twice with sodium cacodylate buffer (NaCac) for 3 min. Afterwards, 
cells were post-fixed with 1% osmium tetroxide in 0.1 M NaCac buffer (pH 7.4) and then 
dehydrated and embedded in epoxy resin. Ultrathin sections (60 nm) were cut perpendicular 
to the insert, post-stained with uranyl acetate and examined with TEM using an acceleration 
voltage of 120 kV. 
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3.12  Statistical analysis 
All the experiments were performed in triplicate and are represented as mean ± 
standard deviation (SD). A one-way analysis of variance (ANOVA) with Bonferroni post hoc-
test (GraphPadPrism, GraphPad software Inc., CA, USA) was used to analyse the data. The 
level of significance was set at probabilities of *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
4. Results and Discussion 
4.1 Characterization of the nanoparticles 
Nanoparticles were developed and characterized on the basis of their particle size, 
PdI and zeta-potential, as shown in Table 4. All of the uncoated nanoparticles presented 
average sizes of approximately 200 nm with low PdI values (≤ 0.12), suggesting the 
monodispersity of the nanosystems. TEM images supported these results in terms of mean 
size and their homogenous distribution (Figure 12). From the TEM images, it can also be 
observed that SLN and PLGA nanoparticles have spherical shape, in contrast with the 
irregular shape of UnTHCPSi nanoparticles. The shape of nanoparticles has also been 
described as having an impact on their interaction at cellular level (Verma and Stellacci, 
2010), wherein round-shaped nanoparticles are taken up more easily than irregular ones with 
sharp edges (Caldorera-Moore et al., 2010). Regarding the surface charge, it was observed 
that all of the uncoated nanoparticles are negatively charged due to the nature of the 
biomaterials used. However, nanoparticles with negative charge would lead to electrostatic 
repulsion with the negatively charged mucus layer on the intestinal wall (50 mV), thereby 
inhibiting the nanoparticles to move closer to the intestinal epithelial wall (Zhang et al., 2012). 
Thus, to improve the interaction of the nanosystems with the intestinal epithelia, the 
nanoparticles were then coated with CS, a positively charged mucoadhesive polymer. 
The inheritance of positive charge from CS to the nanoparticles enhances the 
interactions with negatively charged mucus and cells, which can lead to improvement in the 
permeability and/or cellular internalization of the cells (Wang et al., 2013; Zhang et al., 2012). 
Moreover, CS is described as being an efficient intestinal absorption enhancer since it is able 
to transiently open tight junctions between epithelial cells (Andrade et al., 2011; Chen et al., 
2013). The successful surface modification of the nanoparticles with CS was observed by the 
significant change in the zeta-potential and by the significant increase in the particle size, as 
shown in Table 4. However, the shape of the nanoparticles did not change as seen in Figure 
13. These changes are in accordance with other studies, in which modification of 
nanoparticles with CS were also performed (Wang et al., 2013; Zhang et al., 2012).  
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Table 4. Size, PdI, -potential, association efficiency (AE) and loading degree (LD) of the 
different nanoparticles. Results are presented as mean ± SD (n ≥ 3). The values of uncoated 
nanoparticles were compared with their corresponding CS-coated nanoparticles, *p < 0.05. 
 
 
 
Figure 12. TEM images of (A) PLGA nanoparticles; (B) SLN nanoparticles and (C) 
UnTHCPSi nanoparticles. 
 Size (nm) PDI 
-potential 
(mv) 
AE (%) LD (%) 
PLGA 182.9 ± 5.3 0.08 ± 0.02 20.3 ± 1.0 67.0 ± 10.9 0.17 ± 0.03 
PLGA + CS 198.4 ± 5.7* 0.11 ± 0.01 +17.5 ± 1.2* 60.0 ± 0.8 0.15 ± 0.01 
SLN 217.4 ± 2.0 0.11 ± 0.02 7.5 ± 0.3 73.3 ± 0.6 0.18 ± 0.01 
SLN + CS 223.6 ± 1.1* 0.11 ± 0.01 +13.4 ± 0.3* 57.0 ± 5.6* 0.14 ± 0.01 
UnTHCPSi 196.8 ± 6.0 0.12 ± 0.02 30.1 ± 2.8 85.0 ± 0.6 17.00 ± 0.05 
UnTHCPSi + CS 363.0 ± 8.0* 0.23 ± 0.02 +19.2 ± 0.4* 85.0 ± 0.5 14.16 ± 0.04 
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Figure 13. TEM images of (A) PLGA nanoparticles and (B) PLGA+CS nanoparticles; (C) 
SLN nanoparticles and (D) SLN+CS nanoparticles and (E) UnTHCPSi nanoparticles and (F) 
UnTHCPSi+CS nanoparticles. 
 
4.2 Association efficiency (AE) and loading degree (LD) 
UnTHCPSi nanoparticles, coated and uncoated with CS, presented the highest AE 
with 85 ± 1% of the initial peptide associated to the nanoparticles (Table 4). For PLGA 
nanoparticles, the AE of GLP-1 was 67 ± 11% which was in the same range of values as CS 
coating (PLGA+CS) with 60 ± 1% of AE (p > 0.05). In turn, SLN had significantly higher AE 
than CS-coated SLN nanoparticles (SLN+CS), with values of 73 ± 1% and 57 ± 6%, 
respectively. These reductions in AE for the CS-coated nanoparticles may be due to an 
additional step of mixing the nanoparticles with the CS overnight which could have led to 
some release of the drug (Wang et al., 2013). Taking into account that GLP-1 is a hydrophilic 
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peptide, the AE obtained with these systems seemed to be higher than the usual values 
obtained for other hydrophilic peptides such as insulin (Emami et al., 2009; Fonte et al., 
2011; Sarmento et al., 2007a; Zhang et al., 2012). It could be explained by the production 
method used and the use of ethyl acetate as organic solvent, which is known to enhance the 
rate of encapsulation of hydrophilic molecules (Cohen-Sela et al., 2009). 
Regarding the LD, UnTHCPSi nanoparticles also had the highest LD of 17 %, which 
is 100 times higher than that of PLGA and SLN nanoparticles. Regarding the CS-coated 
nanoparticles it was observed that the LD values were slightly lower with no significant 
changes when compared with the uncoated nanoparticles, except in UnTHCPSi where it 
remained the same (Table 4).  
Such differences in the AE and LD of PLGA and SLN in comparison with UnTHCPSi 
are explained with the methods used in their production. With the UnTHCPSi nanoparticles, 
the payload will be retained in the pores of the nanoparticles, generally by physical 
adsorption. The electrostatic interactions towards the payload will be the main factors 
contributing for its incorporation and retention in the nanoparticles (Kovalainen et al., 2012; 
Liu et al., 2013). However, for the PLGA and SLN nanosystems, the payload needs to be 
entrapped into the nanoparticles. During the production of these nanoparticles, several 
different stages of the double emulsion method are involved, which increases the probability 
of loss of the peptide (Almeida and Souto, 2007; Liu et al., 2013).  
 
4.3 Cell viability studies 
The in vitro cell viability experiments were performed using two different intestinal cell 
lines, Caco-2 and HT29-MTX. As Caco-2 cells resemble enterocytes that represent 
approximately 90% of the total epithelial cells of the intestine and HT29-MTX mimic the 
goblet cells that are approximately 10% of intestinal cells (Araújo and Sarmento, 2013), these 
cell lines are suitable in vitro models to mimic the intestinal epithelia (Antunes et al., 2013; 
Araújo and Sarmento, 2013; Sarmento et al., 2012). Cells viability was measured after 
exposure of the nanoparticles to the cells at different concentrations and incubation periods. 
The aim of using different concentrations is to understand if there is any concentration 
dependent toxicity and to know the lowest safe concentration that can be administrated. Two 
different incubation periods, 3 and 12 h, were tested because they represent the average and 
maximum transit time in the intestinal tract, respectively (Shah et al., 2010). The results are 
presented in Figure 14. 
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Figure 14. Cell viability of the intestinal cells after exposure to PLGA, SLN and UnTHCPSi 
nanoparticles (uncoated and coated with CS) assessed by the CellTiter-Glo® luminescence 
assay. The viability of (A and B) Caco-2 and (C and D) HT29-MTX cells after (A and C) 3 h 
and (B and D) 12 h incubation with different nanoparticles concentrations at 37ºC. All data 
sets were compared to the negative control HBSS buffer. Error bars represent mean ± SD (n 
≥ 3); *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
For Caco-2 cells, it can be observed that the viability of the cells was about 100% for 
all concentrations tested after 3 h of exposure to the nanoparticles (Figure 14A). After 12 h, 
the cell viability decreased in general for all formulations; nevertheless, all of the cells 
presented viability above 80%, with the exception of UnTHCPSi nanoparticles, which 
presented lower viability after 12 h (Figure 14B). Regarding HT29-MTX cells, after 3 h 
incubation, the cell viability for all the formulations was very similar to the control, 
approximately 100%, with the exception of SLN+CS (Figure 14C). After 12 h, no significant 
differences to the control were found for all samples (Figure 14D). With HT29-MTX cells, the 
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nanoparticles showed less toxicity compared to Caco-2 cells at the same time-point. This 
may be explained by the fact that the HT29-MTX cells are mucus-producing cells, and the 
mucus layer protects the cells from interacting strongly with the nanoparticles, minimizing the 
cytotoxicity associated with them (Araújo and Sarmento, 2013; Sarmento et al., 2012).  
 
4.4 In vitro release studies 
The in vitro release tests intended to predict the release profiles of GLP-1 in 
conditions similar to GI tract (stomach and small intestine). Firstly, the nanoparticles were 
added to pH 1.2 buffer, which mimics the gastric environment. Then, after 2 h, the release 
medium was changed to FaSSIF (pH 6.5), which simulates the transit of the nanoparticles to 
the small intestine. The release profiles of GLP-1 from the uncoated and CS-coated 
nanoparticles are shown in Figures 15A and 15B, respectively.  
 
 
Figure 15. Release profiles of GLP-1 from (A) PLGA, SLN and UnTHCPSi nanoparticles and 
from (B) PLGA+CS, SLN+CS and UnTHCPSi+CS nanoparticles. The percentages of peptide 
released from uncoated nanoparticles were compared with their corresponding CS-coated 
nanoparticles at the same time points and compared with the other nanoparticles. All 
experiments were conducted at pH 1.2 in the first 2 h and in FaSSIF (pH 6.5) for 4 h more at 
37 °C and 100 rpm. Errors bars represent the mean ± SD (n = 3). 
 
PLGA nanoparticles did not release significant amounts of GLP-1 at pH 1.2 for 2 h. At 
such low pH, the charge of GLP-1 (isoelectric point pI = 5.4) is highly positive, and thus, the 
interactions with the negatively charged PLGA will be very strong resulting in lower 
percentages of the peptide released (Huotari et al., 2013; Li et al., 2008; Martins et al., 2007; 
Sarmento et al., 2006; Sarmento et al., 2007b). Moreover, the PLGA nanoparticles preserved 
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their physical integrity avoiding the nanoparticle erosion, which also contributed to the 
reduced GLP-1 release (Li et al., 2008; Martins et al., 2007; Sarmento et al., 2006). When 
added to the FaSSIF, a significant release of 22 ± 1.3 % was observed, reaching 28 ± 1.6% 
of GLP-1 release after 6 h. This could be attributed to the increase in the pH, which results in 
a change of the charge of the peptide, thereby causing a reversion in the interaction with the 
nanoparticles and leading to the release of the peptide (Martins et al., 2007; Sarmento et al., 
2006). The biphasic release pattern of drugs from the PLGA nanoparticles has been 
frequently reported in the literature (Buske et al., 2012; Emami et al., 2009; Fredenberg et al., 
2011; Giteau et al., 2008). Regarding the PLGA+CS nanoparticles, a similar GLP-1 release 
profile was observed as with the PLGA nanoparticles but in a more sustained pattern. The 
absence of release at pH 1.2 was followed with a considerable release of 14.1 ± 0.4% in the 
FaSSIF that reached 21% after 6 h. The decreased release of PLGA+CS in comparison with 
uncoated PLGA nanoparticles in FaSSIF can be explained by the interaction of the non-
encapsulated GLP-1. This GLP-1CS interactions probably led to a better release control of 
GLP-1 from the nanoparticles (Zhang et al., 2012). The results obtained are in agreement 
with other reports, in which CS has been described as being able to decrease the burst 
release effect of encapsulated drugs (Chakravarthi and Robinson, 2011; Gupta et al., 2013). 
For UnTHCPSi and UnTHCPSi+CS nanoparticles, burst releases of 24.2 ± 5.2% and 11.8 ± 
6.3% were, respectively, observed at pH 1.2 in the first 30 min followed by a constant release 
plateau. In FaSSIF, a rapid release was again observed for both nanoparticles, followed by a 
sustained GLP-1 release for the next 4 h. At 6 h, the total percentage of GLP-1 released from 
the UnTHCPSi and UnTHCPSi+CS were 43.3 ± 2.7% and 35.3 ± 6.5%, respectively. Once 
again, the CS-coated UnTHCPSi nanoparticles provided less release than the uncoated 
ones, as was also seen for the PLGA nanoparticles. These results confirm that the coating of 
the nanoparticles with CS sustained the release of GLP-1.  
For the SLN nanoparticles, a significant burst release of 68.0 ± 5.5% in the first 30 
min was observed at pH 1.2. After this time-point, the percentage of GLP-1 was decreased 
over time due to its degradation, as observed by HPLC (data not shown). Even in FaSSIF, 
the percentage of GLP-1 did not increase, being the GLP-1 released residual when 
compared to the degraded GLP-1. The burst release followed by a sustained release in this 
kind of systems is common since hydrophilic peptides tend to accumulate at the o/w interface 
during preparation, thus remaining at the surface of the nanocarrier and in this case, the 
nanoparticles were not able to control the release of the peptides (Almeida and Souto, 2007). 
Also of relevance is the fact that SLN were not as much negatively charged as the other 
nanoparticles tested, thus the interaction with the positively charged GLP-1 was not as strong 
as observed for the other nanosystems, resulting in a higher percentage of released GLP-1. 
In contrast, SLN+CS nanoparticles promoted a more sustained release profile, with around 
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40% of the peptide released in the first hour, after which the GLP-1 started to decrease. 
Previous studies showed that under the same conditions, uncoated SLN nanoparticles 
suffered 80% more degradation at 4 h than the coated nanoparticles (Almeida and Souto, 
2007; Garcia-Fuentes et al., 2005). Thus, CS decreases the burst release effect of the 
encapsulated peptides after administration and also increases the stability of nanoparticles 
and macromolecules (Chakravarthi and Robinson, 2011; Garcı́a-Fuentes et al., 2003; Gupta 
et al., 2013).  
Overall, the PLGA is the system which could efficiently retain the GLP-1 from the 
harsh environment of the simulated conditions of the stomach without peptide release at pH 
1.2, with sustained GLP-1 release thereafter. Despite the release at pH 1.2, the UnTHCPSi 
systems had a very similar behaviour to PLGA systems, as the total percentage of GLP-1 
available in FaSSIF at the end of 6 h was in the same range (15-20%). Regarding the SLN 
nanoparticles, they do not retain the peptide at low pH, causing a burst release (more than 
50% of the loaded peptide) in the first 30 min at pH 1.2. Although CS coating more efficiently 
controlled the release from SLN, it still showed a significantly higher GLP-1 release at pH 1.2 
in comparison to the PLGA+CS and UnTHCPSi+CS nanoparticles. The differences between 
the uncoated and coated nanoparticles suggested that CS improve the protection of the 
GLP-1 and its release, providing a controlled drug delivery system.  
 
 
4.5 Interaction of the nanoparticles with Caco-2:HT29-MTX co-culture cells  
As stated before, Caco-2 and HT29-MTX cells represent the two most abundant cells 
in the intestinal epithelia. Thus, Caco-2:HT29-MTX co culture in a 90:10 proportion is a 
reliable model to predict the behaviour of the nanoparticles when in close contact with the 
intestinal mucosa (Araújo and Sarmento, 2013). The interaction between the nanoparticles 
and Caco-2:HT29-MTX co-culture cells were observed with confocal microscopy. In order to 
visualize the nanoparticles, they were loaded with FITC, rendering them the green colour for 
easy detection. The cell membranes were stained with red using CellMask™ Orange.  
As it can be seen in Figure 16, no interaction was seen between the cells and the 
uncoated nanoparticles. Regarding the CS-coated nanoparticles, it was observed that even 
after multiple washes, the nanoparticles were still present in contact with the cells.  
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Figure 16. Confocal microscopy images of Caco-2:HT29-MTX (90:10) co-culture treated with 
different FITC-loaded nanoparticles after incubation for 3 h at 37°C. Red: cell membranes 
stained with CellMask®: Orange; green: FITC. 
 
 
In fact, there were some places where it was possible to observe the yellow colour, 
resulting from the overlap of the green and red labelling, revealing a very close contact with 
nanoparticles co-localized with the cell membranes. This result was expected, due to the 
presence of the mucoadhesive CS on the surface of the nanoparticles which potentiates 
stronger electrostatic interactions with the mucus present in the cellular co-culture and also 
because it is positively charged, gaining much more affinity to the cells membrane (Andrade 
et al., 2011; Sarmento et al., 2007b).  
 
4.6 Cell co-culture monolayers and permeability studies 
To study the permeability of GLP-1 loaded into the three different CS-coated 
nanosystems, a triple co-culture model previously developed by our group was used. This 
model comprises the most important features present in the intestine, namely the presence 
of enterocytes (Caco-2 cells), the mucus producing goblet cells (HT29-MTX) in physiological 
proportions (90:10) and the induction of M-cells, as described elsewhere (Araújo and 
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Sarmento, 2013). M-cells may have an important role in intestinal absorption of drugs since 
they are specialized for antigen and microorganisms uptake, providing a possible gateway for 
the absorption of proteins, as well as for nanoparticles (des Rieux et al., 2005). Together with 
Caco-2 and HT29-MTX cells, they form a monolayer, where cells are joined to each other by 
tight junctions, mimicking the intestinal epithelia (Sarmento et al., 2012).  
The permeability profiles of GLP-1 alone and from different nanosystems are shown 
in Figure 17. The highest GLP-1 permeation, when free in solution, may be explained with 
the high amount of peptide available during the time of the test, whereas a slower GLP-1 
released from the nanoparticles was observed. Moreover, since these experiments were 
performed in HBSS-HEPES buffer to minimize the damage of the cellular monolayers, and 
the buffer did not present any surfactant as in FaSSIF, the GLP-1 release from the 
nanoparticles may have more sustained pattern than could be predicted, thereby explaining 
the higher permeability of GLP-1 in free solution. Regarding the nanoparticles, the 
UnTHCPSi+CS nanoparticles had the highest amount of GLP-1 permeated across the 
intestinal cell monolayers followed by SLN+CS nanoparticles (p > 0.05) and then by the 
PLGA+CS nanoparticles (p < 0.05). These results are in accordance with the data obtained 
for the in vitro release tests that showed that PLGA+CS nanoparticles sustained the release 
of GLP-1 longer than the other nanoparticles. The results obtained for SLN+CS nanoparticles 
also showed a sustained GLP-1 release at pH 6.5. However, in this case, the GLP-1 release 
was not observed in the in vitro release studies, mostly because of the degradation of the 
GLP-1 released at pH 1.2, as previously discussed. The values of the transepithelial 
electrical resistance (TEER), measured before and after the experiment were maintained 
(results not shown), demonstrating the integrity of the co-culture cell monolayer (Araújo and 
Sarmento, 2013). The presence of mucus is one of the most important characteristics of the 
cell model to predict the absorption of drugs in vivo, since the mucus present in the intestinal 
epithelia can significantly limit the effectiveness of the drug delivered by the nanosystems 
(Araújo and Sarmento, 2013; Ensign et al., 2012; Zhang et al., 2012). However, the retention 
of the coated nanoparticles on the cellular mucus layer, due to CS mucoadhesive properties, 
may improve the GLP-1 absorption, and thus, can also improve its bioavailability (Andrade et 
al., 2011).  
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Figure 17. In vitro cumulative permeability profiles of GLP-1 loaded CS-coated nanoparticles 
across Caco-2:HT29-TX:Raji B co-culture monolayers. All experiments were conducted from 
the apical (pH 6.5) to basolateral direction (pH 7.4) in HBSS at 37°C. Error bars represent 
mean ± SD (n = 3). 
 
 
It is possible to observe that all of the CS-coated nanoparticles were in close contact 
with the cells. In fact, some of the UnTHCPSi+CS nanoparticles were found inside of the 
cells as indicated by the arrow in Figure 18 and shown in Figure 19. CS coating of the 
nanoparticles improved some of their characteristics, especially the positive charge, which 
led to cellular internalization (Huhn et al., 2013; Lee et al., 2010). These results are in 
agreement with other reports in the literature that showed that positive surface charge can 
interact with the negative charge moieties of the cell membrane, and lead to internalization 
(Fuller et al., 2008; Shahbazi et al., 2014) 
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Figure 18. TEM images of flat embedded ultrathin sections after permeability showing (A) 
control cells (B) PLGA+CS nanoparticles, (C) SLN+CS nanoparticles and (D) UnTHCPSi+CS 
nanoparticles. 
 
 
Figure 19. TEM images of flat embedded ultrathin sections after permeability showing 
UnTHCPSi+CS nanoparticles with some nanoparticles internalized into the cells (arrows).
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5. Conclusions 
In this study, three different nanosystems were compared with regards to their ability 
to sustain the release of GLP-1 through the harsh environment of the simulated GI tract 
conditions. In addition, the interactions between the developed nanosystems and the 
intestinal cell lines were also evaluated. CS-coated nanosystems presented better results 
than their corresponding uncoated nanoparticles in terms of sustained GLP-1 released and 
improved interaction with the intestinal cells. Among of the CS-coated nanoparticles, 
PLGA+CS and UnTHCPSi+CS presented the best characteristics for the oral delivery of 
GLP-1. PLGA+CS showed almost no release of GLP-1 at pH 1.2 and a controlled GLP-1 
release with increasing pH over time. This was corroborated by the permeability across in 
vitro intestinal Caco-2/HT29-MTX/Raji B monolayers, where the amount of GLP-1 permeated 
was lower compared to the other nanoparticles. UnTHCPSi+CS showed the highest 
association efficiency and loading degree and due to its release profile, the amount of GLP-1 
permeated across the cellular monolayer was the highest. Overall, our results showed that 
PLGA+CS and UnTHCPSi+CS are promising nanocarriers towards the oral delivery of GLP-
1.  
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1. Abstract 
Multifunctional tailorable composite systems, specifically designed for oral dual-
delivery of a peptide (GLP-1) and an enzymatic inhibitor (DPP4 enzyme inhibitor (iDPP4)), 
were assemble through the microfluidics technique. Both drugs were co-loaded into these 
systems for a synergistic therapeutic effect. The systems were composed of CS and cell-
penetrating peptide (CPP) modified PLGA and PSi nanoparticles as nanomatrices, further 
encapsulated in the enteric hydroxypropylmethylcellulose acetylsuccinate (HPMC-AS) 
polymer. The developed multifunctional systems were pH-sensitive, inherited by the enteric 
polymer, enabling the release of the nanoparticles only in the simulated intestinal conditions. 
Moreover, the encapsulation into this polymer prevented the degradation of the 
nanoparticles’ modifications. These nanoparticles showed strong and higher interactions with 
the intestinal cells in comparison with the non-modified ones. The presence of iDPP4 
enhanced the peptide permeability across intestinal cell monolayers. Overall, this is a 
promising platform to simultaneously deliver two drugs from a single formulation. Through 
this approach peptides are expected to increase their bioavailability and efficiency in vivo not 
only by their specific release at the intestinal level but also by the reduced enzyme activity. 
The use of this platform, specifically in combination with these two antidiabetic drugs, has 
clinical potential for the therapy of T2DM. 
 
KEYWORDS: Chitosan; dual-delivery; microﬂuidics; PLGA; porous silicon. 
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2. Introduction 
Nanoparticles composed of biocompatible and biodegradable materials have been 
claimed as promising candidates towards the oral administration of peptides (Gupta et al., 
2013; Patel et al., 2014). These nanoparticles enhance the oral bioavailability of peptides and 
control their release, as well as provide a preserved environment for the encapsulated drugs 
(Araújo et al., 2014; Gundogdu and Yurdasiper, 2014; Morishita and Peppas, 2006). 
Among the mostly studied materials, PLGA and PSi have attracted a lot of attention 
becoming the most desirable materials in the drug delivery field for the administration of 
macromolecules (Araújo et al., 2014; Santos et al., 2014). In one hand, PLGA features can 
be modulated by the ratio between the monomers which constitute the polymer, exhibiting a 
wide range of erosion times, favourable degradation characteristics and tuneable mechanical 
properties. It can be used to encapsulate numerous drugs with different physicochemical 
properties and also to sustain their release (Danhier et al., 2012; Wang et al., 2013). 
Moreover, it has extensive clinical applications, being already approved by the FDA and the 
EMA for parenteral administration (Danhier et al., 2012). On the other hand PSi nanoparticles 
have large surface area, pore volumes with adjustable diameters (2-50 nm), as well as higher 
drug loading capacity compared to the majority of the other materials (Liu et al., 2013a; Liu et 
al., 2014; Shahbazi et al., 2012). Furthermore, the drug loading is usually a simple process 
where the drug is retained inside the mesopores by physical adsorption or electrostatic 
interactions (Liu et al., 2013a). Nevertheless, the oral delivery of PLGA and PSi nanoparticles 
is not in such advanced state. The negative surface charge of the nanoparticles tends to limit 
their interaction with the negatively charged cell’s surface, which is further intensified by the 
rapid turnover of the mucus and the intestinal cells (Araújo et al., 2014). 
To tackle the limitations of these oral drug nanocarriers, the nanoparticles can be 
tailored with other materials to yield a variety of physical properties to overcome the main 
intestinal barriers, such as the mucus layer, epithelium and enzymatic degradation (Guo and 
Gemeinhart, 2008; Pereira et al., 2014). CS and cell penetrating peptides (CPP) are 
polycationic molecules extensively used in the drug delivery field. CS is a biopolymer that 
has been mainly used to modify nanoparticles due to its mucoadhesive characteristics and its 
properties as an intestinal permeability enhancer by transiently open the tight junctions 
existing between the epithelial cells (São Pedro et al., 2009; Sarmento and das Neves, 2012; 
Sosnik et al., 2014). CPP were originally considered as a “Trojan horse” because of their 
ability of entering cells without causing damage or eliciting a cellular response (Palm-Apergi 
et al., 2009; Shi et al., 2014), increasing the transcellular transport (Wang et al., 2014). Yet, a  
major challenge still remains for the oral delivery of peptides in order to overcome the harsh 
conditions of the stomach. In this regard, pH-sensitive polymers have been frequently 
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employed in the drug formulation and/or coating of nano- and microparticles to protect them 
from the very acidic gastric pH (Liu et al., 2014; Zhang et al., 2014).  
In this study, multifunctional systems were developed that can simultaneously load 
peptides and enzymatic inhibitors in a single carrier with the aim to resist the conditions of 
the stomach, to enhance the nanoparticles’ interactions with the intestinal mucus and 
epithelium, and to protect the peptides from enzymatic degradation after the release. An 
antidiabetic peptide, GLP-1, is in the pipeline for the T2DM therapy, and was used here as a 
model peptide. Due to its poor intestinal permeability, GLP-1 needs to be administrated by 
parenteral route, resulting in poor patient compliance (Pawar et al., 2014; Wang et al., 2015). 
Moreover, the success of the GLP-1 therapy is hindered by its rapid degradation (< 2 min) by 
the dipeptidyl peptidase 4 (DPP4) enzyme produced in the intestine (Janardhan and Sastry, 
2014). Therefore, in order to achieve an efficient release and permeability across the 
intestinal epithelium of active GLP-1, the antidiabetic peptide was loaded into different 
nanoparticles composed of PLGA and PSi biomaterials. The PLGA and PSi nanoparticles 
were further modified with the mucoadhesive polymer CS and with an oligoarginine CPP to 
increase the permeability of nanoparticles across the intestinal cells. Afterwards, the 
nanoparticulate systems were encapsulated within an enteric polymer 
hydroxypropylmethylcellulose acetylsuccinate (HPMC-AS) loaded with the DPP4 inhibitor 
(iDPP4), using the microfluidic technique (Figure 20). To the best of our knowledge, this is 
the first time that the combination of these two drugs was formulated in a single delivery 
system. This innovative approach produced monodisperse and uniform particulate structures 
with the desired composition (Liu et al., 2014; Zhang et al., 2014). In comparison to the 
conventional preparation methods with microfluidics, by tuning the flow rates of the 
immiscible fluids, emulsions are formed with an exquisite degree of control and rather high 
encapsulation efficiency (Duncanson et al., 2012; Liu et al., 2013b). The resultant 
multifunctional systems were then characterized for size, morphology, pH-responsiveness, 
drug release, and synergistic antidiabetic peptide GLP-1 permeability across a triple intestinal 
cell co-culture model (Araújo and Sarmento, 2013) in the presence of the enzymatic iDPP4. 
The inhibition capacity of the DPP4 enzyme activity was also evaluated.  
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Figure 20. Schematic representation of the microfluidics approach used to produce the pH-
responsive systems, co-loaded with GLP-1 and iDPP4. The inner fluid consisted of modified 
PLGA and PSi nanoparticles and the enteric polymer dissolved in ethyl acetate. The 
antidiabetic peptide GLP-1 was loaded into the modified nanoparticles, whereas the 
enzymatic iDPP4 was dissolved directly in the inner fluid. The outer continuous fluid was an 
aqueous solution of F127 (2 % w/v) which could efficiently stabilize the oil/water (O/W) 
interface. 
 
3. Materials and Methods 
3.1. Materials and cell lines 
GLP-1 was purchased from United Peptides (USA). iDPP4 (NVP DPP 728 
dihydrochloride) was purchased from Tocris Bioscience (UK) and CPP R9 was purchased 
from GenicBio (China). PLGA 50:50 was obtained from Purac Biomaterials, Purasorb® PDLG 
5004A, The Netherlands. Polyvinyl alcohol (PVA), medium molecular weight CS, 2-(N-
morpholino)-ethanesulfonic acid (MES), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
(EDC), N-hydroxysuccinimide (NHS), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) and glutaraldehyde were purchased from Sigma-Aldrich (USA). HPMC-AS was 
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obtained by Shin-Etsu (Japan). Pluronic® F127 was purchased from BASF (Germany). 
Hank’s balanced salt solution (HBBS), phosphate buffered saline (PBS), Alexa Fluor® 488 
hydrazine, Versene and heat inactivated foetal bovine serum (FBS) were purchased from 
Life Technologies (USA). Dulbecco’s Modified Eagle medium (DMEM), Roswell Park 
Memorial Institute medium (RPMI 1640), L-glutamine, non-essential amino acids, penicillin 
(100 IU/mL) and streptomycin (100 mg/mL), ethylenediamine tetraacetic acid (EDTA) and 
trypsin–EDTA were purchased from HyClone (USA). Human colon carcinoma (Caco-2), 
lymphocytic Raji B cells and human gastric adenocarcinoma (AGS) cell lines were obtained 
from American Type Culture Collection (ATCC, USA), and the human colorectal 
adenocarcinoma modified with methotrexate (HT29-MTX) cells was kindly provided by Dr. T. 
Lesuffleur (INSERM U178, Villejuif, France). 
 
3.2. Preparation of PLGA nanoparticles 
Polymeric PLGA nanoparticles were prepared through modified solvent 
emulsification-evaporation method, based on the water-in-oil-in-water (w/o/w) double 
emulsion technique (Zhang et al., 2006). PLGA 50:50 was used for the preparation of 
polymeric nanoparticles. 100 mg of polymer were dissolved in 1 mL of ethyl acetate. Then, 
100 µL of GLP-1 solution in MilliQ-water (2.5 mg/mL) was added to this solution and 
homogenised for 30 sec with 70% amplitude using a Vibra-Cell™ ultrasonic processor 
(Sonics®, Sonics and Matrials, Inc., USA). The primary emulsion (w/o) formed was then 
added into 4 mL of the surfactant, a 2% aqueous solution of PVA, and homogenised again 
for 30 sec with the same amplitude. The second emulsion formed (w/o/w) was finally added 
to 7.5 mL of surfactant and was left under magnetic stirring at 300 rpm for 3 h for solvent 
evaporation.  
CS solution was prepared by dissolving CS in 1% (v/v) acetic acid solution overnight 
under magnetic stirring. The pH was adjusted to 5.5, followed by filtration through a paper 
filter Millipore #2 and stored at 4ºC. To coat the nanoparticles with the CS, the formulation 
was added into a solution of CS after solvent evaporation, at a ratio of 2:1 (w/w) 
(CS:nanoparticles), and left overnight under magnetic stirring, allowing surface layer 
deposition of the polymer into the nanoparticles.  
Nanoparticles were washed three times in MilliQ-water and separated through 
centrifugation, using an ultra-centrifuge (Optima™ TL, Beckman Coulter, USA), at 34,300 × g 
for 20 min. After centrifugation, the nanoparticles were re-dispersed in MilliQ-water and 
stored at 4°C for further analysis.  
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Drug-free nanoparticles were prepared according to this procedure but using MilliQ-
water instead of GLP-1 solution as the internal aqueous solution. 
 
3.3. Preparation of PSi nanoparticles 
The free-standing PSi films were anodized using single crystal Si wafers <100> of p+-
type with resistivity values of 0.01–0.02 Ωcm. The PSi was prepared by anodizing the wafers 
in hydrofluoric acid (38%)–ethanol mixture. The PSi nanoparticles production was conducted 
by applying three different current pulses to the Si-wafer. The hydrocarbonization treatment 
consisted of exposing the particles to a 1:1 (v/v) flow of N2 and acetylene for 15 min at room 
temperature, followed by 15 min at 500 °C, and then cooling down to room temperature 
under N2 flush. Wet ball milling was used to reduce the size of the hydrocarbonized free-
standing PSi films, and the surface oxidation was minimized by using 1-decene as the milling 
liquid. The final size separation and exchange of the suspension media were done by 
centrifugation. The surface of the nanoparticles was further modified using undecylenic acid 
giving rise to undecylenic modified thermally hydrocarbonized PSi nanoparticles (Shahbazi et 
al., 2013, Kovaleinen et al., 2012). 
For the GLP-1 loading, a ratio of 1:5 (w/w) was used for GLP-1-loaded PSi 
nanoparticles. The GLP-1 loading was performed by dispersing the PSi nanoparticles in a 
GLP-1 solution and stirring at room temperature for 90 min at 300 rpm. After that, the 
suspension was centrifuged at 27,600 × g for 5 min to remove the excess of free GLP-1. To 
coat the nanoparticles with CS through physical adsorption, the nanoparticles were added to 
a CS solution in a ratio of 2:1 (w/w) (CS:nanoparticles), and left overnight under magnetic 
stirring at 300 rpm. For the nanoparticles coated by physical adsorption with CS, the GLP-1 
loading was performed prior to the coating in order to prevent the blockage of the 
nanoparticles pores by CS (Shrestha et al., 2014). 
 
3.4. CPP conjugation to the CS-coated nanoparticles 
  The covalent conjugation between the free amine groups in the CS structure with the 
carboxylic group of CPP was made through the EDC/NHS coupling chemistry. For chemical 
conjugation, 1 mg of PLGA+CS nanoparticles and 300 µg of PSi+CS were separately 
dispersed in 1 mL of 10 mM MES containing EDC (final concentration 10 mM) and NHS (final 
concentration 17 mM) at pH 5.5. CPP was added to this dispersion in a ratio of 1:10 
(CPP:nanoparticles) and the nanoparticles were allowed to conjugate overnight in the dark, 
stirring at 300 rpm originating PLGA+CS-CPP and PSi+CS-CPP, respectively. Afterwards, 
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the nanoparticles were collected by centrifugation at 34,300 × g for 20 min for PLGA+CS-
CPP nanoparticles and at 27,600 × g for 5 min for PSi+CS-CPP, and then washed three 
times with MilliQ-water.  
 
3.5. Fabrication of a Glass-Capillary Microfluidic Flow-Focusing Device 
  The microfluidics device consisted of an assembly of borosilicate glass capillaries on 
a glass slide, as previously described (Chu et al., 2007). One of the ends of the collection 
cylindrical capillary (World Precision Instruments, Inc.) was tapered using a micropipette 
puller (P-97, Sutter Instrument Co., USA) to a diameter of 20 μm. This diameter was further 
enlarged to ca. 80 μm using a microforge (P-97, Sutter Instrument Co., USA). The capillary 
had an inner diameter of approximately 580 µm and an outer diameter of approximately 
1,000 μm and it was hydrophilic, preventing the wetting of the oil shell of the emulsion on its 
wall. Afterwards this cylindrical tapered capillary was inserted into the left end of the square 
capillary (Vitrocom, USA) and coaxially aligned. This square capillary had an inner dimension 
of 1000 μm. Two polyethylene tubes attached to syringes were added to the glass slide to 
allow the entering of the inner and out fluids at constant flow rates controlled by pumps (PHD 
2,000, Harvard Apparatus, USA). A transparent epoxy resin (5 minute® Epoxi, Devcon) was 
used to seal the capillaries and the polyethylene tubes where required. 
 
3.6. Enteric coating of nanoparticles using microfluidics  
The GLP-1 loaded nanoparticles were encapsulated into a pH-sensitive polymer 
(HPMC-AS) using a double emulsion technique, through a microfluidic flow-focusing glass 
device (Figure 11) (Liu et al., 2014). The device consisted of two types of glass capillaries 
with different diameters, in which the outer diameter of the inner cylindrical tapered capillary 
fitted the inner dimensions of the outer capillary, facilitating the alignment of their axes.  
To prepare the co-drug loaded multifunctional systems, 0.5 mg of iDPP4 was added 
into 1 mL of 4% of HPMC-AS dissolved in ethyl acetate (oil phase). To this solution, 100 µL 
of MilliQ-water containing 20 mg of PLGA+CS-CPP or 200 µg of PSi+CS-CPP (water phase) 
were added dropwise and homogenised for 30 s using a Vibra-Cell™ ultrasonic processor 
(Sonics®, Sonics and Matrials, Inc., USA), originating to the first emulsion (w/o). This solution 
was then poured into a syringe to be injected in the microfluidic device as the inner fluid (oil 
phase). The outer fluid used was an aqueous solution of 2% Pluronic® F127 (water phase). 
The inner and outer fluids were both pumped into the microfluidic device in opposite 
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directions at 10 mL/h and 230 mL/h, respectively. This flow-focusing geometry forces the 
inner fluid to breakdown, forming the second monodisperse emulsion (w/o/w) droplets at the 
entrance orifice of the tapered cylindrical glass capillary. The droplets were collected in a 
cylindrical beaker containing 80 mL of an aqueous sucrose solution (100 mOsm/L) in order to 
facilitate the particles deposition. These particles were solidified through the diffusion of ethyl 
acetate to the external aqueous phase. As a result, multifunctional systems containing both 
GLP-1 loaded CS-CPP modified PLGA and PSi nanoparticles and iDPP4 into a pH-sensitive 
polymer were obtained, to form the H-PLGA and H-PSi respectively. 
 
3.7. Particle characterization 
The nanoparticles average size (Z-average), PdI and surface charge were analysed 
by dynamic light scattering using a Malvern Zetasizer Nano ZS instrument (Malvern 
Instruments Ltd, UK).  
The AE and LD of GLP-1 in the developed nanoparticles were calculated by the 
difference between the total amount of GLP-1 used to prepare the loaded nanoparticles and 
the amount of GLP-1 that remained in the aqueous phase, after the nanoparticles isolation by 
centrifugation, as described elsewhere (Araújo et al., 2014). The amount of GLP-1 was 
determined by high performance liquid chromatography (HPLC) (Agilent 1260, Agilent 
Technologies, USA), using a C18 column (4.6 × 150 mm, 5 µm, Supelco Discovery
® C18, 
USA). The mobile phase consisted of 0.1% trifluoroacetic acid (pH 2.0) and acetonitrile 
initially set at the ratio of 70:30 (v/v), which linearly changed to 60:40 (v/v) as a gradient over 
5 min. Afterwards, the ratio was kept constant for 5 more minutes. The flow rate was 1.0 
mL/min and the injected volume of the sample was 75 µL. The column temperature was set 
at room temperature and the detection wavelength at 240 nm. The total area under the curve 
was used to quantify the GLP-1.  
The morphology and surface topography, shape and size of the enteric encapsulated 
particles were assessed by SEM (SEM, Zeiss DSM 962, Germany). 
 
3.8. pH-Sensitive response of the multifunctional particulate systems  
After collection and washing of the particles, they were placed on the SEM supports 
with double sided carbon adhesive tape. The excess of water was removed with filter paper 
and different buffer solutions at pH values of 1.2, 4.0, 5.5, 6.0 and 6.8, were added on top of 
the particles for 2 h. For pH of 6.0 and 6.8, the 10 min time point was also analysed. After 
these time points, the excess of buffer solutions were removed with filter paper and the 
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particles were allowed to dry at room temperature overnight. Afterwards, the particles were 
sputter coated with platinum before visualizing under the SEM. 
 
3.9. In vitro release studies 
The multifunctional system particles, corresponding to 50 µg of GLP-1, were added 
separately to 14 mL of pH 1.2 buffer (50 mM KCl) to simulate the gastric fluid and to FaSSIF 
pH 6.8 (50 mM KH2PO4, 15 mM NaOH, 1.0% (w/v) pancreatin) to simulate the fasted state 
fluid of the intestinal milieu. At specific time points, aliquots of 750 µL were collected and the 
withdrawn volume was replaced with fresh medium, keeping the volume constant. All the 
collected aliquots were centrifuged at 27,600 × g and the supernatant was used for HPLC 
analysis in order to quantify the GLP-1 and iDPP4 released from the systems over time. All 
the tests were performed at 37 ºC and at 100 rpm under sink conditions. 
GLP-1 was quantified by HPLC as described above. iDPP4 was quantified by the total 
AUC through HPLC (Agilent 1260, Agilent Technologies, USA), using a Kinetex 2.6u XB-C18 
100A column (4.6 × 75 mm, Phenomenex®, USA). The mobile phase consisted of 0.025% of 
ammonium hydroxide (pH 9.5 adjusted with 50% of phosphoric acid) and acetonitrile set at 
the ratio of 82:18 (v/v) for 5.5 min. The flow rate was 1.0 mL/min and the injected volume of 
the sample was 5 µL. The column temperature was set at room temperature and the 
detection wavelength at 275 nm. 
 
3.10. Cell culturing 
AGS (passage numbers of 1015) grew in a complete medium consisting of RPMI 
1640 supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine, 1% (v/v) NEAA, and 1% (v/v) 
antibiotic–antimitotic mixture (final concentration of 100 U/mL Penicillin and 100 U/mL 
Streptomycin). Caco-2 (passage numbers of 3140) and HT29-MTX (passage numbers of 
20–50) cells grew separately in culture flasks in a complete medium consisting of DMEM 
supplemented in the same way as described before for RPMI. The cells were sub-cultured 
once a week using 0.25% trypsin–EDTA to detach the cells from the flasks and seeded at a 
density of 0.5 × 106 cells per 75 cm2 flask. The culture medium was replaced every other day. 
Cells were maintained in an incubator (BB 16 gas incubator, Heraeus Instruments GmbH, 
Germany) at 37 ºC and 5- % CO2 and 95 % relative humidity. Raji B cells (passage numbers 
of 26–35) were cultured in flasks with supplemented DMEM and with the same conditions as 
described above.  
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3.11. Cell viability studies 
The viability tests were conducted using the AGS, Caco-2 and HT29-MTX cell lines. 
Typically, 100 μL of 0.5 × 106 cells/mL were seeded separately in 96-well plates and were 
allowed to attach overnight. Afterwards, the medium was aspirated and the wells were 
washed twice with 100 µL of pre-warmed HBSSHEPES buffer (pH 7.4). After washing, 100 
µL of the nanoparticle solutions at concentrations of 0.1, 0.25, 0.5 and 1 mg/mL were added 
to each well and the plates were incubated at 37 ºC for a period of 3 h for AGS, and for 12 h 
for Caco-2 and HT29-MTX cells. Afterwards, the plates were equilibrated at room 
temperature for about 30 min and then washed twice with 100 µL of fresh HBSSHEPES 
buffer (pH 7.4) at room temperature. 50 µL of the reagent assay CellTiter-Glo® (Promega 
Corporation, USA) were added to 50 µL of HBSSHEPES (pH 7.4) in each well. Negative 
(HBSSHEPES buffer, pH 7.4) and positive (1% Triton X-100) control wells were also used 
and treated similarly as described above. The solutions were mixed and protected from the 
light for approximately 10 min on an orbital shaker at room temperature. Finally, the 
luminescence was measured using a Varioskan Flash plate reader (Thermo Fisher Scientific 
Inc., USA). All data sets were compared with a negative control, considered as 100% 
viability. 
 
3.12. Cell–nanoparticle interactions  
 
In order to visualize the nanoparticles, they were conjugated with Alexa Fluor 488™ 
(green fluorescence emission) after their production through the EDC/NHS coupling 
chemistry. The covalent conjugation was made between the free carboxylic groups of the 
nanoparticles and the free amine groups of Alexa Fluor 488™. For chemical conjugation, 1 
mg of PLGA and 300 µg of PSi nanoparticles were separately dispersed in 1 mL of 10 mM 
MES containing EDC (final concentration 10 mM) and NHS (final concentration 17 mM) at pH 
5.5 and activated for 2h in the dark. Afterwards, Alexa Fluor 488™ was added to this 
dispersion in a ratio of 1:70 (w/w) and the materials were allowed to conjugate for 2h in the 
dark, stirring at 300 rpm. After conjugation, the nanoparticles were collected by centrifugation 
at 34300 × g for 20 min for PLGA nanoparticles and at 27,600 × g for 5 min for PSi and 
washed with MilliQ-water. The other modifications were further made as described 
previously. 
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3.12.1. Confocal microscopy studies 
The intestinal cellnanoparticle interactions were evaluated through confocal 
microscopy using a Leica SP5 confocal microscope (Leica Microsystems, Germany). Caco-2 
and HT29-MTX were co-cultured in a 90:10 ratio (Caco-2:HT29-MTX), in Lab-Tek 8-chamber 
slides (Thermo Fisher Scientiﬁc Inc., USA) and allowed to attach overnight (Araújo et al., 
2014). Then, the cells were washed twice with pre-warmed fresh HBSSHEPES buffer (pH 
7.4). 50 µL of Alexa Fluor 488™ labeled nanoparticles at a concentration of 200 µg/mL were 
added to the cells and incubated at 37 C for 3 h. After incubation, the cells were washed 
twice with pre-warmed fresh HBSSHEPES buffer (pH 7.4). Afterwards, the plasma 
membrane was stained by adding 200 µL of CellMask™ Orange (Invitrogen, USA) and 
incubated for 3 min at 37 C. The excess of staining solution was washed twice with pre-
warmed fresh HBSSHEPES buffer (pH 7.4) and the cells were fixed using 2.5% 
glutaraldehyde for 20 min.  
 
3.12.2. Flow cytometry studies 
The quantification of the nanoparticles that are associated to the cells was evaluated 
using flow cytometry. 1 mL of Alexa Fluor 488™ labeled nanoparticles at a concentration of 
300 µg/mL were added to 0.7 × 106 Caco-2:HT29-MTX co-culture cells, in a ratio of 90:10, in 
pre-warmed HBSSHEPES buffer (pH 7.4) and incubated at 37 °C for 3 h. Afterwards, cells 
were washed three times with HBSSHEPES buffer (pH 7.4) and detached with Versene for 
the measurements. Then, the cells were re-suspended in basic sorting buffer that consisted 
of PBS (Ca/Mg2+ free) with 5 mM of EDTA, 25 mM of HEPES and 2% of FBS, to avoid cells 
aggregation, and analysed right after using a Beckman Coulter Galios™ Flow Cytometer with 
a laser excitation wavelength of 488 nm. The results were analysed using the software 
Kaluza Analysis Version 1.3. 
 
3.12.3. Permeability experiments 
For the permeability experiments a triple co-culture cell model was used. For that, 7 × 
104 cells/cm2 of Caco-2 and HT29-MTX cells in a ratio of 90:10 were seeded in 12-Transwell 
cell culture inserts and were allowed to grow and differentiate for 14 days with medium 
replacement every other day. Then, 1.0 × 105 Raji B cell were added to the basolateral 
chamber for 7 days more in order to induce the phenotype change of Caco-2 cells into M 
cells and to obtain a triple co-culture model (Araújo and Sarmento, 2013). The permeability 
experiments across the cell monolayers were performed in the apical-to-basolateral direction 
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in HBSSHEPES (pH 7.4) at 37 ºC using an orbital shaker (100 rpm). After removing the cell 
culture medium, the Transwells were washed twice with pre-warmed fresh HBSSHEPES 
(pH 7.4) buffer and equilibrated for 30 min. Then, 0.5 mL of nanoparticles corresponding to 
an amount of 6 µg/mL of GLP and 40 µg/mL of iDPP4 were pipetted into the apical side of 
the inserts. At different time points (15, 30, 60, 120 and 180 min), 100 µL of samples were 
taken from the basolateral side of the inserts and the same volume of pre-warmed fresh 
HBSSHEPES (pH 7.4) buffer was added to replace the withdrawn volume. Sample 
concentrations were quantified for GLP-1 by EIA GLP-1 Kit (Sigma-Aldrich®, USA), according 
to manufacturer’s instructions and for iDPP4 by HPLC, as previously described. The integrity 
of the cell monolayers was checked before and after the permeability experiments by 
measuring the transepithelial electric resistance (TEER) using Millicell®-Electrical Resistance 
System (Millipore, USA).  
 
3.12.4. DPP4 enzymatic activity 
The enzymatic activity of the DPP4 was measure according to the manufacturer’s 
instructions using a DPP4 Activity Assay Kit (Sigma-Aldrich®, USA). After the permeability 
experiments, the cells were washed once with pre-warmed HBSSHEPES buffer (pH 7.4). 
Then, the cells were lysed with 100 µL of ice-cold Assay Buffer. After lysis, 10 µL of each 
sample was diluted with Assay Buffer to have a final volume of 50 µL. To each test samples 
10 µL of the Assay Buffer was added. To the blank samples, 10 µL aliquots of iDPP4 were 
added, mixed well and incubated for 10 min at 37 °C. Afterwards, 40 µL of the Master 
Reaction Mix was added to each test sample and properly mixed and protected from the 
light. The samples were then incubated for 5 min at 37 °C before starting the fluorescent 
measurements (λex = 360 and λem = 460). The plate was kept at 37°C and protected from the 
light, and the measurements were taken every 5 min for 1 h using a Varioskan Flash plate 
reader (Thermo Fisher Scientific Inc., USA). 
 
 3.13. Statistical analysis 
 
All the experiments were performed in triplicate and represented as mean ± standard 
deviation (SD). A Student t-test and one-way analysis of variance (ANOVA) with 
Uniparametric and Bonferroni post-test (GraphPadPrism, GraphPad software Inc., CA, USA) 
were used to analyse the data, respectively. The level of significance was set at probabilities 
of *p < 0.05, **p < 0.01, and ***p < 0.001. 
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4. Results and Discussion 
4.1. Characterization of the multifunctional systems 
After the production of the nanoparticles and the CSCPP surface functionalization, 
the nanoparticles were characterized in respect to mean size, PdI, surface charge, AE and 
LD, as shown in Table 5. Both the unmodified PLGA and PSi nanoparticles presented a z-
average size of ca. 200 nm with a PdI below 0.1, and negative surface charges. In order to 
increase the interaction of the nanoparticles with the negatively charged intestinal mucus 
layer and to improve the permeability of the antidiabetic peptide GLP-1 across the intestinal 
cells, the nanoparticles were coated firstly with CS to form PLGA+CS and PSi+CS 
nanoparticles (Araújo et al., 2014; Chronopoulou et al., 2013; Wang et al., 2013). The CS-
modified nanoparticles showed an increase in their size and conversion of the zeta-potentials 
to positive values, demonstrating the successful CS coating of the nanoparticles (Araújo et 
al., 2014; Chronopoulou et al., 2013; Guo and Gemeinhart, 2008; Wang et al., 2013). In 
order to improve the transcellular transport, the CS-coated nanoparticles were further 
modified by covalent attachment of polyarginine R9 CPP to the amine groups of the CS. 
CPP, such as R9, are small peptides of few acidic amino acid residues with a high positive 
charge (Wang et al., 2014). Such CPP are known to have a positive role in the translocation 
of some drugs across the intestinal epithelium, increasing their oral bioavailability (Bu et al., 
2014; Chen et al., 2012; Kamei et al., 2008; Liu et al., 2013c; Morishita et al., 2007). Overall, 
when modified with CS and CPP (to form PLGA+CS-CPP and PSi+CS-CPP particles), the 
nanoparticles presented higher particle sizes than the unmodified ones, without significant 
change in the zeta-potential values (Table 5). Together with the size and charge, the 
similarity in the AE and LD values, indicated the high homogeneity of the nanoparticles from 
batch-to-batch (Araújo et al., 2014). 
The CS-CPP modified nanoparticles were further encapsulated within an enteric 
polymer, HPMC-AS, through the microfluidics technique, for their protection, as well as for 
the protection of the CS and CPP, at the low pH conditions of the gastric environment, 
originating the H-PLGA and H-PSi particles. The microfluidics technique has brought 
revolutionary impact in the pharmaceutical technology field by manipulating nanoliter 
volumes, in micro-scalefluidic channels, with high precision and reduced consumption of 
reagents (Liu et al., 2015; Valencia et al., 2012). In contrast with the conventional production 
methods, which yield a polydisperse population with drug loading levels less than ideal, with 
the microfluidics technique the e fficiency of encapsulation is near 100%, the particles formed 
are stable, homogeneous and can be size-controlled (Liu et al., 2014; Zhang et al., 2014). 
Moreover, it can be applicable for diverse constituent fluids, with various chemical 
CHAPTER IV  
116 
compositions and to different cargos, making it a promising technique for the production of 
several drug delivery systems (Herranz-Blanco et al., 2015). The flow-focusing geometry 
used in this work is a droplet-based method widely used to produce different types of fluid 
entities on a continuous basis by applying an extensional coflow (Herranz-Blanco et al., 
2015). In this method, fluids are forced through a narrow orifice where high shear and 
capillary instability break bubbles off the tip, forming monodisperse emulsion droplets (Zhang 
et al., 2014). 
As shown by the scanning electron microscopy (SEM) (Figure 21), the produced 
particles had a regular and spherical shape with smooth surface and size around 59.44  
8.01 µm. The SEM images also showed a homogeneous size distribution, suggesting the 
production of monodisperse particles by the microfluidic technique (Liu et al., 2014). The 
loading degree of GLP-1 was of 0.030 ± 0.007% and 0.7300 ± 0.0001 % for the PLGA and 
PSi systems encapsulated into HPMC-AS, respectively, and for iDPP4 of 1.00 ± 0.01% and 
1.260 ± 0.008%, respectively.  The iDPP4 encapsulation efficiency was 20 ± 5%. Considering 
the amount (mass) of iDPP4 in the final formulation and that the IC50 of the iDPP4 is of 14 
nM, the amount of inhibitor present in the current formulation should be more than enough to 
be active and to inhibit the enzyme activity efficiently. However, higher values can certainly 
be obtained in the final formulation, for example, by increasing the viscosity of the system 
(e.g., the viscosity of the HPMC-AS polymer) in order to retain strongly the iDPP4 in the 
polymer matrix, by increasing the osmolality of the collection solution or the solution viscosity, 
or by encapsulating the iDPP4 in the nanoparticles either together with the GLP-1 or alone. 
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Table 5. Characterization of the nanoparticles in respect to their size, PdI, surface charge (-
potential), AE and LD of GLP-1 of different nanoparticles. Results are presented as mean ± 
standard deviation, n ≥ 3. 
 
 
 
 
 
 
 
 
 
 
 
Sample 
Size 
(nm) 
PdI 
-potential 
(mv) 
AE 
(%) 
LD 
(%) 
PLGA 199.0 ± 4.1 0.08 ± 0.02 23.6 ± 0.2 58.9 ± 6.9 0.14 ± 0.03 
PLGA+CS 243.0 ± 2.2 0.26 ± 0.01 24.8 ± 2.7 59.7 ± 0.7 0.07 ± 0.01 
PLGA+CS-CPP 
277.2 ± 3.8 0.32 ± 0.02 21.6 ± 3.8 59.7 ± 0.7 0.07 ± 0.01 
PSi 193.7 ± 3.0 0.09 ± 0.03 16.3 ± 0.3 75.0 ± 0.6 15.00 ± 0.05 
PSi+CS 282.9 ± 8.0 0.34 ± 0.02 19.2 ± 0.4 75.0 ± 0.5 7.50 ± 0.03 
PSi+CS-CPP 
320 ± 9.8 0.33 ± 0.02 19.1 ± 1.0 75.0 ± 0.5 7.50 ± 0.03 
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Figure 21. Dissolution behaviour of the CS-CPP modified nanoparticles encapsulated in the 
HPMC-AS polymer at different pH conditions of 1.2 and 5.5 for 2 h, and at pH 6.0 and 6.8 for 
10 min and 2 h. The SEM images show the morphology of the prepared particles. The control 
group was composed by particles at pH 4.0. At pH values below 6.0 the structural integrity of 
the particles was maintained. At pH 6.0 and 6.8 the structure of the polymeric matrix was 
destroyed by the dissolution of the polymer. 
 
4.2. pH-Sensitive response of the multifunctional systems  
HPMC-AS is a polymer insoluble in acidic conditions and highly soluble at neutral or 
alkaline pH (pH > 6.0) (Liu et al., 2014). To evaluate whether the prepared nanoparticles 
were successfully encapsulated in the polymer and whether the multifunctional system could 
stand the harsh conditions of the stomach, the particles were observed under SEM at 
different pH conditions. As shown in Figure 21, at pH 1.2 and 5.5, the shape and surface 
morphology of particles were regular and smooth, similarly to the observed control particles, 
showing that the HPMC-AS encapsulation using the microfluidics technique was effective 
and that the nanoparticles were protected at the acidic conditions. When the multifunctional 
particulate system was in contact with buffer at pH 6.0, the polymer started to dissolve and 
the particles structure started to be compromised already after the first 10 min. After 2 h of 
incubation, the surface of the particles appeared rough with some visible holes as an 
indication for the dissolution of the polymer. At pH 6.8, this behaviour was even more 
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pronounced with greater changes in the particles’ structure during the first 10 min. After 2 h 
the polymer was completely dissolved. These results are in accordance with the pH 
responsive characteristics of the polymer, as described elsewhere (Liu et al., 2014; Zhang et 
al., 2014). 
 
4.3. Cell viability studies 
  The viability studies were performed in three different cell lines at two different time 
points and using different concentrations of the particles. AGS is a gastric epithelial cell line 
originated from human gastric adenocarcinoma (Afshari et al., 2014), and the cell viability 
was assessed after 3 h of incubation with the particulate systems. Caco-2 and HT29-MTX 
are intestinal cell lines originated from colon adenocarcinomas, representing the enterocytes 
and mucus producing goblet cells (Antunes et al., 2013; Araújo and Sarmento, 2013), 
respectively, and their viability was measured after 12 h of incubation with the particles. 
Testing these three cell lines in the two different time points covered the maximum transit 
time that the particles would be in the stomach and intestine when orally administered, 
making this a suitable assay to understand whether there is any concentration or component 
dependent toxicity (Araújo et al., 2014; Shrestha et al., 2014). Non-modified nanoparticles, 
CS-CPP-modified nanoparticles, and CS-CPP modified nanoparticles further encapsulated 
with HPMC-AS particles were tested. 
  With regards to the PLGA systems, it was observed in the three cell lines studied, that 
none of the non-modified nanoparticles, CS-CPP modified nanoparticles and CS-CPP 
modified nanoparticles encapsulated with HPMC-AS presented toxicity at the tested 
concentrations, as depicted in Figure 22. PLGA is commonly accepted for its low cytotoxic 
and good biocompatibility and biodegradability properties, and has already been approved by 
the FDA for clinical use (Liu et al., 2013c; Shi et al., 2014). On the other hand, positively 
charged particles are usually described as interacting more with the surface of the cell 
membranes than the negatively charged particles, which may lead to higher cellular 
cytotoxicity (Kumari and Yadav, 2011; Verma and Stellacci, 2010). However, in this study, 
despite the positive surface charge of the CS-CPP modified nanoparticles, no decrease in 
cell viability was observed in all the cell lines tested. This indicates that the amounts of CS 
and CPP used did not trigger cytotoxicity reaction, and thus, could be considered as safe for 
oral drug administration purposes. Previously, some studies have also demonstrated that 
certain CPPs, including oligoarginine, did not cause any harm to the intestinal epithelial cells 
(Kilk et al., 2009; Morishita et al., 2007).  
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Figure 22. Cell viability levels of the gastric and intestinal cells after exposure to the particles 
assessed by the CellTiter-Glo® luminescence assay. (A and B) Viability of AGS after 3 h of 
incubation with different particles concentrations at 37 °C. (C and D) Viability of Caco-2 and 
(E and F) HT29-MTX cells after 12 h incubation with different particle concentrations at 37 
°C. All the data sets were compared to the negative control (Hank’s Balanced Salt Solution, 
HBSS) using a Student’s t-test with an unpaired post-test. Error bars represent mean ± 
standard deviation (n ≥ 3), and the difference probabilities were set at *p < 0.05, **p < 0.01, 
and ***p < 0.001. 
 
  HPMC-AS has been used as a pharmaceutical excipient and has a median lethal 
dose (LD50) higher than 2.5 g/kg, which is much higher than the amounts used in our particle 
formulation (Hoshi et al., 1985). Moreover, the organic solvent used to dissolve the polymer, 
ethyl acetate (EA), is considered a rather non-toxic organic solvent (Liu et al., 2009), and it is 
believed that no residues of the solvent would be present in the final formulation. In fact, due 
to its high solubility in water, EA presented a fast diffusion rate to this solvent which allowed 
the fast solidification of the particles in the collecting solution, after their formation in the 
microfluidics device (Liu et al., 2009; Zhang et al., 2014). 
  For the PSi particles, it was observed that the non-modified nanoparticles, CS-CPP 
modified nanoparticles, and the CS-CPP modified nanoparticles encapsulated with HPMC-
AS presented concentration dependent cytotoxicity values. The CS-CPP modified 
nanoparticles presented higher viability values than the non-modified ones with the exception 
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of the HT29-MTX cells. This behaviour may be related to the presence of CS on the surface 
of the nanoparticles, which would increase the interaction of the nanoparticles with the 
mucus secreting cells due to the mucoadhesive properties (Shrestha et al., 2014), as 
described elsewhere (Araújo et al., 2014). When the pH-sensitive polymer was used to 
encapsulate the CS-CPP modified nanoparticles, there were no statistically significant 
changes in the viability of the three cell lines. Although there was a tendency for improved 
cell viability values by the encapsulated nanoparticles compared to the non-encapsulated 
ones.  
 
4.4. In vitro release studies 
  To confirm the successful protection of the CS-CPP modified nanoparticles and the 
loaded drugs from the acidic gastric conditions, as well as to predict the release profiles of 
the antidiabetic peptide GLP-1 and the enzymatic iDPP4, in vitro release studies were 
performed. In order to mimic the environment of the stomach, the study was conducted at pH 
1.2 for 2 h. Similarly, to mimic the intestinal environment, the study was performed using 
simulate fasted state intestinal fluid (FaSSIF) at pH 6.8 for 6 h. The time points chosen are 
similar to the estimated time for the gastric and intestinal transit, respectively (Araújo et al., 
2014). 
  The release profiles of GLP-1 from the H-PLGA+CS-CPP and H-PSi+CS-CPP 
particles at pH 1.2 and 6.8 are shown in the Figures 23A and 23B, respectively. At pH 1.2, 
during the 2 h, the release of GLP-1 was less than 2% and 5% from the PLGA and PSi 
systems, respectively. However, at pH 6.8 the amount of GLP-1 released from particles was 
higher, reaching 40% release after 6 h for both the systems. For the H-PLGA+CS-CPP 
particles, the release was sustained along with the time, unlike in the case of H-PSi+CS-CPP 
release profile, in which there was a GLP-1 burst release, with 40% of the peptide released in 
the first 30 min and a very slow release thereafter. These biphasic release patterns 
dependent on the pH-value confirmed the controlled properties of encapsulation with the 
enteric polymer, and thus confirmed the fact that the CS-CPP modified nanoparticles and 
GLP-1 were indeed protected from the acidic conditions. These results are also in agreement 
with previous studies using the enteric polymer for oral drug delivery (Liu et al., 2014). The 
differences observed in the amounts that were released from H-PLGA+CS-CPP and H-
PSi+CS-CPP over time were related with the characteristics of each nanoparticle and the 
methods used to load the GLP-1 in both of them. In PLGA nanoparticles, the GLP-1 was 
encapsulated inside of a polymer matrix, while in the PSi nanoparticles the GLP-1 was 
loaded mainly through physical adsorption in the pores of the nanoparticles which allowed a 
faster release (Araújo et al., 2014). 
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  With regards to the enzymatic iDPP4 the release was not pH dependent, unlike to 
what was observed for GLP-1. As it can be observed in Figures 23C and 23D, 80% of the 
iDPP4 was released at pH 1.2 during the first 30 min for both the formulations, reaching 
100% release in less than 1 h. This can be explained by the very high solubility of the 
inhibitor in both aqueous solutions and in the organic solvents (Liu et al., 2009). The double 
emulsion technique could retain the aqueous solution in the organic solvent, and thus, retain 
the CS-CPP modified nanoparticles dispersed in water, until the complete polymer 
dissolution. However, this was not efficient in retaining the enzymatic iDPP4 and it started to 
diffuse into the organic solvent. When the particles were collected, the organic solvent 
started to diffuse to the water due to its high solubility. With the fast solidification process of 
the microdroplets, the iDPP4 was trapped in the outer layer of HPMC-AS matrix leading to 
the release of the enzymatic iDPP4 (Liu et al., 2009). Nevertheless, the enzymatic iDPP4 has 
been reported to be successfully administrated orally by adding it into the food and water, 
without compromising its activity, meaning that the enzymatic iDPP4 can resist the harsh 
conditions of the stomach (Mitani et al., 2002; Reimer et al., 2002). 
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Figure 23. Release profiles of the GLP-1 and the enzymatic iDPP4 from H-PLGA and H-PSi 
particles (A and C) at pH 1.2 for 2 h and (B and D) at pH 6.8 for 6 h. All the experiments 
were performed at 37 °C and 100 rpm. The statistical analysis was done using a one-way 
analysis of variance (ANOVA) with a Bonferroni post-test. Error bars represent the mean ± 
standard deviation (n = 3). 
 
4.5. Cell–nanoparticle interaction studies 
  Once in the small intestine, the CS-CPP modified nanoparticles were completely 
unconfined due to the dissolution of the pH-sensitive polymer. The interactions of the CS-
CPP modified nanoparticles were analysed qualitatively using confocal fluorescence 
microscopy and quantitatively by flow cytometry experiments. For the confocal microscopy 
and flow cytometry experiments, the nanoparticles were labelled with Alexa Fluor® 488 
hydrazine (green fluorescence emission) and the cell membranes were labelled with 
CellMask™ Red (red fluorescence emission). In line with the viability experiments, the Caco-
2 and HT29-MTX cells, which are representative of the majority of the intestinal cells, were 
used to perform the cell–particle interaction studies. A ratio of 90:10 for Caco-2 and HT29-
MTX cells, respectively, was used in order to mimic the physiological conditions of the 
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intestine (Araújo and Sarmento, 2013). The confocal fluorescence microscopy are shown in 
Figure 24A. 
 
Figure 24. Interactions between the different nanoparticles and the Caco-2:HT29-MTX 
(90:10) co-culture after incubation for 3 h at 37 °C. (A) Confocal microscopy images of the 
cell membranes stained in red by CellMask® Red and the nanoparticles in green conjugated 
with Alexa Fluor® 488. Flow cytometry quantification of the interactions by (B) PLGA and (C) 
PSi nanosystems. The results were related to the fold increase of the percentage of cells 
interacting with the nanoparticles. Data sets were compared to the control (*p < 0.05, **p < 
0.01, and ***p < 0.001) and between them (#p < 0.05, ##p < 0.01, and ###p < 0.001) using a 
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Student’s t-test with a uniparametric post-test. Error bars represent mean ± standard 
deviation (n ≥ 3).  
   
  It was observed that for the unmodified nanoparticles there were no significant 
interactions with the cells for either the PLGA or the PSi nanoparticles. When the 
nanoparticles were modified with CS, the cell–nanoparticle interactions were greatly 
increased and many of the nanoparticles were observed in the close vicinity of the cell 
membranes. This increase in interaction could be due to the cationic nature and the 
mucoadhesive properties of the CS, causing strong electrostatic interactions with the mucus 
producing cells of the co-culture (Chen et al., 2013; Wang et al., 2013), as described 
elsewhere (Araújo et al., 2014; Shrestha et al., 2014). After the modifications with CS and 
CPP, the cell–nanoparticle interactions were even higher as compared to the non-modified 
nanoparticles, as more nanoparticles were associated to the cells’ surface. In this case, the 
nanoparticles were interacting with the cell membranes and were also taken up by the cells. 
Even after the encapsulation with the enteric polymer, and once the polymer was dissolved 
at a higher pH, the nanoparticles presented a high capacity to interact and to be internalized 
by the cells. 
  Quantitative studies of the cell-particles interaction with flow cytometry demonstrated 
that the CS-CPP modified PLGA and CS-CPP modified PSi nanoparticles presented a 5.6-
fold and 1.3-fold increase in the interaction with the intestinal cells in the co-culture, 
compared to the unmodified nanoparticles, respectively (Figure 24B and 24C). The cationic 
nature of the CS and the CPP were important features that led to high cell–nanoparticle 
interactions (Shi et al., 2014). 
 
4.6. GLP-1 permeability across the intestinal cell monolayers in the presence 
of iDPP4  
  The permeability of the antidiabetic peptide GLP-1 was studied for H-PLGA+CS-CPP 
and H-PSi+CS-CPP particles in the presence and absence of the iDPP4. As observed in 
Figures 25A and 25B, the GLP-1 permeation across the monolayers was higher for the H-
PSi+CS-CPP particles than for the H-PLGA+CS-CPP particles. The difference between the 
amounts of GLP-1 permeated across the cell monolayers by the two systems may be due to 
the differences observed in the release profiles of GLP-1 loaded in both the particles. For the 
PSi system, it was observed a burst release of GLP-1 during the first 30 min, while for the 
PLGA system the release was more sustained over time. Thus, the amount of GLP-1 
available to permeate across the cell monolayers in the presence of the PSi system was 2-
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fold compared to the amount of the PLGA system, which justifies the observed permeability 
results after 3 h (Araújo et al., 2014). In the presence of the enzymatic iDPP4, the 
permeability of GLP-1 across the cell monolayers was even higher, with ≈ 1.5-fold increase 
for the PSi systems and ≈ 5-fold increase for the PLGA systems when compared to the 
permeability values without the enzymatic iDPP4 (Figure 25C). The synergistic effect of 
GLP-1 permeation in the presence the enzymatic DPP4 inhibitor is probably due to the 
inhibition of the DPP4 enzyme, which helped to protect the GLP-1 from degradation when 
permeating across the cell monolayer. Studies conducted in animal models have shown that 
when the iDPP4 was orally administrated, the plasma levels of intact and active GLP-1 were 
increased, which indicated that it was not rapidly degraded by the DPP4 enzyme (Reimer et 
al., 2002; Takasaki et al., 2004).  
 
 
Figure 25. (A) Permeability profiles of GLP-1 from H-PLGA and H-PSi particles in the 
presence and absence of iDPP4. (B) GLP-1 permeability of H-PLGA and H-PSi across the 
Caco-2/HT29-MTX cell monolayers in the presence of iDPP4. (C) Differences between GLP-
1 permeability across the Caco-2/HT29-MTX cell monolayers in the presence and absence of 
the iDPP4. The statistical analysis was done using a Student’s t-test and one-way analysis of 
variance (ANOVA) with uniparametric and Bonferroni post-test. Error bars represent mean ± 
standard deviation (n ≥ 3), set at probabilities of *p < 0.05, **p < 0.01, and ***p < 0.001. 
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  When analysing the enzymatic activity of DPP4 (Figure 26A) after the 4 h incubation 
with the particles, it was observed that the enzymatic activity of DPP4 in the cells exposed to 
the inhibitor was significantly lower for both the PLGA (>20 µU/min) and PSi systems (40 
µU/min) than in the cells with no exposure to the inhibitor (≈ 1062 µU/min). When compared 
to the free form of the inhibitor, the activity of the inhibitor loaded in the particles was not 
affected, and despite of no statistically significant difference, these values were lower than in 
the case of the free form of iDPP4. The similar permeability profiles of the enzymatic iDPP4 
(Figure 26B) across the cell monolayers corroborate these results. It has been shown in in 
vivo studies that in the presence of iDPP4 the enzymatic activity was changed from 3.26 ± 
0.19 mU/mL to 0.01 ± 0.03 mU/mL, and that the inhibition of the enzyme was dose 
dependent (Reimer et al., 2002; Takasaki et al., 2004). 
  Because iDPP4 has also been demonstrated has having a positive effect in 
decreasing the blood glucose levels, it will have an additional benefit of our system for future 
in vivo applications (Ahren et al., 2002; Reimer et al., 2002; Takasaki et al., 2004; Villhauer et 
al., 2002). 
 
 
Figure 26. (A) DPP4 enzymatic activity after cellular incubation with particles loaded with the 
iDPP4. (B) Permeability profiles of DPP4 across the Caco-2/HT29-MTX cell monolayers in 
the free form and when loaded in both the multifunctional particulate systems. The statistical 
analysis was done using a Student’s t-test and one-way analysis of variance (ANOVA) with 
uniparametric and Bonferroni post-test. Error bars represent mean ± standard deviation (n ≥ 
3), set at probabilities of *p < 0.05, **p < 0.01, and ***p < 0.001. 
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5. Conclusions 
   
  In this study, two novel multifunctional composite systems were prepared in a highly 
reproducible, efficient and reliable manner using the innovative microfluidics technique. The 
systems consisted of CS-CPP modified PLGA and PSi nanoparticles used as nanomatrices 
encapsulated into an enteric polymer, which were co-loaded with an antidiabetic peptide 
GLP-1 and an enzymatic iDPP4. The co-delivery of these two drugs was for the first time 
described. Due to the characteristics of the enteric polymer, the multifunctional composite 
systems were able to protect the CS-CPP modified nanoparticles and consequently prevent 
the premature release of the peptide and its degradation in the adverse conditions of the 
gastrointestinal tract. By precisely releasing the CS-CPP modified nanoparticles and 
subsequently the peptide in the upper intestine, the bioavailability of peptide and its 
permeation would be greatly improved. Moreover, due to the modifications of the 
nanoparticles, the interactions and the retention time of the nanoparticles with the intestinal 
cells were also greatly improved. It was also shown that the release of both the drugs had a 
synergistic effect since the presence of the enzymatic iDPP4 decreased drastically the 
activity of the enzyme, improving further the amount of active peptide permeated across the 
intestinal cells. Thus, taking particularly into account the GLP-1 peptide and the enzymatic 
iDPP4, these multifunctional particulate systems might be very promising for clinical 
applications in the therapy of T2DM, due to the potential to increase in GLP-1 half-life in an in 
vivo situation. Overall, due to the flexibility of the techniques employed here, and the 
multifunctional character of the particulate systems, they have potential to orally deliver 
sensitive biomolecules in combination with other drugs with different physicochemical 
properties. 
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In vivo dual delivery of glucagon-like peptide-1and 
dipeptidyl peptidase 4 through PLGA-based composites 
prepared by microfluidics for diabetes therapy 
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1. Abstract 
Oral delivery of proteins is still a challenge in the pharmaceutical field. Nanoparticles 
are among the promising carrier systems for the oral delivery of proteins by increasing their 
oral bioavailability. However, most of the existent data regarding the nanosystems for oral 
protein delivery concerns in vitro studies, lacking in vivo experiments to evaluate the efficacy 
of these systems. Herein, a multifunctional composite system, tailored by droplet 
microfluidics, was used for dual delivery of GLP-1 and dipeptidyl peptidase-4 inhibitor 
(iDPP4) in vivo. Oral delivery of GLP-1 with nano- or micro-systems has been studied before, 
but the simulataneous nanodelivery of GLP-1 with iDPP4 is a novel strategy presented here. 
The T2DM rat model induced through the combined administration of streptozotocin and 
nicotinamide, a non-obese model of T2DM, was used. The combination of both drugs 
resulted in an increase in the hypoglycemic effects in a sustained, but prolonged manner, 
where the iDPP4 improved the GLP-1 therapeutic efficacy. Four hours after oral 
administration of the system, blood glucose levels were decreased by 44%, and were 
constant for another 4h, presenting half of the glucose area under the curve when compared 
to the control. An enhancement of the plasmatic insulin levels was also observed 6h after 
oral administration of the dual-drug composite system and, despite no statistic significant 
differences exists the amount of pancreatic insulin was also higher. These are promising 
results for the oral delivery of GLP-1 to be pursued further in a chronic diabetic model study. 
 
 
KEYWORDS: oral delivery; glucagon like peptide-1; dipeptidyl peptidase-4; in vivo; type 2 
diabetes mellitus; nanoparticles 
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2. Introduction 
The development of therapeutic proteins has increased exponentially over the past 
decades (Leader et al., 2008). Owing to their natural origin, proteins and peptides have 
exquisite effectiveness, activity, specificity and relative lower toxicity, which has a significant 
impact in the treatment of numerous diseases (Fonte et al., 2015). However, due to their 
delicate structure, they must be administrated through parenteral routes. The use of proteins 
as therapeutic agents for oral delivery is still under achieved, which keeps the desired oral 
administration of proteins yet in its infancy (Li et al., 2013; Soudry-Kochavi et al., 2015).  
With an expanding knowledge in nanomedicine the development of nanosized 
delivery systems is revolutionizing the pharmaceutical field, by considerably improving the 
therapeutic effect of most drugs and their bioavailability. Nanoparticles are also regarded as 
promising nanocarriers for oral protein delivery (Morishita and Peppas, 2006; Yu et al., 
2015). These nanoparticles are formed by biomaterials that can be tailored towards the 
desired administration route and can further be associated with other molecules in order to 
improve their interaction with the target organ (Pereira et al., 2014). Nevertheless, despite 
the huge efforts in the development of nanoparticles, most of the existent data essentially 
addresses in vitro studies, lacking in vivo experiments to evaluate the efficacy of the 
developed nanosystems. 
Herein, an innovative approach for T2DM therapy is proposed. Within a 
multifunctional tailorable composite system for dual-drug delivery previously described 
(Araújo et al., 2015), GLP-1 and a iDPP4 drug were combined in a single system, aiming to 
overcome the side effects associated to each one of them separately. Due to its incretin 
effect (insulin secretion after a meal, in a glucose-dependent manner) GLP-1 is one of the 
most promising therapeutic molecules for T2DM therapy, avoiding the well-known 
hypoglycemic effects of current drugs (Araújo et al., 2012; Baggio and Drucker, 2007). 
Nevertheless, GLP-1 has a very short half-life, being cleaved by the DPP4 enzyme in less 
than 2 minutes (Araújo et al., 2014). This system was assembled through the droplet 
microfluidics technique (Araújo et al., 2015) and it is based on the use of polymeric PLGA 
nanoparticles. These nanoparticles were claimed as adequate candidates to provide a 
protective, stable and biocompatible environment to the encapsulated peptides and proteins 
(Danhier et al., 2012; Fonte et al., 2015; Hosseininasab et al., 2014). The nanoparticles were 
functionalized with CS and a CPP and, as previously described by our group, showed high 
and strong interactions with intestinal cells in vitro (Araújo et al., 2015; Zhu et al., 2015). CS 
is a positively charged polymer used in large extent due to its advantageous characteristics 
of adhesion to negatively charged mucosae and cell membranes, thereby increasing cell 
permeability of intestinal cells by transiently opening tight junctions and affecting the 
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paracellular and intracellular pathways, without changing the junctional morphology or cause 
any damage to the cells (Canali et al., 2012; Chen et al., 2013). In turn, CPP has the ability to 
cross the cellular membranes without causing a cellular response, increasing the 
transcellular transport (Bechara and Sagan, 2013; Shi et al., 2014). We have previously 
shown in vitro that the dual-release of the peptide and the drug had a synergistic effect 
regarding GLP-1 permeability. In the presence of the iDPP4, the activity of the enzyme 
responsible for degrading GLP-1, thus considerably decreasing its bioavailability, was 
drastically reduced, further improving the amount of active peptide permeated in vitro across 
the intestinal cell monolayers (Araújo et al., 2015). Additionally, using the microfluidics 
system, the functionalized nanoparticles were encapsulated within an enteric polymer - 
hydroxypropylmethylcellulose acetylsuccinate (HPMC-AS) - conferring pH-sensitivity to the 
system and thus enabling the release of the nanoparticles only in the simulated intestinal 
conditions (Liu et al., 2014; Zhang et al., 2014). This synergetic effect was also described for 
other carriers (Yuan et al., 2015; Zhao et al., 2015). Both PLGA and HPMC-AS polymers are 
approved by FDA for parenteral and food administration, respectively. Previous studies also 
show that they are extensively used in the drug delivery field without toxicity effects after 
acute and chronic administrations (Araújo et al., 2015; Danhier et al., 2012; Hoshi et al., 
1985; Shrestha et al., 2015). 
Pursuing these promising results, in the present work the developed system was 
orally delivered to T2DM rat models, induced by the combination of STZ and nicotinamide 
drugs. Blood glucose, plasmatic insulin levels, and insulin pancreatic content were quantified 
over time during this study. 
 
 
3. Materials and methods 
3.1. Materials 
GLP-1 acetate (7-37, MW 3355.7 Da) was purchased from United Peptides (USA). 
iDPP4 (NVP DPP 728 dihydrochloride, MW 375.77 Da) was purchased from Tocris 
Bioscience (UK) and CPP R9 was purchased from GenicBio (China). PLGA 50:50 was 
obtained from Corbion Purac, Purasorb® PDLG 5004A, The Netherlands. Polyvinyl alcohol 
(PVA), medium molecular weight CS, 2-(N-morpholino)-ethanesulfonic acid (MES), 1-ethyl-3-
(3-dimethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccinimide (NHS), STZ, 
nicotinamide and isoflurane were purchased from Sigma-Aldrich (USA). HPMC-AS was 
obtained from Shin-Etsu (Japan). Pluronic® F127 was purchased from BASF (Germany). 
Lancet Unistik 2 Normal Fixed Depth Lancet Needle 2.4 mm 21 Gauge were purchased from 
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Owen Mumford, Ltd (France) and FreeStyle Precision Blood Glucose Test Strips from Abbott 
Diabetes Care (Portugal). 
 
3.2. Preparation of GLP-1 loaded PLGA-CS nanoparticles 
PLGA nanoparticles were produced based on the water-in-oil-in-water (w/o/w) double 
emulsion technique, through the modified solvent emulsification.evaporation method, using 
2% of PVA as surfactant, as described elsewhere (Araújo et al., 2014; Araújo et al., 2015). 
Afterwards, in order to functionalize the nanoparticles with CS, the formulation was added 
into a CS solution at a ratio of 1:2 (w/w), regarding the solid content of the solutions, and left 
overnight under magnetic stirring (Araújo et al., 2015). 
 
3.3. CPP conjugation to the CS-functionalized nanoparticles 
EDC/NHS coupling chemistry was used to covalently conjugate the free amine groups 
in the CS structure with the carboxylic group of CPP, as previously described (Araújo et al., 
2015). Briefly, the CS-functionalized nanoparticles were dispersed in MES solution 
containing EDC and NHS (pH 5.5.). CPP was then added to this dispersion in a ratio of 1:10 
(CPP:nanoparticles, w/w) and the conjugation occurred overnight in the dark under 300 rpm 
stirring, forming PLGA+CS-CPP.  
 
3.4. Characterization of nanoparticles 
The nanoparticles were characterized in respect to their average size (Z-average), 
polydispersity (PdI) and surface charge zeta ()-potential) by dynamic light scattering using a 
Malvern Zetasizer Nano ZS instrument (Malvern Instruments Ltd, UK).  
The AE and LD of GLP-1 were calculated by the difference between the total amount 
of GLP-1 used to prepare the nanoparticles and the amount of GLP-1 that remained in the 
aqueous phase after the nanoparticles isolation by centrifugation at 20,000 × g for 30 min at 
4°C. The amount of GLP-1 was determined by high performance liquid chromatography 
(HPLC), as described elsewhere (Araújo et al., 2015). 
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3.5. Microfluidics enteric encapsulation of nanoparticles 
The GLP-1 loaded nanoparticles were encapsulated within the HPMC-AS pH-
sensitive polymer, loaded with the iDPP4, using a double emulsion technique through a 
microfluidic flow-focusing glass device. The preparation of the co-drug loaded multifunctional 
systems was previously described in detail (Araújo et al., 2015). The modified nanoparticles 
encapsulated in the HPMC-AS polymer are defined as H-PLGA particles. 
The shape, size, morphology and surface topography of the enteric encapsulated 
particles were assessed by scanning electron microscopy (SEM, Zeiss DSM 962, Germany). 
The AE of the iDPP4 was calculated by dissolving the enteric encapsulated particles in a pH 
7.4 solution. The amount of iDPP4 was determined by HPLC, as described elsewhere 
(Araújo et al., 2015). 
 
3.6. Type 2 diabetic animals 
Male Wistar rats, 7-weeks old, weighing 150-200 grams, obtained from Harlan 
Laboratories, Inc. (Spain) were used for the study. They were maintained in standard 
laboratory conditions (12h light/dark cycles, temperature of 21 ± 2°C and relative humidity of 
35% to 60%). They were fed with standard pellet and water ad libitum.  
The rats were randomly divided into 6 groups, with 5 animals per group. The groups 
were named according to the different formulations that were given as oral gavage: group 1 – 
normal animals (control group of normal rats and with no T2DM induction); group 2 – 
phthalate buffer solution at pH 4.0 (control group); group 3 – GLP-1 and iDPP4 aqueous 
solution; group 4 – H-PLGA empty particles; group 5 – H-PLGA particles loaded with GLP-1 
(H-PLGA-GLP-1); and group 6 – H-PLGA particles loaded with GLP-1 and iDPP4 (H-PLGA-
GLP-1-iDPP4) (study group). The amount of administered particles was equivalent to a GLP-
1 content of 200 µg/kg of weight of the rat. This dose was chosen taking into account the 
administration doses of the GLP-1 analogs that are in the market [liraglutide (Victoza®) and 
exenatide (Byetta®)], which is around 20-30ug/kg and previous study performed by Huotari 
and co-workers where an amount of GLP-1 of 50 µg was s.c. administrated per mouse 
(Huotari et al., 2013). 
Animal experiments were approved by the Local Ethics Committee at the University of 
Porto and conducted under the guidelines and recommendations of FELASA and the 
European Directive 2010/63/EU. 
Induction of T2DM in animals, with exception of group 1, was made in overnight-
fasted rats, by an intraperitoneal (i.p.) injection of 120 mg/kg of nicotinamide and, 15 min 
after, 60 mg/kg of STZ. STZ was freshly dissolved in citrate buffer (0.1 M; pH, 4.5) and 
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nicotinamide was dissolved in normal physiological saline buffer (pH 7.4), maintained on ice 
prior to use (Masiello et al., 1998). 
Glucose tolerance was determined by the intraperitoneal glucose tolerance test 
(IPGTT) 3 days after the T2DM induction. Overnight-fasted animals were administered i.p. 
with a glucose solution (2 g/kg). Blood samples were taken by puncturing with the help of a 
lancet from the tail tip at different time points (-15, 30, 60, 90, and 120 min) after glucose 
administration. Blood glucose was measured using a glucometer Precision Xtra (Abbott 
Diabetes Care, Portugal) by placing a small drop of blood on a new test strip and recording 
the measurements. 
 
3.7. Hypoglycemic effect in vivo 
After proving the successful T2DM induction through the IPGTT experiments, different 
formulations were orally administrated in a phthalate buffer (pH 4.0), according to the groups 
defined in the previous section and blood glucose and insulin levels in plasma and pancreas 
were measured. 
 
3.7.1. Blood glucose measurements.  
The blood samples were withdrawn from the tail vein and blood glucose levels were 
measured for 8h at different time points (0, 0.5, 1, 2, 4, 6 and 8h) after administration. The 
AUC over 8h was calculated for each group. The total hypoglycemic decrease (HD%) in 
serum glucose levels were calculated as follows (Jin et al., 2009; Li et al., 2013). 
 
3.7.2. Plasmatic insulin measurements.  
At the time points of 0, 2 and 6h after administration, the withdrawn blood was 
collected into eppendorf tubes containing 0.5 M of EDTA (10% of the final volume) to prevent 
the blood clotting. The samples were centrifuged at 5,400 × g for 10 min at 4°C. The 
supernatants were collected and stored at –20°C until further studies. Insulin quantification 
was made according to the manufacturer’s instructions using a rat Insulin Elisa kit from 
Mercodia (Sweden). 
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3.7.3. Pancreatic insulin content determination.  
At the end of the study, the animals were sacrificed by cervical dislocation, after 
isoflurane anesthesia, and the pancreases were extracted. The pancreases were isolated by 
removing the fat and the connective tissues, and they were weighed. Then, they were placed 
separately in 3 mL of ice cold acid ethanol (0.18 M HCl in 70% ethanol) and kept on ice. 
Pancreases were further homogenized with a probe sonicator and 3 mL more of acid ethanol 
were added into the tube of the tissue homogenate and stored overnight at 4°C. Afterwards, 
the samples were centrifuged at 3500 rpm for 45 min at 4°C and the supernatant was 
transferred to another tube to be stored at –20°C. These steps were repeated twice more 
and the supernatants from the different centrifugations were collected together. Before the 
quantification of the insulin content, using the Rat Insulin Elisa kit from Mercodia (Sweden), 
samples were left at room temperature, mixed by vortexing, and diluted 1000–1500 times. 
 
3.8. Statistical analysis 
All the experiments were performed in triplicate and represented as mean ± standard 
deviation (SD). A Student t-test and one-way analysis of variance (ANOVA) with unpaired 
and Bonferroni post-test (GraphPadPrism, GraphPad software Inc., CA, USA) were used to 
analyze the data, respectively. The level of significance was set at probabilities of *p < 0.05, 
**p < 0.01, and ***p < 0.001. 
 
 
4. Results and Discussion 
4.1. Characterization of nanoparticles  
As previously demonstrated by our group, CS is able to increase the permeability of 
the antidiabetic peptide GLP-1 across the intestinal cells (Araújo et al., 2014; Shrestha et al., 
2014). Due to its positive surface charge, CS conferred a positive charge to the 
nanoparticles, which increases the interaction with the negatively charged intestinal cells and 
mucus layer. Additionally, CPP was also conjugated to the CS-functionalized PLGA 
nanoparticles, further enhancing the intestinal permeability of the GLP-1-loaded CS-modified 
nanoparticles (Araújo et al., 2015; Kamei et al., 2008; Liu et al., 2013; Zhu et al., 2015). 
After production and CS-CPP surface functionalization, the PLGA nanoparticles were 
characterized on the basis of the different physicochemical parameters that are known to 
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have an impact in their interaction with cells and in the drug delivery (Verma and Stellacci, 
2010). The mean size, PdI, surface charge (-potential), AE and LD of GLP-1 were 
evaluated, as shown in Table 6. Comparing the non-modified nanoparticles with the CS-CPP 
conjugated nanoparticles, an increase in the size from 174 ± 5 to 351 ± 4 nm, an increase in 
PdI and an inverse of charge from –20 ± 2 to 40 ± 0 mV was observed, proving the efficient 
modification of the prepared PLGA nanoparticles (Araújo et al., 2014; Araújo et al., 2015). 
Due to the adding of CS-CPP to the system, the final mass was increased resulting in the 
decrease of the LD from 0.017 ± 0.03 to 0.08 ± 0.01. However, despite these surface 
modifications, the AE did not significantly change (approximately 70%). 
 
 
Table 6. Characterization of the nanoparticles in respect to their size, PdI, -potential, AE 
and LD of GLP-1. Results are presented as mean ± SD (n ≥ 3). 
 
 
Size  
(nm) 
PdI 
-potential 
(mV) 
AE 
(%) 
LD 
(%) 
PLGA 174.4 ± 4.9 0.120 ± 0.045 - 20.0 ± 1.5 69.5 ± 10.3 0.17 ± 0.03 
PLGA+CS 286.7 ± 5.5 0.188 ± 0.015 34.7 ± 2.8 ≈ 69.5 ± 10.3 0.08 ± 0.001 
PLGA+CS-CPP 351.3 ± 3.5 0.210 ± 0.024 40.0 ± 0.1 ≈ 69.5 ± 10.3 0.08 ± 0.001 
 
 
Further encapsulation of the CS-CPP modified nanoparticles with a pH-sensitive 
HPMC-AS polymer was made using the droplet microfluidics technique (Liu et al., 2014; 
Zhang et al., 2014), to form H-PLGA particles. These particles presented sizes around 60 ± 7 
µm with a regular and smooth surface and a spherical shape (Figure 27). The similarities 
between the particles are characteristic from the microfluidic production technique, which 
originates uniform structures, with the additional advantage of providing an AE of near 100% 
(Araújo et al., 2015; Liu et al., 2014; Zhang et al., 2014). The iDPP4 AE was 21 ± 4 %. Since 
HPMC-AS is only soluble at pH 6.0 or higher, at low pH conditions of the gastric milieu, the 
particles will remain intact protecting the integrity of the CS-CPP modified nanoparticles 
(Araújo et al., 2015; Liu et al., 2014). 
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Figure. 27. SEM image of CS-CPP modified PLGA nanoparticles encapsulated in the 
HPMC-AS polymer (H-PLGA particles). 
 
4.2. In vivo assessment of antidiabetic effect 
A non-obese T2DM rat model induced by the administration of STZ combined with 
nicotinamide, was firstly proposed by Masiello and co-workers in 1998 (Masiello et al., 1998). 
This model was described as being the most suitable to study the biochemical and 
pharmacological antidiabetic drug effects, and was previously used to test GLP-1 analogs 
(Badole et al., 2013; Chen et al., 2013; Ghasemi et al., 2014). It is based on the protective 
effects of nicotinamide against the β-cytotoxic effects caused by the STZ, a widely used drug 
to induce diabetes mellitus in rodents (Masiello, 2006). This model presents a number of 
features similar with T2DM, as described in detail elsewhere (Ghasemi et al., 2014). Briefly, it 
provides a stable and moderate hyperglycemia, does not require exogenous insulin for 
animals to survive, results in glucose intolerance, reduction of β cells and presence (although 
impaired) of glucose-stimulated insulin secretion (Palsamy and Subramanian, 2008). 
After 3 days of STZ–nicotinamide administration, a glucose tolerance test (IPGTT) 
was performed to verify the efficacy of the induction of the T2DM (Ghasemi et al., 2014). The 
glucose tolerance test was used to assess the ability of the body to metabolize glucose, and 
thus, to detect disorders in glucose metabolism. After the i.p. administration of glucose, the 
blood glucose levels were measured for 2h in the different groups. As shown in Figure 28A, 
the normal animals group had a rapid increase in the blood glucose levels 30 min after 
glucose administration, but the levels reached normal values 60 min after glucose 
administration and were constant, thereafter, i.e., the animals were tolerant to the glucose 
(Nayak et al., 2014). In contrast, the other groups could not recover from the glucose 
administration. There was a maximum peak between 30 to 60 min, similar to the normal 
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animals, but the blood glucose levels never reached the normal values in the 2h period after 
glucose injection. As shown in Figure 28B, all the groups presented a higher and statistically 
significant AUC compared to the normal animals group, in the period of -15–120 min of the 
study, which indicates that all the animals were intolerant to the glucose, and thus, were 
considered as presenting T2DM (Nayak et al., 2014).  
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Figure 28. (A) Blood glucose levels of T2DM-induced rats following i.p. administration of a 
glucose solution (2 g/kg). The values were normalized by the normal animals group. Results 
are presented as mean ± SD (n = 5). (B) Blood glucose AUC in the period of -15–120 min 
after glucose administration. Results are presented as mean ± SD (n = 5). The levels of 
significance were set at probabilities of **p < 0.01, and ***p < 0.001, as compared with 
normal animals group. 
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To evaluate the efficacy of our developed composite system, different formulations 
were orally administrated to the animals through gavage, as previously described in the 
Materials and Methods section. The drug-loaded H-PLGA particles (H-PLGA-GLP-1-iDPP4) 
showed remarkable decreased in the hyperglycemic effects (decrease in the blood glucose 
levels) in a sustained and prolonged manner. 2h after administration, the blood glucose 
levels decrease significantly, remaining low until the end of the experiment (8h). In 
comparison with other groups, at 4, 6 (*p < 0.05) and 8h (***p < 0.001) after administration, 
results with H-PLGA-GLP-1-iDDP4 particles were statistically different (Figure 29A). The 
determination of glucose AUC of the whole experiment (0–480 min), shown in Figure 29B, 
proved that the GLP-1 and iDPP4 co-loaded particles had a statistically significant effect in 
decreasing the overall glucose levels comparing to the control and the pure drugs, as well as 
in comparison with the empty H-PLGA and H-PLGA-GLP-1 particles (**p < 0.01). The 
hypoglycemic decrease (HD%) presented in Table 7 also gives consistency to the obtained 
results, showing a HD% of approximately 0 for the GLP-1-iDPP solution and H-PLGA-GLP-1, 
4.3 ± 6.4 % for the empty H-PLGA particles, which is a negligible hypoglycemic efficacy (Jin 
et al., 2009), and 44.3 ± 4.0 % for the DPP4-loaded H-PLGA particles. This hypoglycemic 
efficacy was similar (Jin et al., 2009) or even higher (Nguyen et al., 2011; Youn et al., 2008) 
than the results obtained in other studies where GLP-1 analogs were tested. Since the 
analogs are resistant to the DPP4 enzyme activity, we can assume that the dual delivery of 
GLP-1 and iDPP4 was effective, and that they had a synergetic effect regarding the blood 
glucose levels, as previously described for the in vitro experiments (Araújo et al., 2015; 
Shrestha et al., 2015). Moreover, the functionalization of the PLGA nanoparticles improved 
the permeability of cells to the GLP-1 and contributed to the overall increase in efficacy 
(Araújo et al., 2014; Araújo et al., 2015). 
Being a powerful insulinotropic peptide, GLP-1 stimulates pancreatic insulin secretion 
and release in a glucose-dependent manner. Even in a T2DM scenario, the insulin response 
to GLP-1 remains intact (Lynn et al., 2001), which means that after administration of GLP-1 
in therapeutic dosages, the insulin secretory function can be restored in T2DM patients 
(Garber, 2011). This glucose dependency assures the safety of GLP-1 over other agents in 
the market that increase insulin secretion via glucose-independent mechanisms (Nguyen et 
al., 2011; Youn et al., 2008). 
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Figure 29. (A)  Blood glucose levels of T2DM-induced rats following oral administration of 
phthalate buffer solution (control), GLP-1-iDPP4 solution, H-PLGA particles, H-PLGA-GLP-1 
particles and H-PLGA-GLP-1-iDPP4 particles. Results are presented as mean ± SD (n = 5) 
(B) Blood glucose AUC in the period of 0–480 min after oral administration. Results are 
presented as mean ± SD (n = 5). The levels of significance were set at the probabiliy of ***p 
< 0.001, as compared with the H-PLGA-GLP-1-iDPP4. 
*** * * 
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Table 7. Total hypoglycemic decrease (HD %) in serum glucose levels in the 8h experiment, 
regarding the control. 
 
Thus, the plasmatic insulin levels were also measured for the time points of 0, 2 and 
6h after oral administration. As can be depicted in Figure 30A, no differences between the 
groups were found for the initial times points (0 and 2h). However, at 6h after oral 
administration, the H-PLGA-GLP-1-iDPP4 particles presented significantly higher plasmatic 
insulin levels compared to the control, the oral GLP-1-iDPP4 solution, the H-PLGA empty 
particles and the H-PLGA-GLP-1 groups (***p < 0.001). These results are in accordance with 
the blood glucose level measurements where the blood glucose levels were lower at the time 
point of 6h (*p < 0.05) in comparison with the 0 and 2h time points. This is also in agreement 
with other study that showed an insulin increase in a slow, but prolonged manner along 8h 
(Nguyen et al., 2011).  
The insulin pancreatic contents of the different groups after oral administration were 
also evaluated at the end of the 8h experiment, as shown in Figure 30B. The H-PLGA-GLP-
1-iDPP4 group presented a higher amount of insulin compared with the other groups; 
however, this difference was only statistically significant regarding the control group. These 
results might be due to the single dose administration, while an increase in the insulin 
pancreatic content was reported to exist only in long-term studies (Moritoh et al., 2008, 2009; 
Reimer et al., 2002; van Genugten et al., 2012; Wu et al., 2012). Thus, despite promising, 
these results must be followed up in a chronic diabetic model system. 
 
 
 
 
 
 
GLP-1-iDPP4  
solution 
H-PLGA H-PLGA-GLP-1 H-PLGA-GLP-1-
iDPP4 
≈ 0 4.3 ± 3.6 ≈ 0 44.3 ± 2.9 
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Figure 30. (A) Plasmatic insulin levels in T2DM-induced rats following oral administration of 
buffer solution (control), GLP-1-iDPP4 solution, H-PLGA empty particles and H-PLGA-GLP-
1-iDPP4 particles. Results are presented as mean ± SD (n = 5). (B) Pancreatic insulin 
content 8h after oral administration of buffer solution (control), GLP-1-iDPP4 solution, H-
PLGA empty and H-PLGA-GLP-1-iDPP4 particles. Data shown as mean ± SD (n = 5). The 
level of significance was set at the probability of ***p < 0.001 between the control group and 
the H-PLGA-GLP-1-iDPP4. 
 
 
* 
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Overall, the combined administration of GLP-1 and iDPP4 resulted in an increase in 
the hypoglycemic effects after oral administration, namely a decrease of blood glucose levels 
and enhancement of the insulin secretion. A clear improvement of the therapeutic efficacy of 
GLP-1 was observed by the presence of the iDPP4 (Balkan et al., 1999; Green et al., 2005; 
Tian et al., 2010). 
 
 
5. Conclusions 
 
In this work, a dual-drug delivery multifunctional composite system was prepared 
through the highly reproducible microfluidics technique. The system was loaded with GLP-1 
and iDPP-4 and tested in vivo in a non-obese T2DM rat model, induced by streptozotocin 
and nicotinamide. The combination of both GLP-1 and iDPP-4 resulted in an increase in the 
hypoglycemic effects in a sustained and prolonged manner. The blood glucose AUC was 
significantly lower than the control group, with a hypoglycemic decrease of 44%. An 
enhancement of the plasmatic insulin levels was also observed 6h after the oral 
administration of the system. These are very promising results towards the development of 
oral protein/peptide delivery systems for T2DM therapy. 
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1. Concluding Remarks 
Materials science has been playing a paramount role in innovation and successful 
development of the biomedical field. Therapeutical approaches may beneficit from the 
modulation of payload delivery, provided by cutting-edge materials, in chronic and 
widespread diseases as type 2 diabetes mellitus (T2DM). As discussed in this thesis work, 
multistage platforms, considered as advanced delivery systems for the administration of 
peptides and proteins through the oral route, present various beneficial features. The specific 
engineering of carriers, namely by combining materials and tailoring their properties through 
functionalization, opened new avenues that potentiate mechanical, chemical and biological 
properties, and render positive characteristics to the materials. Additionally, modifying the 
surface of the particulate systems may contribute to the successful oral delivery of peptides 
and proteins in such a way that the traditional barriers along the gastrointestinal tract can 
now be considered as exciting opportunities for enhancing drug bioavailability.  
In this work, particulate-based systems were developed as oral carrier systems for 
glucagon-like peptide-1 (GLP-1), aiming to enhance GLP-1 oral bioavailability. Among 
different materials (poly(lactic-co-glycolic acid) (PLGA), Witepsol E85 and porous silicon 
(PSi)), the PLGA and PSi nanoparticles modified with chitosan, with sizes around 200 nm 
and 360 nm, respectively, and positive charge, exhibited the best combinations of properties 
regarding the association efficiency (AE) of GLP-1, namely 60% for PLGA and 85% for PSi 
nanoparticles, and enhanced the cellular compatibility and interactions with intestinal cell 
lines. These nanoparticles were further functionalized with a cell penetrating peptide (CPP), 
and were encapsulated into hydroxypropylmethylcellulose acetylsuccinate (HPMC-AS) 
microparticles of ca. 60 µm, in which a dipeptidyl peptidase 4 (DPP4) (enzyme responsible to 
cleave, and hence, inactivate GLP-1) inhibitor, to enhance GLP-1 half-life, was co-loaded 
(AE of ca. 20%). The loading degree of GLP-1 was of 0.030 ± 0.007% and 0.730 ± 0.001 % 
for the PLGA and PSi systems encapsulated into HPMC-AS, respectively, and for iDPP4 of 
1.00 ± 0.01% and 1.26 ± 0.01%, respectively. The smoth surface multistage composites were 
prepared in a highly reproducible, efficient and reliable manner using a microfluidics 
technique, taking into consideration a future scale up of the production. The use of the 
enteric polymer prevented the premature release of GLP-1 and its degradation at pH 1.2, 
which mimicks the gastric pH, and thus the adverse conditions of the gastrointestinal tract, 
since it only degrades at pH ≥ 6.0. Thus, a pH-responsive system efficient in protecting GLP-
1 premature release was obtained. The functionalization of the nanoparticles with the CPP 
increased the permeability of GLP-1 and the interaction with the intestinal cells was even 
stronger, namely 5.6-fold for PLGA and 1.3-fold for PSi systems in comparison with non-
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modified nanoparticles. It was also shown that the release of both GLP-1 and DPP4 inhibitor 
had a synergistic effect and that the DPP4 inhibitor further improved the amount of active 
peptide permeated across the intestinal cells by decreasing the activity of the DPP4 enzyme 
over 20-fold. The amount of GLP-1 permeated across a triple intestinal model increased 5- 
and ca. 1.5-fold for the PLGA- and PSi-based systems, respectively, in the presence of the 
DPP4 inhibitor, in comparison with systems without the DPP4 inhibitor. Moreover, the oral 
delivery of GLP-1 using the PLGA-based multisystem composites was assessed in an in vivo 
scenario, in a non-obese T2DM rat model. The composites combining GLP-1 and DPP4 
inhibitor promoted a decrease in the hyperglycemic effects (blood glucose levels decreased 
45%) in a sustained and prolonged manner (from 4 until, at least, 8h after oral 
administration). The blood glucose area under the curve was also significantly lower than the 
control group. An enhancement of the plasmatic insulin levels was likewise observed 6h after 
the oral administration of the system, as well as the pancreatic insulin content. 
Overall, the multifunctional and multistage GLP-1 delivery system developed, based 
on the study of distinct biomaterials that were surface functionalized using mucoadhesion 
and permeation enhancers, and further encapsulated into a pH-sensitive polymer, revealed 
to increase the GLP-1 oral bioavailabilty after their oral administration, which are promising 
characteristics for clinical applications in the treatment of T2DM.  
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2. Future Perspectives 
 
Multistage platforms for oral delivery of peptides and proteins are the product of 
cumulative research in the technology and pharmaceutical fields applied to modern medicine. 
Advancing the understanding of the design of these platforms is paving the way for 
significant progress to be achieved with respect to their synthesis, functionalization and 
future application in a myriad of worldwide diseases. 
In this particular work, the development of new and “smart” delivery systems to orally 
deliver peptides was pursued, especially designed to overcome the barriers along the 
gastrointestinal tract. The promising results obtained opened new and exciting possibilities 
for exploration!  
An interesting alternative strategy relies in the encapsulation of GLP-1 analogs 
instead of GLP-1. Those analogs, such as Exenatide (Byetta®) and Liraglutide (Victoza®), are 
claimed to have a longer half-life than GLP-1, thereby requiring lower amounts of 
administered formulation or higher efficiency for the same amount used here. However, 
these analogs are also known to cause some side-effects and thus strategies need to be 
envisaged to avoid them. Similarly to what was reported in this thesis, an alternative 
multistage delivery system could be developed, loaded with a drug molecule able to prevent 
those side-effects, in addition or replacing the DPP4 inhibitor. 
To confirm the in vivo efficacy of the system developed and enhance its significance, 
more clinically relevant animal models need to be used, with increased similarity with the 
human, such as pig. Also, despite constituting a good model of T2DM, the STZ-nicotinamide 
induced rat model is only temporary since the animals’ hyperglycemia starts dropping a few 
weeks after. Assessing the behavior of the developed multisystem composite in a chronic 
disease model, namely to understand its efficacy in controlling blood glucose levels during 
longer periods of time, would be of great relevance. The safety of the developed system 
should also be assessed in a chronic disease model study, including a detailed analysis of 
the immune response along with a thorough whole body histological evaluation to assess the 
systemic effects of regularly administered particles.  
Another interesting aspect requiring optimization is the production of the systems. In 
the present work, particles were produced through a low yield and time-consuming 
microfluidics technique that cannot be scaled-up at an industrial level. However, the 
optimization of the microfluidics system may result in a continuous flux of microparticle 
production, as already explored by biomedical companies such as Dolomite Microfluidics and 
MiniFAB. Alternatives to explore include using different techniques to deliver the 
nanoparticles into enteric materials, or lyophilization of the nanoparticles using an optimized 
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protocol ensuring the bioactivity of GLP-1, followed by encapsulation into macroscopic 
capsules or pills, constituted by enteric coating materials. From an industrial point of view, 
strategies to reduce the production time and making possible the scaling-up of GLP-1 loaded 
nanoparticles would be of great relevance. 
  In a more general perspective, the flexibility of the techniques employed for the 
development of the system, coupled with the multifunctional character of the particulate 
system developed, indicate great potential to orally deliver other sensitive biomolecules such 
as other peptides or proteins and antibodies in combination with other drugs, with different 
physicochemical properties, such as the chemical drugs conventionally used in the clinical 
practice. The strategies and multistage delivery systems developed herein could be also of 
interest to orally deliver other molecules for different purposes than T2DM therapy, for 
instance in cancer therapy. Most of the drugs used in cancer therapy are expelled from cells 
by the P-glycoprotein (P-gp); using this multysistem, the drug can be co-loaded with a P-gp 
inhibitor increasing thus its absortion. Another potential application may be the co-
administration of lumen enzyme or bacteria inhibitors that prematurely degrade active 
molecules prior to their absorption. 
  Overall, it is expected that drug delivery multistage platforms, as developed in the 
present thesis, could be validated and effectively applied to overcome physiological, 
technological and social limitations in biomedical fields.  
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Similar as with the PLGA composite systems, also the PSi composite systems were 
tested in vivo, pursuing the promising in vitro results obtained and described in Chapter IV. 
As previously shown, the PSi composites have the ability to sustain the release of 
GLP-1 in pH conditions below 6.0 due to the HPMC-AS polymer properties, which only 
dissolves at pH ≥ 6.0, and the dual release of GLP-1 and iDPP4 showed to have a synergetic 
effect in the permeability of GLP-1 through intestinal monolayers (Araújo et al., 2015). 
The animal model used was a non-obese STZ and nicotinamide induced T2DM rat 
model (Araújo et al, 2016). Glucose tolerance was determined by the intraperitoneal glucose 
tolerance test (IPGTT) 3 days after the T2DM induction to verify its efficacy. Overnight-fasted 
animals were administered i.p. with a glucose solution (2 g/kg). Blood samples were taken by 
puncturing with the help of a lancet from the tail tip at different time points (−15, 30, 60, 90, 
and 120 min) after glucose administration. Blood glucose was measured using a glucometer 
Precision Xtra (Abbott Diabetes Care, Portugal) by placing a small drop of blood on a new 
test strip and recording the measurements. Results are shown in Figure A1.  
The IPGTT results (Figure A1A) showed that the group of the normal animals had a 
rapid recover, with constant values subsequently, after an increase in the blood glucose 
levels, 30 min after glucose administration. This means that the animals were tolerant to 
glucose. In contrast, the other groups could not recover from the glucose administration and 
the blood glucose levels never reached the normal values in the 2 h period after glucose 
injection. These results were confirmed by the statistically significant increase in the AUC of 
all groups in comparison with normal animals, in the period of −15–120 min of the study, after 
oral administration, which indicates that all the animals were intolerant to glucose (Figure 
A1B). Hence the animals were considered as having the T2DM disease. 
Next, and to evaluate the efficacy of the PSi developed composite systems, different 
formulations were orally administrated to different animal groups through gavage: i) buffer 
solution, ii) GLP-1 and iDPP4 in solution, iii) empty H-PSi and iv) H-PSi-GLP-1-iDPP4. Blood 
samples were withdrawn from the tail vein and the blood glucose levels were measured for 
8h at different time points (0, 0.5, 1, 2, 4, 6 and 8h) after administration. The AUC over 8h 
was calculated for each group. 
As seen in Figure A2A, the blood glucose levels of all the groups were very similar 
for all the measured time points, with no decrease in the values when compared to the initial 
ones. Moreover, comparing the AUC of all the groups (Figure A2B), none of them was 
statistically significant different from the other groups, corroborating the blood glucose levels 
results. 
Being a powerful insulinotropic peptide, GLP-1 stimulates pancreatic insulin secretion 
thus we evaluated the plasmatic insulin levels and the insulin pancreatic content. However, 
the values obtained were below the detection limit of the kit so, no conclusion can be taken 
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from these particular experiments. An increase in the insulin pancreatic content was reported 
to exist only in long-term studies, which may explain these results since we only made a 
single dose administration (Moritoh et al., 2008, 2009; Reimer et al., 2002; van Genugten et 
al., 2012; Wu et al., 2012). Moreover, the animal number used to perform these experiments 
(n = 3 per group) was small considering the huge inherent variations of this disease.  
Thus, no concrete conclusion can be taken with the results obtained and assuming 
that the PSi composite systems did not work seems very hasty. A study using a higher 
number of animals per group and for a longer period of time (chronic study) would be needed 
to have reliable results and know if the PSi composite systems are or not promising 
candidates to use as a therapy for T2DM. 
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Figure A1. (A) Blood glucose levels of T2DM induced rats following i.p. administration of a 
glucose solution (2 g/kg). The values were normalized by the normal animals group. Results 
are presented as mean ± SD (n = 3). (B) Blood glucose AUC in the period of -15–120 min 
after glucose administration. Results are presented as mean ± SD (n = 3). The levels of 
significance were set at probabilities of **p < 0.01, and ***p < 0.001, as compared with 
normal animals group. 
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Figure A2. (A) Blood glucose levels of T2DM induced rats following oral administration of 
buffer solution (control), GLP-1-iDPP4 solution, H-PSi particles and H-PLGA-GLP-1-iDPP4 
particles. Results are presented as mean ± SD (n = 3). (B) Blood glucose AUC in the period 
of 0– 480 min after oral administration. Results are presented as mean ± SD (n = 3). 
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